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ABSTRACT 
EVALUATION OF YB-1 TRANSCRIPTIONAL FACTOR, DNA 
GLYCOSYLASE hNTH1 AND HUMAN TOPOISOMERASE I 
FUNCTIONS IN RELATION TO DRUG RESISTANCE AND DNA 
REPAIR MECHANISMS 
SENARISOY, Müge 
PhD in Biotechnology 
Supervisor: Dr. Joanna TIMMINS 
Co-Supervisor: Prof. Dr. Zeki TOPCU 
September 2018, 209 pages 
 Acquired resistance to anti-cancer therapy is common and is a major 
clinical issue. Functional DNA repair pathways provide a common mechanism for 
drug resistance, but it can also result from mutations or reduced expression of the 
targeted protein. The overexpression or nuclear localisation of the multifunctional 
Y-box binding protein (YB-1) is considered as a prognostic marker for drug 
resistance in tumours. YB-1 has several interaction partners in cells; in this study, 
we have focused on its interaction with the human DNA repair enzyme NTH1 
(hNTH1) and human DNA topoisomerase I (hTopoI), two enzymes that have been 
shown to be stimulated by YB-1. The abundance of the hNTH1/YB-1 complex 
was shown to increase in cisplatin-resistant tumour cells. Human TopoI is an 
essential enzyme involved in cellular regulation of DNA supercoiling and is the 
target of several anti-cancer agents. YB-1 enhances the activity of hTopoI and its 
sensitivity to hTopoI inhibitor, camptothecin in tumour cells. We have 
characterised the YB-1/hNTH1 and YB-1/hTopoI complexes in vitro and in vivo 
using Fluorescence Resonance Energy Transfer (FRET) measurements to identify 
and develop new strategies for the treatment of drug-resistant tumours. We also 
designed and optimised an original FRET-based biosensor to screen two medium-
sized chemical libraries in order to find potential inhibitors of the hNTH1/YB-1 
complex. Several “hits” were identified that significantly reduced the FRET level 
of our biosensor. For some of these compounds, we have reproduced these results 
starting from powders, have performed dose-response curves and have validated 
their actions as inhibitors of the hNTH1/YB-1 interface using alternative binding 
assays. Taken together, our results demonstrate that YB-1 directly interacts and 
stimulates a DNA repair and a DNA relaxing enzyme and targeting the YB-
1/hNTH1 interface represents an interesting new strategy for the development of 
anti-cancer drugs. 
Keywords: Cancer, DNA Repair, Topoisomerase I, Protein-protein interactions, 
FRET 
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RÉSUMÉ 
ETUDES DES FONCTIONS DU FACTEUR DE TRANSCRIPTION 
YB-1, DE L'ADN GLYCOSYLASE hNTH1 ET DE LA 
TOPOISOMERASE HUMAINE I DANS LE CONTEXTE DE LA 
RÉSISTANCE AUX DROGUES ET EN RELATION AVEC LES 
VOIES DE RÉPARATION DE L'ADN 
SENARISOY, Müge 
Doctorat en Biotechnologie 
Directeur: Dr. Joanna TIMMINS  
Co-Directeur: Prof. Dr. Zeki TOPCU 
Septembre 2018, 209 pages 
 La résistance acquise aux traitements anticancéreux représente un problème 
clinique majeur. Les voies de réparation de l'ADN fournissent un mécanisme de 
résistance, mais celle-ci peut aussi résulter de mutations ou d'une expression 
réduite de la protéine ciblée. La surexpression ou la localisation nucléaire de la Y-
Box binding (YB-1) protéine est considérée comme un marqueur pronostique de 
chimiorésistance de la tumeur. YB-1 interagit avec plusieurs partenaires ; dans 
cette étude, nous nous sommes concentrés sur son interaction avec l'enzyme de 
réparation de l'ADN NTH1 (hNTH1) et l'ADN topoisomérase I (hTopoI), deux 
enzymes stimulées par YB-1. L'abondance du complexe hNTH1/YB-1 est accrue 
dans les cellules tumorales résistantes au cisplatine. La TopoI humaine est une 
enzyme essentielle impliquée dans la régulation cellulaire du surenroulement de 
l'ADN et est la cible de plusieurs agents anticancéreux. YB-1 augmente la 
sensibilité à l'inhibiteur de TopoI, la camptothécine, dans les tumeurs. Nous avons 
caractérisé les complexes YB-1/hNTH1 et YB-1/hTopoI in vitro et in vivo en 
utilisant des mesures de transfert d'énergie par résonance en fluorescence (ou 
FRET) pour identifier et développer de nouvelles stratégies pour le traitement de 
tumeurs chimio-résistantes. Nous avons développé et optimisé un biosenseur 
original basé sur le FRET pour cribler deux chimiothèques de taille moyenne afin 
d’identifier des inhibiteurs potentiels du complexe hNTH1/YB-1. Plusieurs «hits» 
ont été identifiés qui réduisent de façon significative le niveau de FRET de notre 
biosenseur. Pour certains de ces composés, nous avons reproduit ces résultats à 
partir de poudres, effectué des courbes dose-réponse et validé leurs actions en tant 
qu'inhibiteurs de l'interface hNTH1/YB-1 en utilisant d'autres tests d’interactions. 
Ensemble nos résultats démontrent que YB-1 interagit directement et stimule des 
enzymes de la réparation de l'ADN et du relaxation de l’ADN, et que cibler 
l’interface YB-1/hNTH1 représente une nouvelle stratégie intéressante pour le 
développement de traitements anticancéreux. 
Mots clés: Cancer, Réparation de l'ADN, Topoisomérase I, Interactions protéines-
protéines, FRET  
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ÖZET 
YB-1 TRANSKRİPSİYON FAKTÖRÜ, DNA GLİKOZİLAZ hNTH1 
VE İNSAN TOPOİZOMERAZ I ENZİMİ İŞLEVLERİNİN İLAÇ 
DİRENCİ VE DNA TAMİR MEKANİZMASI KAPSAMINDA 
DEĞERLENDİRİLMESİ  
ŞENARISOY, Müge 
Doktora Tezi, Biyoteknoloji Anabilim Dalı 
Tez Danışmanı: Prof. Dr. Zeki TOPÇU 
İkinci Danışmanı: Dr. Joanna TIMMINS 
Eylül 2018, 209 sayfa 
 Anti-kanser tedavisine karşı kazanılan direnç yaygın ve önemli bir klinik 
sorundur. Fonksiyonel DNA onarım yolları, ilaç direnci için yaygın bir 
mekanizma sağlamaktadır, ancak aynı zamanda, hedeflenen proteinin 
mutasyonlarından veya ekspresyonunun azalmasından da kaynaklanabilmektedir. 
Çok işlevli Y-box bağlanma proteinin (YB-1) aşırı ekspresyonu veya nükleer 
lokalizasyonu, tümörlerde ilaç direnci için bir prognostik belirteç olarak kabul 
edilmektedir. YB-1'in hücrelerde birkaç etkileşim partneri vardır; bu çalışmada, 
YB-1 ile aktiviteleri uyarıldığı gösterilen insan DNA onarım enzimi NTH1 
(hNTH1) ve insan DNA topoizomeraz I (hTopoI) ile olan etkileşimleri üzerine 
odaklandık. Cisplatin-dirençli tümör hücrelerinde hNTH1/YB-1 kompleks 
oluşumunun arttığı gösterilmiştir. İnsan TopoI, DNA süpersarmallarının hücresel 
regülasyonunda yer alan ve birkaç anti-kanser ajanının hedefi olan önemli bir 
enzimdir. YB-1, hTopoI aktivitesini ve tümör hücrelerinin hTopoI inhibitörü 
Campthotecin’e olan duyarlılığını artırmaktadır. Bu çalışmada YB-1/hNTH1 ve 
YB-1/hTopoI komplekslerini in vitro ve in vivo olarak, ilaca dirençli tümörlerin 
tedavisi için yeni stratejiler tanımlamak ve geliştirmek için Fluoresans Rezonans 
Enerji Transferi (FRET) ölçümlerini kullanarak karakterize ettik. Ayrıca, 
hNTH1/YB-1 kompleksinin potansiyel inhibitörlerini bulmak için iki orta ölçekli 
kimyasal kütüphaneyi taramak üzere orijinal bir FRET-bazlı biyosensör tasarladık 
ve optimize ettik. Biyosensörümüzün FRET seviyesini önemli ölçüde azaltan 
birkaç “hit” tespit ettik. Bu bileşiklerin bazıları için, toz bileşiklerden başlayarak 
bu sonuçları tekrar ürettik, doz-cevap eğrileri gerçekleştirdik ve alternatif bağlama 
deneyleri kullanarak hNTH1/YB-1 arayüzünün inhibitörleri olarak onayladık. 
Birlikte ele alındığında, sonuçlarımız YB-1'in DNA onarımı ve DNA relakse edici 
enzimleriyle doğrudan etkileşime girip uyardığını ve YB-1/hNTH1 arayüzünü 
hedef almanın, anti-kanser ilaçlarının geliştirilmesi için ilginç yeni bir stratejiyi 
temsil ettiğini göstermektedir. 
 Anahtar sözcükler: Kanser, DNA tamiri, Topoizomeraz I, Protein-protein 
etkileşimleri, FRET 
 
 
 
 
viii 
 
 
  
 
 
 
 
ix 
ACKNOWLEDGEMENTS 
I am very grateful to my thesis advisor, Dr. Joanna Timmins, for giving me 
the opportunity to do my PhD work in her laboratory. I also want to thank her for 
her valuable and constructive suggestions in every step of my research. I would 
like to express my deep gratitude to Prof. Dr. Zeki Topcu, my thesis co-advisor, 
for his guidance since my bachelor degree and his encouragements about my 
career. 
I would like to thank my rapporteurs Dr. Xavier Morelli and Prof. Dr. 
Meltem Müftüoğlu, for giving their precious time to evaluate my thesis work, and 
the President of my jury, Dr. Dominique Bourgeois and the examiner Prof. Dr. 
Hilmi Orhan, for accepting to take part in my jury and assessing my work. I also 
want to thank my thesis progress committee members Assoc. Prof. Dr. Serap 
Evran and Dr. Jean-Philippe Kleman, for their feedback and guidance during my 
PhD. 
I wish to thank various people for their contribution to this project; Dr. Jean-
Philippe Kleman for his advice and help in analyzing the in vitro and in vivo 
FRET data; François Lacroix for her valuable technical support on the M4D 
platform; Dr. Caroline Barette, for the high-throughput screening on the CMBA 
platform; Dr. Meike Stelter, for preliminary results on the hNTH1/YB-1 complex 
characterisation; Dr. Joanna Timmins, for performing the AlphaScreen dose-
response assays. 
I am also very thankful to all my past and present lab mates; from the VIC 
Group at IBS: Kevin Floc’h, Dr. Mizar Oliva, Salvatore DeBonis, Marjolaine 
Noirclerc-Savoye, Fabienne Hans, Anne-Sophie Banneville, Anna Seck, Anthoula 
Mettou; from Zeki’s lab at EGE: Dr. Sevil Zencir, Gizem Çalışkan, Dr. Mustafa 
Kotmakçı, Dr. Esra Öztürk Yiğit, Ezgi Öner, Dr. Pakize Cantürk Kılıçkaya and 
my bachelor friend Pelin Dinsel. 
I wish to thank my colleagues and friends; Ana Sosa Fajardo, Quentin 
Bertrand, Laura Lemel, Lynda Djerbal, Rana Elmasri, Silvia Achilli, Marko 
Nedelkovich, Daniel Thedie, Tomas Hosek, Simon Harris, Raleb Taher, Clarissa 
Liesche, Joël Beaudouin, and Joyce Woodhouse for their pleasant company in 
Grenoble during my PhD and further. 
This work is dedicated to my mother, Deniz Durgut and my dearest brother, 
Hakan Şenarısoy who always love me and believe in me. They supported me in 
any case. I would also like to thank my aunt Şeniz Tosun, my uncle Oğuz Durgut, 
and my cousins Gizem and Nerin Tosun for their valuable support. 
My PhD study was supported by The Scientific and Technological Research 
Council of Turkey (TUBITAK) 2214/B International Joint PhD Fellowship 
Programme and by the Labex GRAL.  
 
 
 
 
x 
  
 
 
 
 
xi 
TABLE OF CONTENTS 
PAGE 
 
 
ABSTRACT ..................................................................................................... iii 
RÉSUMÉ .......................................................................................................... v 
ÖZET… .......................................................................................................... vii 
ACKNOWLEDGEMENTS .............................................................................. ix 
LIST OF FIGURES ......................................................................................... xv 
LIST OF TABLES .......................................................................................... xxi 
LIST OF ABBREVIATIONS ....................................................................... xxiii 
Chapter 1. Introduction ...................................................................................... 1 
Summary ........................................................................................................... 3 
1.1 Cancer and its treatment ............................................................................. 11 
1.2. Acquired resistance to chemotherapy ........................................................ 13 
1.2.1. Alterations of drug metabolism and membrane transport ..................... 14 
1.2.2. Failure to induce apoptosis .................................................................. 15 
1.2.3. Enhanced DNA repair pathways .......................................................... 16 
1.2.4. Changes in drug target or drug target level .......................................... 18 
1.3. Y-box Binding Protein 1 as a prognostic marker of drug resistance ........ 19 
1.3.1. Protein properties of YB-1 .................................................................. 20 
1.3.2. Functions of YB-1 in cells ................................................................... 22 
1.4. Importance of protein-protein interactions in cellular processes .............. 24 
1.4.1. Methods for identification of PPI ........................................................ 24 
1.4.2. Chemical library screening in order to find PPI inhibitors.................... 25 
1.4.2.1. Fluorescence Resonance Energy Transfer ............................................ 26 
1.4.2.2. Homogeneous Time-Resolved Fluorescence (HTRF) Assay ................ 28 
1.4.2.3. Amplified Luminescent Proximity Homogeneous (AlphaScreen) Assay29 
1.5. Human Endonuclease III (hNTH1) and its role in Base Excision Repair . 30 
 
 
 
 
xii 
1.5.1. Base Excision Repair Pathway............................................................. 30 
1.5.2. Human Endonuclease III (hNTH1) ...................................................... 34 
1.6. Preliminary data obtained for the study of YB-1/hNTH1 complex .......... 38 
1.7. DNA topoisomerase I as an anticancer drug target .................................. 39 
1.7.1. DNA Topology....................................................................................... 40 
1.7.2. DNA Topoisomerases ............................................................................ 41 
1.7.3. Human Topoisomerase I (hTopoI) .......................................................... 44 
Objectives ........................................................................................................ 49 
Chapter 2. Materials and Methods .................................................................... 51 
Summary ......................................................................................................... 53 
2.1. Cloning ..................................................................................................... 57 
2.1.1. Mammalian Expression Vector ............................................................... 59 
2.1.2. Bacterial Expression Vector ................................................................... 60 
2.1.2.1. Fluorescent Protein Coupled Constructs .............................................. 61 
2.1.2.2. Biosensor constructs ............................................................................ 61 
2.2. Protein expression and purification ............................................................ 63 
2.2.1. Expression and purification of fluorescent proteins ................................. 63 
2.2.2. Expression and purification of fluorescent protein fusion proteins, 
Biosensor constructs and human Topoisomerase I (hTopoI) ............................. 63 
2.2.3. Large-scale purification of Biosensor 1 for chemical library screening ... 67 
2.2.4. Preparation of proteins for AlphaScreen Assay ....................................... 67 
2.3. In vitro Fluorescence Resonance Energy Transfer (FRET) measurements . 68 
2.4. In vitro high-throughput screening with Biosensor 1.................................. 71 
2.4.1. Optimization of Biosensor 1 FRET measurements .................................. 71 
2.4.2. Chemical library screening at CMBA platform ....................................... 72 
2.5. AlphaScreen Assay ................................................................................... 75 
2.6. DNA relaxation activity assays .................................................................. 76 
2.7. Maintenance and transfection of mammalian cells ..................................... 77 
2.8. FRET measurements in mammalian cells .................................................. 78 
 
 
 
 
xiii 
Chapter 3. Results ............................................................................................ 81 
Summary ......................................................................................................... 83 
Part I. YB-1/hNTH1 complex .......................................................................... 91 
3.1. YB-1/hNTH1 interaction in mammalian cells............................................ 91 
3.1.1. FRET measurements in hNTH1-mTQ2 expressing MCF7 cells .............. 92 
3.1.2. Design of Biosensor construct ................................................................ 94 
3.2. YB-1ΔC/hNTH1 interaction in vitro ......................................................... 95 
3.2.1. Purification of fluorescent protein fusion constructs ............................... 95 
3.2.1.1. Fluorescent proteins ............................................................................ 95 
3.2.1.2. YB-1∆C fusion constructs ................................................................... 96 
3.2.1.3. hNTH1 fusion constructs ..................................................................... 97 
3.2.1.4. Biosensor constructs ............................................................................ 99 
3.2.2. FRET measurements ............................................................................ 101 
3.2.2.1. Mixture of individual proteins ........................................................... 101 
3.2.2.2. Biosensors ......................................................................................... 103 
3.3. High-throughput chemical library screening with Biosensor 1 ................. 107 
3.3.1. Optimization of Biosensor 1 ................................................................. 108 
3.3.2. Life Chemicals Protein-Protein Interaction Fragment Library ............... 111 
3.3.3. Prestwick Chemical Library ................................................................. 113 
3.4. Validation of hits from screening ............................................................ 117 
3.4.1. Autofluorescence of compounds .......................................................... 117 
3.4.2. Effect of compounds on the FRET signal of the Fusion construct ......... 118 
3.4.3. Effect of compounds on the FRET signal of Biosensor 1 ...................... 119 
3.4.4. AlphaScreen Assay .............................................................................. 126 
Part II. YB-1-hTopoI complex ....................................................................... 128 
3.5.  YB-1-hTopoI interaction in vitro ............................................................ 128 
3.5.1. Expression and purification of human Topoisomerase I (hTopoI) ......... 128 
3.5.2. DNA relaxation activity assays............................................................. 131 
3.5.3. Stimulation of hTopoI’s relaxation activity by YB-1 ............................ 132 
3.5.4. In vitro FRET measurements ................................................................ 133 
 
 
 
 
xiv 
3.5.4.1. Expression and purification of hTopoI fusion constructs .................... 133 
3.5.4.2. Mixture of individual proteins ........................................................... 135 
3.6. YB-1/hTopoI interaction in mammalian cells .......................................... 137 
3.6.1. FRET measurements in HeLa cells ....................................................... 137 
3.6.2. FRET measurements in MCF7 cells ..................................................... 140 
3.6.3. FRET measurements in PC-3 cells ........................................................ 142 
Chapter 4. Discussion..................................................................................... 145 
Summary ....................................................................................................... 147 
Part I. YB-1/hNTH1 complex ........................................................................ 155 
Part II. YB-1/hTopoI complex ........................................................................ 163 
Part III. Both hNTH1 and hTopoI complexes with YB-1 ................................ 168 
Part IV. Conclusions and Future Prospects ..................................................... 169 
ANNEX ......................................................................................................... 171 
REFERENCES .............................................................................................. 193 
CURRICULUM VITAE ................................................................................ 213 
 
   
 
 
 
 
xv 
LIST OF FIGURES  
FIGURE            PAGE 
1.1. Hallmarks of tumour cells ......................................................................... 12 
1.2. Illustration of the different mechanisms of chemotherapeutic drug 
resistance in tumour cells...................................................................... 14 
1.3. Overview of DNA repair pathways involved in repairing toxic DNA 
lesions formed by cancer treatments ..................................................... 17 
1.4. Schematic diagram of YB-1 domain organization ..................................... 21 
1.5. Structural information about YB-1 ............................................................ 21 
1.6. Schematic diagram showing the numerous functions of YB-1 that affect all 
hallmarks of cancer .............................................................................. 22 
1.7. Jablonski diagram showing the various steps involved in fluorescence 
excitation and emission ........................................................................ 26 
1.8. Illustration of FRET principle ................................................................... 27 
1.9. Principle of HTRF assay ........................................................................... 28 
1.10. Illustration of AlphaScreen Assay ........................................................... 30 
1.11. Schematic diagram illustrating the various steps and enzymes involved in 
Base Excision Repair ............................................................................ 33 
1.12. Schematic diagram of hNTH1 domain organization ................................ 34 
1.13. The 3D structure of EndoIII-1 from Deinococcus radiadurans ................ 35 
1.14. Pyrimidine-derived lesions excised by hNTH1 ........................................ 36 
1.15. Schematic illustration of the bifunctional reaction mechanism catalyzed 
by hNTH1 and the effect of XPG, APE1, and YB-1 on the regulation of 
its activity............................................................................................. 37 
1.16. Stimulation of hNTH1 AP-lyase activity by YB-1 ................................... 38 
1.17. AlphaScreen binding assays of YB-1 and hNTH1 ................................... 39 
1.18. Illustration of the different DNA topologies. ........................................... 41 
1.19. Reactions of Type I and Type II topoisomerases ..................................... 43 
1.20. Mechanism of Human Topoisomerase I targeting drugs .......................... 44 
1.21. The structure and domain organization of hTopoI ................................... 45 
 
 
 
 
xvi 
1.22. Active site of hTopoI and its reaction ...................................................... 46 
1.23. hTopoI-mediated DNA relaxation by controlled rotation ......................... 47 
1.24. Schematic illustration of the complex and diverse roles of YB-1 in 
regulating the sensitivity and resistance of tumour cells to 
chemotherapeutic drugs ........................................................................ 49 
2.1. Illustration of the domain organisation of YB1, hNTH1 and hTopoI and 
their various constructs used in this study ............................................. 57 
2.2. Strategies used to assemble the complete hTopoI gene using the three 
fragments obtained from Eurofins MWG .............................................. 58 
2.3. Maps of pEGFP-C1 and N-1 mammalian expression vectors ..................... 59 
2.4. Maps of bacterial expression vectors used for protein expressions ............. 60 
2.5. Illustration of the purification protocol steps used in our various protein 
purifications.......................................................................................... 64 
2.6. Excitation and emission spectra of mTQ2 and sYFP2 fluorescent proteins 
used in this study .................................................................................. 68 
2.7. Schematic representation of the FRET measurements performed in order to 
calculate the FRET efficiency ............................................................... 69 
2.8. Fluorescence spectra showed spill-over factors between channels.............. 70 
2.9. Illustration of screening plates ................................................................... 73 
2.10. Representative agarose gel image to show the mobility of the supercoiled 
substrate, the nicked circles, and the relaxed topoisomers ..................... 76 
2.11. Illustration of the confocal, spinning disk microscopy platform setup used 
for the acceptor photobleaching experiments on fixed cells. .................. 78 
3.1. MCF7 cells transfected with hNTH1-mTQ2, YB-1-sYFP2 and YB-1ΔC-
sYFP2................................................................................................... 92 
3.2. hNTH1-YB-1 FRET measurements in transfected MCF7 cells .................. 93 
3.3. Biosensor design ....................................................................................... 94 
3.4. Example of a hNTH1-YB-1 FRET measurement in MCF7 cells transfected 
with Biosensor 1 ................................................................................... 95 
3.5. Illustration of fluorescent proteins used in our work .................................. 95 
3.6. Example of Stain-Free gel image of fluorescent proteins ........................... 96 
3.7. Illustration of YB-1∆C constructs fused to sYFP2 used in our work .......... 96 
 
 
 
 
xvii 
3.8. Illustration of the different chromatographic steps used to purify YB-1∆C 
fusion constructs................................................................................... 97 
3.9. Illustration of hNTH1 constructs fused to mTQ2 used in our work ............ 97 
3.10. Illustration of the different chromatographic steps used to purify hNTH1 
fusion constructs................................................................................... 98 
3.11. NtailhNTH1-mTQ2 ion-exchange chromatography. ................................ 98 
3.12. Illustration of the Biosensor constructs used in our work ......................... 99 
3.13. Representative gels and chromatograms of Biosensor 1 purification ...... 100 
3.14. Stain-free gel analysis of purified Biosensor constructs ......................... 100 
3.15. mTQ2 and sYFP2 spectra of the sYFP2 and mTQ2 alone and mixed in a 
1:1 ratio, and sYFP2-mTQ2 fusion construct at 1.5µM in 200mM NaCl 
GF buffer ........................................................................................... 101 
3.16. FRET efficiencies of individual protein mixes of hNTH1 and YB-1C 
constructs ........................................................................................... 102 
3.17. FRET measurements of Biosensor 1 and its comparison with Fusion 
construct ............................................................................................. 103 
3.18. FRET measurements of all Biosensors and Fusion construct at different 
NaCl concentrations ........................................................................... 104 
3.19. FRET efficiencies of Fusion and Biosensor constructs at 1 μM 
concentration in 50 mM NaCl in the presence of 6 M urea.................. 105 
3.20. FRET measurements in order to find a potential competitor of YB-
1/hNTH1 interaction for Biosensor 1 construct ................................... 106 
3.21. FRET measurements of Fusion and Biosensor constructs at different 
protein concentrations in buffer containing 50mM NaCl ..................... 107 
3.22. Stability of FRET signal of 0.2 µM Fusion and Biosensor 1 construct in 
presence of increasing amounts of DMSO .......................................... 108 
3.23.Inhibition of Biosensor 1 FRET by addition of hNTH1 DNA substrate .. 109 
3.24. Stability of FRET signal of Biosensor 1 construct during 2 hours .......... 109 
3.25. Equation of Z' factor and categorization of screening assay by the value 
of the Z' factor .................................................................................... 110 
3.26. Overall results obtained from the first HTS of Life Chemicals PPI library111 
3.27. Overall results obtained from the second HTS of Life Chemicals PPI 
library with selected 30 compounds .................................................... 112 
 
 
 
 
xviii 
3.28. Potential hits identified in Life Chemicals PPI library ............................ 113 
3.29. Overall results obtained from the first HTS of Prestwick Chemical library114 
3.30. Overall results obtained from the secondary HTS of Prestwick Chemical 
library with 30 selected compounds .................................................... 115 
3.31. Characterisation of the top 8 hits identified from the Prestwick chemical 
library ................................................................................................. 115 
3.32. Effect of selected compounds on the FRET efficiency of the Fusion 
construct ............................................................................................. 119 
3.33. Inhibition of Biosensor 1 FRET by Life Chemicals test compounds ...... 120 
3.34. Inhibition of Biosensor 1 FRET by seven Prestwick compounds ........... 121 
3.35. Comparison of the extent of inhibition of seven selected Prestwick 
compounds from different sources ...................................................... 122 
3.36. Spectral analysis of Prestwick compounds ............................................. 123 
3.37. Dose response curves of selected Prestwick hits ordered from Sigma, 
dissolved in DMSO and stored at 4ºC for 2 days or 3 months prior to 
measurements ..................................................................................... 124 
3.38. Dose response curves of seven Prestwick hits provided by CMBA 
platform .............................................................................................. 125 
3.39. Dose response curves of selected Prestwick hits ordered from Sigma and 
stored at 4ºC for 2 days determined by AlphaScreen assay .................. 127 
3.40. Illustration of hTopoI constructs used in our work ................................. 128 
3.41. Purification of hTopoI-FL and hTopoI-70 ............................................. 129 
3.42. Mass spectrometry analysis of hTopoI-FL and hTopoI-70 fractions ....... 130 
3.43. DNA relaxation activity of purified hTopoI ........................................... 131 
3.44. DNA relaxation activity of wild-type and K172A hTopoI ...................... 131 
3.45. Inhibition of the DNA relaxation activity of hTopoI by CPT ................. 132 
3.46. Stimulation of hTopoI DNA relaxation activity by YB-1∆C .................. 133 
3.47. Illustration of hTopoI fusion constructs used in our work ...................... 134 
3.48. Purification of hTopoI-mTQ2 ................................................................ 134 
3.49. Representative gel of the purified proteins for in vitro FRET 
measurements ..................................................................................... 135 
 
 
 
 
xix 
3.50. FRET efficiencies of individual protein mixes of hTopoI and YB-1C 
constructs ........................................................................................... 136 
3.51. Effect of salt concentration on YB-1/hTopoI interaction........................ 137 
3.52. Schematic illustration of mammalian expression vector constructs used 
for in vivo FRET experiments. ............................................................ 137 
3.53. Nuclear localisation of hTopoI-mTQ2 in HeLa cells ............................. 138 
3.54. Schematic illustration of 2A co-expression constructs used in mammalian 
cells .................................................................................................... 139 
3.55. FRET measurements between YB-1C and hTopoI in HeLa cells. ........ 139 
3.56. FRET measurements between YB-1C and hTopoI in MCF7 cells using 
the 2A constructs ................................................................................ 140 
3.57. FRET measurements in MCF7 cells co-transfected with YB-1C and 
hTopoI ............................................................................................... 142 
3.58. Cellular distribution of sYFP2 and mTQ2 signals in PC-3 cells 
transfected with 2A constructs ............................................................ 143 
3.59. FRET measurements in PC-3 cells co-transfected with YB-1C and 
hTopoI ............................................................................................... 143 
4.1. The steps of high throughput chemical library screening with Biosensor 1 
in order to find potential inhibitors of YB-1/hNTH1 complex ............. 158 
 
  
 
 
 
 
xx 
  
 
 
 
 
xxi 
LIST OF TABLES  
TABLE            PAGE 
1.1. Classification of human DNA topoisomerases and their properties, 
activities, and mechanisms ................................................................... 42 
2.1. Alpha Factor calculation with mTQ2 and sYFP2 fluorescent proteins ....... 71 
3.1.  Properties of purified hNTH1 fusion proteins ........................................... 99 
3.2.  Properties of purified Biosensor proteins ................................................ 101 
3.3. Z' factor values obtained for our Biosensor 1 assay ................................. 110 
3.4. List of compounds from Prestwick Chemical Library after second 
screening ............................................................................................ 116 
3.5. The level of intrinsic fluorescence of potential hits from Life Chemicals 
and Prestwick Chemical Library at 50μM concentration ..................... 118 
3.6. IC50 values of Prestwick hits ordered from Sigma .................................. 125 
3.7. IC50 values of Prestwick hits provided by CMBA platform .................... 125 
3.8. IC50 values of Prestwick hits determined by AlphaScreen assay ............. 127 
3.9.  Properties of purified hTopoI proteins .................................................... 130 
3.10.  Properties of purified hTopoI fused to mTQ2 proteins .......................... 134 
  
 
 
 
 
xxii 
  
 
 
 
 
xxiii 
LIST OF ABBREVIATIONS 
3D Three-dimensional 
8-oxoG 8-oxo-7,8-dihydroguanine 
βME β-mercaptoethanol 
BSA Bovine serum albumin 
cDNA Complementary Deoxyribonucleic Acid 
CV Column Volume 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DMSO Dimethyl sulfoxide 
dsDNA Double Stranded Deoxyribonucleic Acid 
ECACC European Collection of Authenticated Cell Cultures 
EDTA Ethylenediaminetetraacetic acid 
EMA European Medicines Agency 
EMSA Electrophoretic Mobility Shift Assay  
FDA Food and Drug Administration 
FMDV Foot-and-mouth disease virus 
FPLC Fast Protein Liquid Chromatography 
GF Gel Filtration 
IC50 Half Maximal Inhibitory Concentration 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
mRNA Messenger Ribonucleic Acid 
mRNP Messenger Ribonucleoprotein 
PCR Polymerase Chain Reaction 
ROI Region of Interest 
SDS Sodium dodecyl sulfate 
TCEP Tris(2-carboxyethyl)phosphine 
Tg Thymine glycol 
THF Tetrahydrofuran 
UV Ultraviolet 
  
 
 
 
 
xxiv 
  
 
 
 
 
1 
 
 
 
 
 
 
Chapter 1. Introduction 
  
 
 
 
 
2 
  
 
 
 
 
3 
Summary 
FRENCH 
Le cancer tue des millions de personnes chaque année. C'est une maladie 
génétique dans laquelle un groupe de cellules anormales se multiplie de façon 
incontrôlable en ne tenant pas compte des règles normales de la division cellulaire 
et peuvent envahir les tissus voisins. Il existe différents types de thérapies 
anticancéreuses : chirurgie, radiothérapie, chimiothérapie, immunothérapie, 
endocrinothérapie et thérapie génique. La chimiothérapie est l'un des principaux 
modes de traitement contre le cancer et peut être définie comme l'utilisation de 
médicaments ayant une toxicité sélective contre les cellules tumorales. Le 
développement de la résistance aux médicaments dans les cellules tumorales est 
un problème majeur de chimiothérapie et provoque des échecs de traitement du 
cancer. La résistance acquise peut se développer pendant le traitement de tumeurs 
initialement sensibles et peut être causée par des mutations survenant pendant le 
traitement, ainsi que par diverses autres réponses adaptatives. Il existe de 
nombreux mécanismes de résistance aux médicaments anticancéreux dans les 
cellules tumorales, tels que le transport membranaire altéré impliquant la p-
glycoprotéine produite par le gène de résistance multiple (MDR), les 
modifications du métabolisme des médicaments et l'interaction médicamenteuse 
avec d'autres molécules subcellulaires, des protéines du cycle cellulaire mutées 
telles que p53, une réparation améliorée de l'ADN ou une enzyme cible altérée. 
La protéine multifonctionnelle Y-box Binding 1 (YB-1) est un marqueur 
métastatique établi, et une expression élevée de YB-1 est en corrélation avec 
l'agressivité tumorale et la faible survie des patients dans divers types de tumeurs.  
YB-1 est un membre de la famille de protéines se liant à l'ADN/ARN avec des 
domaines de choc froid (CSD) évolutifs. La protéine YB-1 humaine comprend 
trois domaines fonctionnels: (i) Le domaine N-terminal variable est riche en 
résidus alanine et proline et est donc également appelé domaine A / P, (ii) Le CSD 
agit comme un domaine de liaison d'acide nucléique, (iii) la région C-terminale 
hydrophile de YB-1 contient des répétitions alternées de groupes d'acides aminés 
acides et basiques et a été décrite comme se liant à la fois aux acides nucléiques et 
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à un certain nombre des protéines différentes y compris YB-1 elle-même. Le plus 
souvent, une majorité de YB-1 est dans le cytoplasme en association avec l'ARN. 
Cependant, en réponse à certains signaux intra- et extracellulaires, une partie 
significative de YB-1 peut se déplacer vers le noyau de la cellule. Lorsque YB-1 
se retrouve dans le noyau, elle devient impliquée dans la transcription de divers 
gènes, dans la réparation et la réplication de l'ADN, et dans l'épissage de pré-
ARNm. Il a été montré qu’YB-1 peut interagir avec l'ADN glycosylase hNTH1 à 
travers un criblage double-hybride de levure et une augmentation de l'association 
YB-1/hNTH1 a été observée dans la lignée cellulaire de tumeur mammaire MCF7 
dans des conditions spécifiques d'endommagement de l'ADN. YB-1 peut 
également interagir directement avec la Topoisomérase I humaine (hTopoI) et 
stimuler l’activité de relaxation de l'ADN de celle-ci. Cette interaction améliore la 
sensibilité à la Camptothécine (CPT) dans les cellules PC-3 du cancer de la 
prostate humain, mais pas dans les cellules HeLa du cancer du col de l'utérus. 
Pendant mes études de doctorat, je me suis concentrée sur les interactions de YB-
1 avec la protéine de réparation de l'ADN NTH1 et l'ADN Topoisomérase I, et 
leurs implications dans la résistance aux médicaments anticancéreux. 
La NTH1 humaine est une ADN glycosylase bifonctionnelle, responsable de 
l'élimination des pyrimidines oxydées à l'étape initiale de réparation d'excision de 
base. Les ADN glycosylases bifonctionnelles, en plus de leur activité glycosylase, 
ont une activité AP-lyase. Après l'élimination de la base lésée, elles clivent le brin 
d'ADN 3' au site AP par β-élimination, ce qui nécessite un traitement final avant 
la réparation ultérieure. Les produits finaux de la β-élimination peuvent être traités 
par APE1 générant une extrémité 3'-OH, ou par l'ADN polymérase β, l'enzyme 
qui effectue également la tâche de remplacer la base manquante. La réparation est 
ensuite complétée par ligature, une étape qui est généralement catalysée par 
l'ADN ligase III en association avec son partenaire de liaison XRCC1. hNTH1 est 
une protéine de 34 kDa, constituée d'un domaine catalytique composé de deux 
sous-domaines α-hélicoïdaux contenant un motif hélice-tour-hélice et une boucle 
groupée [4Fe-4S], et un domaine N-terminal spécifique des mammifères. La 
réaction enzymatique de hNTH1 est régulée par XPG, APE1 et YB-1. 
L'interaction directe de YB-1 avec hNTH1 entraine une augmentation de l'activité 
de la lyase de hNTH1. 
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L'ADN Topoisomérase I est un membre de la famille des enzymes ADN 
topoisomérases. Ce sont des enzymes essentielles, qui sont responsables de la 
régulation de la topologie de l'ADN dans les cellules. Elles sont impliquées dans 
des fonctions cellulaires vitales telles que la réplication, la transcription, la 
recombinaison et la réparation de l'ADN. Ces enzymes catalysent les changements 
de conformation de la topologie de l'ADN en générant la rupture concertée et le 
retour des brins d'ADN sans modifier la structure chimique de l'ADN. En raison 
de leur rôle crucial dans la prolifération des cellules, elles sont la cible de 
médicaments anticancéreux. Les topoisomérases sont divisées en deux classes 
principales: les type I, qui clivent l'ADN simple brin, et les type II, qui clivent 
l'ADN double brin. Les topoisomérases de type I sont subdivisées en deux sous-
groupes mécaniquement différents: les type IA, s’attachent à la cassure simple 
brin au niveau du groupe 5'-phosphate, et les enzymes de type IB se lient au 
groupe 3'-phosphate du site de rupture. hTopoI est une topoisomérase de type IB 
et résout les problèmes topologiques de l'ADN en générant des brins d'ADN 
uniques réversibles. hTopoI est une enzyme monomérique de 91 kDa qui forme 
une pince protéique asymétrique qui entoure l'ADN double brin. hTopoI contient 
quatre domaines: un domaine N-terminal mal conservé, un domaine central 
hautement conservé, un domaine lieur formé par une paire étendue d'hélices α et 
un domaine C-terminal conservé. L'activité de relaxation de l'ADN de hTopoI est 
régulée par p53, NKX3.1, PARP-1 et YB-1. YB-1 peut interagir directement avec 
hTopoI et stimuler son activité de relaxation. 
Les objectifs de mon travail de thèse étaient d'étudier la formation des 
complexes YB-1/hNTH1 et YB-1/hTopoI in vitro et in vivo (dans diverses lignées 
cellulaires de mammifères) en utilisant des approches FRET et de concevoir et 
optimiser un Biosenseur à base de FRET, qui pourrait être utilisé pour le criblage 
haut débit de chimiothèques afin d'identifier des inhibiteurs potentiels de ces 
complexes pour une utilisation en thérapie combinée.  
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Özet 
TURKISH 
Kanser, her yıl milyonlarca insanın ölümüne neden olmaktadır. Bir grup 
anormal hücrenin, hücre bölünmesi kurallarını göz ardı ederek kontrolsüz bir 
şekilde bölündüğü ve yakın dokuları istila edebildiği bir genetik hastalıktır. Farklı 
türde antikanser tedavileri vardır. Bunlara bazı örnekler; cerrahi, radyoterapi, 
kemoterapi, immünoterapi, endokrin tedavisi ve gen tedavisidir. Kemoterapi, 
kansere karşı başlıca tedavi yöntemlerinden biridir ve tümör hücrelerine karşı 
seçici toksisiteli ilaçların kullanımı olarak tanımlanabilir. Tümör hücrelerinde ilaç 
direncinin gelişmesi önemli bir sorundur ve kanser tedavisi başarısızlıklarına 
neden olmaktadır. Kazanılmış ilaç direnci, başlangıçta duyarlı olan tümörlerin 
tedavisi sırasında gelişmektedir ve tedavi sırasında oluşan mutasyonların yanı sıra 
çeşitli diğer adaptif yanıtlar yoluyla da ortaya çıkabilmektedir. Tümör 
hücrelerinde antikanser ilaç direncinin gelişmesinde birçok mekanizma rol oynar. 
Çoklu ilaç direnci geninin ürünü p-glikoproteini içeren değiştirilmiş membran 
taşınması, ilaç metabolizmalarındaki değişiklikler ve diğer alt-hücresel moleküller 
ile ilaç etkileşimi, mutasyona uğramış p53 gibi hücre döngüsü proteinlerinin 
sonucunda apoptoz uyarımının başarısızlığa uğraması, geliştirilmiş DNA onarımı 
veya değiştirilmiş hedef enzim bunlar arasındadır. Çok fonksiyonlu Y-box 
bağlanma proteini 1 (YB-1) bir metastatik belirteçtir. YB-1'in yüksek ifadesi, 
tümör agresivitesi ve çeşitli tümör tiplerinde zayıf hasta sağkalımı ile 
ilişkilendirilmiştir.  
YB-1, evrimsel eski soğuk şok domainlerine (CSD) sahip DNA/RNA 
bağlayıcı ailesi proteinlerinin bir üyesidir. İnsan YB-1 proteini üç fonksiyonel 
domainden oluşur: (i) Değişken N-terminal domaini alanin ve prolin kalıntıları 
bakımından zengindir ve bu nedenle de A/P domaini olarak adlandırılır, (ii) CSD, 
bir nükleik asit bağlama alanı olarak davranır (iii) YB-1'in hidrofilik C-terminal 
bölgesi, asidik ve bazik amino asit kümelerinin dönüşümlü tekrarlarını içerir ve 
hem nükleik asitlere hem de YB-1'in kendisi de dahil olmak üzere bir dizi farklı 
proteinlere bağlandığı belirlenmiştir. Çoğu zaman, YB-1'in büyük bir kısmı, RNA 
ile bağlantılı olarak sitoplazmadadır. Bununla birlikte, bazı hücre içi ve hücre dışı 
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sinyallere cevap olarak YB-1'in önemli bir kısmı hücre çekirdeğine hareket 
edebilir. YB-1 çekirdeğe yer değiştirdiğinde, çeşitli genlerin transkripsiyonunda, 
DNA onarımında ve replikasyonunda ve mRNA uç birleştirmede yer alır. YB-
1'in, maya iki hibrit taraması ile DNA glikozilazı hNTH1 ile etkileştiği 
bulunmuştur ve spesifik DNA hasarı koşulları altında MCF7 meme tümörü hücre 
hattında YB-1/hNTH1 kompleksinde bir artış gözlenmiştir. YB-1'in İnsan 
Topoizomeraz I (hTopoI) ile doğrudan etkileştiği ve DNA relaksasyon aktivitesini 
arttırdığı bulunmuştur. Bu etkileşim, insan prostat kanseri PC-3 hücrelerinde 
Camptothecin (CPT) duyarlılığını artırır, ancak servikal kanser HeLa hücrelerinde 
bu artış gözlenmemiştir. Çalışmamızda YB-1'in insan DNA onarım proteini 
NTH1 ve insan DNA topoizomeraz I ile etkileşimlerine ve bunların antikanser 
ilaç direncindeki etkilerine odaklanılmıştır.  
İnsan NTH1, baz eksizyon onarımının ilk basamağında oksitlenmiş 
pirimidinlerin çıkarılmasından sorumlu iki fonksiyonlu bir DNA glikozilazdır. 
Glikosilaz aktivitelerinin yanı sıra iki fonksiyonlu DNA glikozilazlar, AP-liyaz 
aktivitesine sahiptirler. Baz lezyonunun çıkarılmasından sonra, AP bölgesinin 3' 
ucunu β-eleminasyonu ile sonraki onarımdan önce son işlem gerektiren DNA 
uçları oluşturarak keserler. Βeta-eliminasyonunun son ürünleri, APE1 tarafından 
3'-OH ucu oluşturacak şekilde işlenir. DNA polimeraz β, oluşan tek baz 
boşluğunu doldurma görevini yerine getiren enzimdir. Onarım daha sonra 
bağlanma partneri XRCC1 ile birlikte DNA ligaz III ile katalize edilen çentiğin 
ligasyonu ile tamamlanır. hNTH1, bir sarmal-hairpin-sarmal motifi ve bir [4Fe-
4S] küme döngüsü ve ilave bir memelilere özgü N-terminal domaini içeren iki α-
sarmal alt domainden oluşan bir katalitik domainden oluşan bir 34 kDa proteindir. 
hNTH1’in enzimatik aktivitesi XPG, APE1 ve YB-1 tarafından düzenlenir. 
hNTH1'in YB-1 ile doğrudan etkileşiminin, hNTH1'in liyaz aktivitesini arttırdığı 
gösterilmiştir.  
DNA topoizomeraz I, DNA topoizomeraz enzim ailesinin bir üyesidir. 
Bunlar, hücrelerdeki DNA topolojisini düzenlemekten sorumlu olan temel 
enzimlerdir. Replikasyon, transkripsiyon, rekombinasyon ve DNA onarımı gibi 
hayati hücresel işlevlerde rol alırlar. Bu enzimler, DNA topolojisindeki yapısal 
değişiklikleri, DNA'nın kimyasal yapısını değiştirmeden, DNA zincirlerinin 
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kontrollü kırılmasını ve yeniden birleşmesini sağlayarak katalize ederler. 
Proliferatif hücrelerde önemli rolleri nedeniyle, bunlar antikanser ilaçlarının 
hedefleri olmuşlardır. Topoizomerazlar iki ana sınıfa ayrılır: tek zincirli DNA'yı 
kesen tip I ve çift zincirli DNA'yı kesen tip II. Tip I topoizomerazlar, mekanik 
olarak farklı iki alt gruba ayrılır: tek zincir kırıklarında 5'-fosfata bağlanan tip IA, 
ve kırılma bölgesindeki 3'-fosfata bağlanan IB enzimleri. hTopoI, bir Tip IB 
topoizomerazıdır ve geri dönüşümlü tek DNA zinciri kırıkları üreterek DNA'nın 
topolojik problemlerini çözer. hTopoI, çift zincirli DNA'yı çevreleyen bir 
asimetrik protein kelepçesi oluşturan 91 kDa'lık bir monomerik enzimdir. hTopoI, 
dört domain içerir. Zayıf olarak korunmuş bir N-terminal domaini, yüksek ölçüde 
korunmuş bir çekirdek domain, uzatılmış bir çift heliks ile oluşturulan bir 
bağlayıcı domain ve korunmuş bir C-terminal domaini. hTopoI'nin DNA 
relaksasyon aktivitesi p53, NKX3.1, PARP-1 ve YB-1 ile düzenlenir. YB-1'in 
hTopoI ile doğrudan etkileştiği ve relaksasyon aktivitesini uyardığı gösterilmiştir.  
Tez çalışmamın amacı, FRET yaklaşımını kullanarak in vitro ve in vivo 
(çeşitli memeli hücre hatlarında) YB-1/hNTH1 ve YB-1/hTopoI 
komplekslerinin oluşumunu araştırmak ve kombinasyon terapisinde 
kullanım için bu komplekslerin potansiyel inhibitörlerini tanımlamak 
amacıyla yüksek verimli kimyasal kütüphane taraması için kullanılabilir bir 
FRET-bazlı biyosensörü tasarlamak ve optimize etmektir.   
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1.1 Cancer and its treatment 
Cancer causes millions of people to die each year. It is a genetic disease in 
which a group of abnormal cells grow uncontrollably by disregarding the normal 
rules of cell division and can invade nearby tissues (Bertram, 2000). Normal cells 
in the human body are constantly subject to signals that dictate whether the cell 
should divide, differentiate into another cell or die. But cancer cells develop a 
degree of autonomy from these signals, resulting in uncontrolled growth and 
proliferation. If this uncontrolled proliferation is allowed to continue and spread, it 
can be fatal. In fact, almost 90% of cancer-related deaths are due to a tumour 
spreading - a process called metastasis (Hanahan and Weinberg, 2011).  
The development of cancer called carcinogenesis/oncogenesis is a complex 
multi-step process involving the accumulation of genetic and epigenetic 
alterations over time. These alterations can cause genomic instability and 
mutations in genes critical for the control of cell growth. At the end of this 
process, a normal cell is transformed into a cancer cell (Hoeijmakers, 2001). 
Several molecular pathways take part in this complex transformation. Cancer cells 
acquire several biological capabilities during this process, which are referred to as 
hallmarks of cancer providing a concept for understanding the complex cancer 
biology (Hanahan and Weinberg, 2011). The six principle hallmarks of cancer are: 
(i) growth signal autonomy, (ii) evasion of growth suppressors, (iii) resistance to 
cell death, (iv) replicative immortality, (v) induction of angiogenesis, and (vi) 
activation of invasion and metastasis (Figure 1.1). There are two other emerging 
hallmarks: the ability to avoid the immune system and to reprogram energy 
metabolism (Hanahan and Weinberg, 2011).  
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Figure 1.1. Hallmarks of tumour cells. Light pink rectangles specify the eight hallmarks; white 
rectangles specify two enabling characteristics that are necessary for obtaining the hallmarks of 
cancer. Taken from Pecorino, 2008. 
Because cancer is a result of genomic instability caused by random 
mutations, each patient harbours a different cancer regarding which genes are 
mutated, regarding the nature of each mutation and regarding the sequence of 
appearance of these mutations. This can explain why different patients suffering 
from the same cancer may respond differently to a same treatment (Marin et al., 
2012; Gerlinger et al., 2012). To treat human cancer, drugs that interfere with each 
of the acquired capabilities necessary for tumour growth and progression have 
been developed and are in clinical trials or in some cases approved for clinical use 
(Hanahan and Weinberg, 2011). It is thus useful to understand molecular 
pathways in cells in order to understand carcinogenesis but also to develop new, 
more efficient therapeutic strategies (Farrell, 2011). 
There are different types of anticancer therapies: surgery, radiotherapy, 
chemotherapy, immunotherapy, endocrine therapy and gene therapy 
(Urruticoechea et al., 2010). Depending on the type of cancer, one or more of 
these treatments are selected and applied to patients. Surgery is not applicable for 
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all cases, making chemotherapy one of the principal modes of treatment against 
cancer.  
Chemotherapy can be defined as the use of drugs with selective toxicity 
against tumour cells. These chemotherapeutic agents, such as EGFR, cyclin-
dependent kinase, telomerase, PARP and topoisomerase inhibitors, selectively 
target one or more hallmarks of cancer. Such therapies mostly kill highly 
proliferating cells by generating DNA damage. DNA damage causes cell-cycle 
arrest and leads to apoptosis. However, cancer cells manage to find ways to 
escape from death after exposure to therapeutic agents.  
Development of drug resistance in tumour cells is a major problem of 
chemotherapy and causes cancer treatment failures. Resistance to anticancer drugs 
can be divided into two categories: intrinsic and acquired. Intrinsic resistance 
occurs in the tumour cells, which have genetic alterations existing before 
treatment that make the therapy ineffective. Acquired drug resistance can develop 
during treatment of tumours that were initially sensitive and can be caused by 
mutations arising during treatment, as well as through various other adaptive 
responses (Zahreddine and Borden, 2013). 
1.2. Acquired resistance to chemotherapy 
There are many mechanisms of anticancer drug resistance in tumour cells, 
such as altered membrane transport involving p-glycoprotein product of multidrug 
resistance gene (MDR), changes in drug metabolisms and drug interaction with 
other subcellular molecules, failure to induce apoptosis as a result of mutated cell 
cycle proteins such as p53, enhanced DNA repair or altered target enzyme (Figure 
1.2) (Housman et al., 2014; Rebucci and Michiels, 2013). Mechanisms of 
resistance can change according to the action of the cytotoxic agent and mutations 
and/or epigenetic changes acquired in the genome of tumour cells.  
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Figure 1.2. Illustration of the different mechanisms of chemotherapeutic drug resistance in tumour 
cells. Taken from (Mansoori et al., 2017). 
There are lots of studies aiming to find a solution to overcome drug 
resistance. The use of combination drug therapy using different classes of drugs, 
inhibition of essential enzymes involved in DNA repair pathway, gene knockout 
using antisense molecules are some examples of approaches used in order to block 
drug resistance. In my study, my work focused on anticancer drug resistance 
mechanisms involving enhanced DNA repair and alterations of the target 
molecule.  
1.2.1. Alterations of drug metabolism and membrane transport 
Lack of prodrug activation or epigenetic silencing of genes involved in drug 
processing are examples of potential causes of resistance and are frequently 
tumour-specific. Drug-metabolizing enzymes take part in the activation and 
deactivation of drugs, and can therefore affect the susceptibility of organs and 
tissues to their therapeutic and toxic effects. Drug-metabolizing enzymes include 
the cytochrome P450 (CYP) system, glutathione-S-transferase (GST) superfamily, 
and uridine diphospho-glucuronosyltransferase (UGT) superfamily (Michael and 
Doherty, 2005). Drugs such as fluorouracil (5-FU) and irinotecan (CPT-11) must 
be converted to their active metabolites to exert their anticancer effects. CPT-11 is 
converted to SN-38 by carboxylesterase (Xu and Villalona-Calero, 2002), and 
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several in vitro studies have indicated that the level of carboxylesterase activity in 
cancer cells is an important determinant of CPT-11 sensitivity (Kojima et al., 
1998; Longley and Johnston, 2005). For many DNA interacting agents, e.g. 
alkylating agents, anthracyclines, and platinum drugs, an important mechanism of 
inactivation is related to the overexpression of GSTs that metabolize the drugs 
into inactive molecules (Kauvar et al., 1998). 
The most studied drug resistance mechanism is the increased drug efflux by 
ATP binding cassette (ABC) membrane transporters. Increasing the release of 
drugs outside the cells results in insufficient accumulation of drug inside the cells 
and decrease in drug efficiency. This mechanism provides a resistance to various 
anticancer drugs that are structurally and functionally different from the initial 
anticancer drug (Glavinas et al., 2004). Three membrane transporters—multidrug 
resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and 
breast cancer resistance protein (BCRP)—are implicated in many drug resistant 
cancers. All three transporters have broad substrate specificity and are able to efflux 
many xenobiotics, including vinca alkaloids, epipodophyllotoxins, anthracyclines, 
taxanes, and kinase inhibitors, from cells (Housman et al., 2014). One of the well-
known members of ABC transporter is MDR1 gene product P-glycoprotein. 
Increased expression of P-glycoprotein has been correlated with drug resistance to 
various anticancer agents (Gottesman et al., 2002). The Y-box Binding Protein 1 
(YB-1), which is the focus of my study, binds to MDR1 gene promoter containing 
Y-boxes and regulates its expression in drug resistant tumours (Kuwano et al., 
2004). 
1.2.2. Failure to induce apoptosis 
The resistance to anticancer drugs can also be due to the fact that in cancer 
cells, apoptotic pathways are frequently dysfunctional. Anti-apoptotic BCL-2 
family members, inhibitors of apoptosis proteins and caspases are key proteins of 
this mechanism (Colmegna et al., 2017). The caspases are a large group of 
proteins that play a central role in apoptosis. They work at two levels: initiator 
caspases (e.g. caspase-2, -8, -9, and -10) are responsible for the initiation of the 
apoptotic pathway and effector caspases (caspase-3, -6, and -7) are responsible for 
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the actual cleavage of cellular components during apoptosis. Decreased levels of 
these proteins or impaired functions can block apoptosis thus contributing to 
resistance. 
The p53 protein is one of the best-known tumour suppressor proteins whose 
mutation acquired oncogenic property. Defects in the p53 tumour suppressor gene 
have been linked to more than 50% of human cancers (Bai and Zhu 2006) because 
it is not only involved in the induction of apoptosis, but it is also a key player in 
cell cycle regulation, development, differentiation, gene amplification, DNA 
recombination, chromosomal segregation, and cellular senescence. Mutations in 
the p53 gene impair the connection between DNA damage (caused by 
chemotherapeutic agents) and activation of apoptosis (Mansoori et al., 2017), 
thereby leading to drug resistance. 
1.2.3. Enhanced DNA repair pathways  
The most common non-surgical cancer treatments function by generating 
DNA damage. Many anticancer drugs induce DNA damage either directly (for 
example, platinum-based drugs) or indirectly (for example, topoisomerase 
inhibitors). Damage to DNA induces several cellular responses that enable the cell 
either to eliminate or cope with the damage or to activate a programmed cell death 
process, presumably to eliminate cells with potentially catastrophic mutations 
(Sancar et al., 2004). DNA double-strand breaks (DSBs) are generally considered 
to be the most toxic of all DNA lesions. Enhanced DNA repair pathways provide 
a resistance to initially effective cytotoxicity of these therapies (Helleday et al., 
2008). 
There are 5 main DNA repair pathways in mammals: Base-excision repair 
(BER), Nucleotide-excision repair (NER), Homolog recombination (HR), Non-
homologous end joining (NHEJ) and Mismatch repair (Hoeijmakers, 2001). Each 
pathway deals with different types of DNA damage and together are responsible 
for genomic stability. Deficiencies in any of these pathways may accelerate the 
process of carcinogenesis and at the same time may cause drug resistance to 
therapies targeting them (Tubbs and Nussenzweig, 2017). Enhanced DNA repair 
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can also cause drug resistance against DNA-damaging agents (Helleday et al., 
2008), since efficient repair of toxic lesions in tumour cells can prevent cell death. 
Cancer cells deficient in one or more DNA repair pathways may be more sensitive 
to therapeutic agents targeting one of the remaining pathways than the 
neighbouring healthy cells. On the other hand, deficiency in the targeted repair 
pathway may result in a loss of sensitivity to the therapeutic agent.   
An overview of the toxic lesions occurring after cancer treatments and the 
major repair pathways involved in reducing their cytotoxicity is provided in 
Figure 1.3 (Helleday et al., 2008). 
	 
Figure 1.3. Overview of DNA repair pathways involved in repairing toxic DNA lesions formed by 
cancer treatments taken from Helleday et al., 2008. NHEJ, non-homologous end joining; SSBR, 
DNA single-strand break repair; HR, homologous recombination; AT, alkyltransferase; TLS, 
translesion synthesis; O2G, DNA dioxygenases; RecQ, RecQ-mediated repair; FA, Fanconi 
anaemia repair pathway; ENDO, endonuclease mediated repair. 
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Ionizing radiation, UV radiation and several anticancer drugs induce 
oxidative stress in tumour cells. Base excision repair is mostly responsible for 
repair of oxidatively induced DNA modifications (Dizdaroglu, 2015). Some of 
DNA repair proteins are promising targets in cancer treatments (Sánchez-Pérez, 
2006) and the proteins involved in BER are increasingly considered as targets for 
cancer treatment (Dianov, 2011). One of the proteins I studied during my PhD, the 
DNA glycosylase hNTH1, plays a role in the early steps of the BER pathway. 
1.2.4. Changes in drug target or drug target level  
Acquired drug resistance may also occur as a result of the alteration of the 
target molecule. During treatment, target proteins can be subjected to several 
mutations and the expression levels of target proteins can increase or decrease. 
These changes in turn affect the efficiency of cytotoxic therapy (Rebucci and 
Michiels, 2013). Resistance to tyrosine kinase inhibitors is an example of this 
mechanism. Imatinib is a specific inhibitor of the kinase resulting from the fusion 
of Bcr and Abl genes. Because of the reactivation of the kinase due to a point 
mutation in the ATP binding domain of the kinase preventing imatinib binding, 
the treatment of patients becomes inefficient (O’Hare et al., 2005). On the other 
hand, in vitro, resistance is most often related to Bcr-Abl mRNA and protein 
overexpression.  
Topoisomerases solve topological problems in DNA ahead of the replication 
fork and of the RNA polymerase during transcription by transiently inducing 
single or double-strand breaks. They are important anticancer agent targets 
(Holden, 2001). The most toxic topoisomerase inhibitors function by stabilizing 
the formation of a DNA-enzyme complex. Mutations occurring in the enzyme can 
influence the formation of the cleavable complex leading to reduce efficiencies of 
the inhibitors. Reduced levels of topoisomerases also play an important role in 
cellular sensitivity to their inhibitors (Beck et al., 1999; Beretta et al., 2013). 
Human topoisomerase I (hTopoI) is also one of the proteins I studied during the 
course of my work. Cellular resistance to hTopoI inhibitor Camptothecin (CPT) 
has been associated with the post-translational modifications of hTopoI and its 
interaction with other proteins that modulate its enzymatic activity 
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(Bandyopadhyay et al., 2012; Horie et al., 2002). Low hTopoI activity may also 
cause a resistance to CPT (Pommier, 2006). hTopoI directly interacts with 
different proteins involved in DNA replication, transcription and repair (Czubaty 
et al., 2005). Some of these interaction partners affect hTopoI’s activity and in 
turn these interactions modulate cellular sensitivity to CPT (Das et al., 2016; Wu 
et al., 2014). 
1.3. Y-box Binding Protein 1 as a prognostic marker of drug 
resistance 
The multifunctional Y-box binding protein 1 (YB-1) is now an established 
metastatic marker, and high expression of YB-1 correlates with tumour 
aggressiveness and poor patient survival in diverse tumour types (Kohno et al., 
2003; Lasham et al., 2013). Many reports associated with drug resistance have 
also shown a possible link between the multifunctional YB-1 and drug resistance 
both in cell cultures and in clinical human tumour samples. It has been shown that 
the extent of YB-1 expression and its localisation correlate with cellular 
sensitivities to the cytotoxic effects of cisplatin and other DNA-damaging agents 
(Ohga et al., 1996, Stavrovskaya et al., 2012). Several studies have indeed 
indicated that the level of nuclear expression of YB-1 is predictive of drug 
resistance and poor prognosis in breast tumours, ovarian cancers, and synovial 
sarcomas (Bargou et al., 1997; Janz et al., 2002; Oda et al., 2003; Rubinstein et 
al., 2002; Yahata et al., 2002; Dahl et al., 2009).  
The mode of action of YB-1 is still unclear. YB-1 regulates the activity of 
the MDR genes MDR1 and LRP and has been suggested to be an early and global 
marker of MDR in tumours (Saji et al., 2003; Vaiman et al., 2006). Several forms 
of p53 have also been shown to cause YB-1 to accumulate in the nucleus, which 
in turn inhibits p53 activity and makes cells more resistant to apoptosis (Zhang et 
al., 2003). The nuclear localisation of YB-1 has also been shown to be induced by 
UV irradiation and a C-terminally truncated form of YB-1 was mainly localized in 
the nucleus (Koike et al., 1997). These studies suggest that YB-1 may itself have a 
key role in self-defence signalling mechanisms, being initiated in response to 
environmental poisons such as oxidative stress or DNA damaging reagents, such 
 
 
 
 
20 
as chemotherapeutic agents.  
1.3.1. Protein properties of YB-1 
YB-1 is a member of the DNA/RNA-binding family of proteins with 
evolutionally ancient cold shock domains (CSD). It is a 324 amino acid-long 
protein (35.9kDa), that exhibits, however, an aberrant electrophoretic mobility 
close to 50kDa (Cohen et al., 2010). It binds to the Y-box, a cis-acting element, 
which regulates gene expression, containing an inverted CCAAT box (Didier et 
al., 1988). Several eukaryotic genes including genes encoding major 
histocompatibility class II antigens, thymidine kinase, proliferating cell nuclear 
antigen, DNA polymerase α, epidermal growth factor receptor, DNA 
topoisomerase IIα and multidrug resistance I protein contain the Y-box binding 
consensus sequence in their regulatory regions (Wolffe et al., 1992; Wolffe, 1994; 
Ladomery and Sommerville, 1995; Asakuno et al., 1994). YB-1 gene is comprised 
of 8 exons and 7 introns spanning 19kb of genomic DNA and is located on 
chromosome 1 p 34 (Toh et al., 1998). 
The human YB-1 protein comprises three functional domains (Wolffe, 
1994) (Figure 1.4). The variable N-terminal domain is rich in alanine and proline 
residues and is therefore also termed A/P domain. The CSD acts as a nucleic acid 
binding domain being involved in both specific and unspecific interactions with 
DNA and RNA (Eliseeva et al., 2011). Structurally, CSD is comprised of a five-
stranded β-barrel (Wistow, 1990; Kloks et al., 2002) (Figure 1.5) containing RNP-
1 and RNP-2 like consensus motifs (Landsman, 1992) and belongs to the β-sheet 
RNA-binding protein group (Graumann and Marahiel, 1996). The hydrophilic C-
terminal region (CTD) of YB-1 contains alternating repeats of acidic and basic 
amino acid clusters and has been described to bind to both nucleic acids and a 
number of different proteins including YB-1 itself (Das et al., 2016; Ise et al., 
1999; Okamoto et al., 2000; Skabkin et al., 2004). Furthermore, the CTD contains 
sequences governing the nucleo-cytoplasmic distribution of YB-1: a non-
canonical nuclear localization signal (NLS, amino acids 186–205) and a 
cytoplasmic retention site (CRS, amino acids 267–293), which prevails over the 
NLS and therefore leads to a mainly cytoplasmic localization of YB-1 (Eliseeva et 
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al., 2011; Lasham et al., 2013).  It contains a cleavage site for the 20S proteasome, 
which provides a regulatory mechanism for nuclear-cytoplasmic transport of YB-
1 when cells are exposed to genotoxic stress (Sorokin et al., 2005). 
The N- and C-terminal domains of YB-1 are predicted to be largely 
disordered. Such proteins are unable to fold spontaneously into stable, well-
defined globular three-dimensional structures but are dynamically disordered and 
fluctuate rapidly over an ensemble of conformations that cover a continuum of 
conformational space ranging from extended statistical coils to collapsed globules 
(Dyson and Wright, 2005). Probably this is the reason why there has been no 
success in determining the three-dimensional structure of the intact YB-1.  
	 
Figure 1.4. Schematic diagram of YB-1 domain organization. A/P domain: Alanine and proline 
rich N-terminal domain. CSD: A cold shock domain. The C-terminal domain (CTD) of YB-
1consists of four alternating clusters of positively (basic) and negatively charged (acidic) amino 
acids, each about 30 amino acids in length (indicated by pluses and minuses). NLS: A nuclear 
localization signal, CRS: A cytoplasmic retention site. Reviewed in Eliseeva et al., 2011. 
	 
Figure 1.5. Structural information about YB-1. Ribbon diagram of the lowest energy structure of 
CSD from Kloks et al., 2002. 
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YB-1 and its homologs form oligomers with a mass up to 800 kDa in the 
absence of RNA (18 S) (Evdokimova et al., 1995). Oligomerization may occur 
due to interaction with oppositely charged amino acids clusters of the C- terminal 
domain from different protein molecules (Tafuri and Wolffe, 1992). 
1.3.2. Functions of YB-1 in cells 
YB-1 plays a role in the regulation of several different pathways due to its 
ability to interact with nucleic acids and other proteins (Figure 1.6)  
	 
Figure 1.6. Schematic diagram showing the numerous functions of YB-1 that affect all hallmarks 
of cancer (Lasham et al., 2013). 
At most times, a majority of YB-1 is within the cytoplasm in association 
with RNA. It is the major packing protein of messenger ribonucleoproteins 
(mRNPs) (Wu et al., 2015), regulates mRNA translation, provides for its stability, 
and is involved in its localization. However, in response to some intra- and 
extracellular signals a significant portion of YB-1 can move to the cell nucleus. 
When YB-1 translocates into the nucleus, it becomes involved in transcription of 
various genes, in DNA repair and replication, and in pre-mRNA splicing (Eliseeva 
et al., 2011).  
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YB-1 both enhances and represses the expression of genes, which contain 
the specific Y-box-containing regions in their promoters as well as with single 
stranded regions that can have no Y-box sequence. YB-1 also interacts with 
proteins involved in transcription and regulates their functions. hTopoI regulates 
gene transcription by controlling supercoils in DNA during this process (Puc et 
al., 2015; Baranello et al., 2016). YB-1 has been found to interact directly with 
hTopoI and enhance its DNA relaxation activity (Wu et al., 2014). This 
interaction enhances CPT sensitivity in human prostate cancer PC-3 cells, but not 
in cervical cancer HeLa cells. 
There are indications that YB-1 may also be involved in DNA repair. Its 
high affinity for damaged DNA, its weak 3'-5'-exonuclease activity on single-
stranded DNA and weak endonuclease activity on double-stranded DNA are 
features that support its possible implication in DNA repair (Hasegawa et al., 
1991; Izumi et al., 2001). It has been shown that YB-1 can separate DNA duplex 
of different oligonucleotides less than 36bp long and this activity is increased 
when duplex molecules contain either mispaired bases or cisplatin modifications 
(Gaudreault et al., 2004). In addition, YB-1 interacts with several proteins 
involved in repair and can regulate the activity of some of them (Das et al., 2007; 
Chattopadhyay et al., 2008). PARP1, the key regulator of DNA repair events, was 
stimulated by YB-1 and this interaction decreased sensitivity to PARP1 inhibitors 
(Alemasova et al., 2018). YB-1 was found to interact with the DNA glycosylase 
hNTH1 through a yeast two hybrid (Y2H) screen and in this same study YB-1 
was shown to stimulate the lyase activity of hNTH1 by enhancing the formation 
of an Schiff base intermediate between enzyme and apurinic/aprimidinic (AP) site 
(Marenstein et al., 2001). Another study showed an increase in YB-1-hNTH1 
association in the MCF7 breast tumour cell line under specific DNA-damaging 
conditions (Guay et al., 2008). Interestingly, knockdown of one or the other of the 
two proteins results in restored sensitivity to both cisplatin and UV light. 
During my PhD studies, I focused on the interactions of YB-1 with the 
human DNA repair protein NTH1 and human DNA topoisomerase I, and their 
implications in anticancer drug resistance. 
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1.4. Importance of protein-protein interactions in cellular processes 
Protein-protein interactions (PPIs) constitute a complex network and take 
part in many cellular processes. Most pathological conditions of mammalian cells 
result from dis-functioning or variations in these interactions. The identification of 
interacting partners can shed light on a protein’s cellular function and can provide 
new therapeutic strategies in case of disease. PPIs represent specific physical 
contacts between proteins in particular biological conditions (De Las Rivas and 
Fontanillo, 2010).  
1.4.1. Methods for identification of PPI 
Large-scale genomics and proteomics programs have identified complete 
networks of protein interactions within a cell (called the interactome) and have led 
to major breakthroughs in understanding biological pathways, host–pathogen 
interactions and cancer development (Lievens et al., 2010). There are two 
approaches to obtain information about molecular interactions: computational and 
experimental. A number of experimental methods, based on distinct, physical 
principles have been developed to identify PPIs such as the yeast two-hybrid 
method (Y2H) (Topcu and Borden, 2000), affinity purification-mass spectrometry 
approaches and protein microarrays (Ruffner et al., 2007).  
For verification of these interactions, confocal microscopy, 
coimmunoprecipitation, surface plasmon resonance and spectroscopic studies are 
useful methods (Berggård et al., 2007). Fluorescence (Föster) Resonance Energy 
Transfer (FRET) is also a routinely used biophysical method for the study of 
protein-protein interactions. FRET is non-radiative energy transfer from a donor 
fluorophore (coupled to protein X) to an acceptor fluorophore (coupled to a 
protein Y) if protein X and Y are close enough to each other (Föster radius). This 
method can be applied both in vivo and in vitro with resolution in the nanometer 
range (Ngounou Wetie et al., 2014). 
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1.4.2. Chemical library screening in order to find PPI inhibitors 
In recent years, targeting PPIs represents a new avenue for drug 
development (Wells and McClendon, 2007). PPIs are druggable, but discovering 
small-molecules that disrupt PPIs is very challenging. The analysis of PPI 
interfaces is important in order to faciliate the identification of potential 
inhibitors of protein complexes (Milhas et al., 2016).  
The nature of PPIs differs depending on the type of complexes (obligate 
and non-obligate). The minimum protein surface for non-obligate protein-
protein complexes is suggested to be around 900 Å2 (about 500 Å2 provided 
by each partner) and consists of arond 12 residues on each partner 
(Villoutreix et al., 2014). Most atoms in non-obligate interfaces are in contact 
with the solvent. These interfaces are lacking residues such as glutamic acid, 
aspartic acid and lysine and contain mostly methionine, tyrosine and 
tryptophan (Villoutreix et al., 2014). The interface of obligate protein-protein 
complexes is more hydrophobic, and aliphatic and aromatic residues are 
abundant compared to non-obligate protein complexes. In these interfaces, 
some residues are directly involved in the stabilization of the complex by 
largely contributing to the binding energy of the interaction, and are referred 
to as hotspots (Chakrabarti and Janin, 2002). Tryptophan, arginine and 
tyrosine are often found at hotspots in contrast leucine, serine, threonine and 
valine are unfavourable (Bogan and Thorn, 1998). Hydrogen bonding, but 
also electrostatic and hydrophobic interactions formed at PPIs can be 
disrupted by small chemical compounds (Arkin and Wells, 2004). 
Several databases and chemical libraries have recently been developed 
taking into account the specific properties of PPIs in order to facilitate the search 
for potential inhibitors of PPIs (Basse et al., 2016; Milhas et al., 2016) and various 
experimental approaches, described below, are used to identify initial lead 
compounds. 
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1.4.2.1. Fluorescence Resonance Energy Transfer  
 Fluorescence Resonance Energy Transfer or FRET is a fluorescence-based 
technique. Fluorescence is a type of luminescence, and corresponds to the 
emission of light by a particular chemical compound or protein (fluorophore) 
within nanoseconds after the absorption of light. In this process, an electron from 
the fluorophore is excited to a higher energy state and then returns to a lower 
energy state accompanied by the emission of a photon. The difference between the 
excitation and emission wavelengths, called the Stokes shift, is the important 
feature that makes fluorescence so useful. The outermost electron orbitals in the 
fluorophore molecule determine both its efficiency and the wavelengths of 
absorption and emission. The effciency of the fluorescence process is defined by 
its quantum yield, which is the ratio of the number of photons emitted to the 
number of photons absorbed. When fluorophores in their so-called ‘ground state’ 
(S0) absorb light energy (photons), alterations in the electronic, vibrational and 
rotational states of the molecules can occur. If the absorbed photon’s energy is 
greater than that needed for the transfer from the ground state to the lowest energy 
level of S1, the molecule will also undergo a change in vibration, rotation and/or 
move into an even higher electronic orbital. This transition to an ‘excited state’ 
(S2) arises in femtoseconds (Lichtman and Conchello, 2005). The molecule uses 
several different pathways, like vibrational relaxation and fluorescence emission, 
to shed the absorbed energy and return to its low-energy ground state. The 
processes, which occur between the absorption and emission of light are 
illustrated in the Jablonski diagram (Lakowicz, 2006) (Figure 1.7). 
	 
Figure 1.7. Jablonski diagram showing the various steps involved in fluorescence excitation and 
emission. Adapted from Lichtman and Conchello, 2005. 
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 FRET involves a non-radiative transfer of energy from an excited donor 
fluorophore to an adjacent acceptor fluorophore. Due to the nature of the 
transition dipole interaction between the two fluorophores, energy transfer is more 
efficient when they are in close proximity than when they are further apart, 
allowing one to measure relative distances of up to 10 nm between donor and 
acceptor, making FRET extremely sensitive to small changes in distance (Piston 
and Kremers, 2007). The donor molecules typically emit at shorter wavelengths, 
which overlap with the absorption spectrum of the acceptor.  
 In our study, fluorescent proteins-based FRET was used, which is suitable 
for both in vivo and in vitro studies of PPIs. Fluorescence microscopy is a very 
useful technique to explore processes in live or fixed cells, and fluorescent 
proteins (FPs) are commonly used as markers for such studies (Day and 
Davidson, 2009). Recent developments in fluorescence microscopy and in FPs 
have greatly widened the capabilities of cellular imaging (eg. high resolution 
imaging) and have significantly contributed to a better understanding of various 
biological processes (Adam et al., 2009; Bourgeois, 2017). FPs suitable for FRET 
measurements are known as FRET pairs, and numerous of these have been 
described that display different properties, such as spectral overlap between FPs, 
the brightness of FPs, donor:acceptor stoichiometry (Bajar et al., 2016). We used 
the CFP (Cyan Fluorescent Protein) and YFP (Yellow Fluorescent Protein) 
variants, mTurquoise2 and sYFP2, two bright colour variants of GFP (Green 
Fluorescent Protein), as donor and acceptor fluorophores (Figure 1.8). All proteins 
used for in vitro FRET measurements were expressed as fusion proteins with 
either of these two fluorescent proteins. FRET can be either intra- or inter-
molecular.  
	 
Figure 1.8. Illustration of FRET principle. The blue square and the green circle represent two 
interacting proteins. The cyan and yellow cylinders represent mTQ2 and sYFP2 respectively. 
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FRET signal is detected when the two fluorescent proteins are within 10nm proximity of each 
other. 
 In the literature, several protein-based fluorescent biosensors have been 
developed to study cellular processes, like enzyme-substrate relation, post-
translational modifications, and protease activity (Tamura and Hamachi, 2014). In 
such biosensors, intramolecular FRET is usually measured. 
1.4.2.2. Homogeneous Time-Resolved Fluorescence (HTRF) Assay 
The homogeneous time-resolved fluorescence (HTRF) system from CisBio 
International (Bagnols/Cèze Cedex, France) is one of a family of technologies 
based on time-resolved fluorescence resonance energy transfer (TR-FRET) 
(Newton et al., 2008). This method uses rare-earth lanthanides with long emission 
half-lives as donor fluorophores. The method provides significant advantages to 
drug discovery researchers in high throughput screening (HTS), including assay 
flexibility, reliability, increased assay sensitivity, higher throughput, and fewer 
false positive/false negative results (Figure 1.9) (Degorce et al., 2009). 
	 
Figure 1.9. Principle of HTRF assay. The energy pulse from the excitation source (flash lamp, 
laser) is followed by a time delay, allowing interfering short-lived fluorescence (compounds, 
proteins, medium etc.) to decay. The red line: FRET signal intensity generated at 665 nm; black 
line, emission of donor cryptate at 620 nm; orange line, fluorescent signal generated from acceptor 
fluorophores. Taken from (Degorce et al., 2009). 
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1.4.2.3. Amplified Luminescent Proximity Homogeneous (AlphaScreen) 
Assay 
Alpha Technology (Amplified Luminescent Proximity Homogeneous 
Assay) is a highly flexible, homogeneous no-wash assay ideal for the 
measurement of protein interactions and complexes. The technology of 
AlphaScreen was originally developed under the name of LOCI® (Luminescent 
Oxygen Channeling Immunoassay) by Dade Behring, Inc. of Germany (Ullman et 
al., 1994). This technique is a bead-based proximity assay and relies on excited 
emission of luminescence upon proximity of donor and acceptor beads, which are 
coupled to the respective interaction partners. Excitation of the donor bead leads 
to the formation of singlet oxygen, which diffuses to the acceptor and stimulates 
emission. Unlike FRET, acceptor emission occurs at a higher energy (lower 
wavelength) than donor excitation. 
Donor beads contain a photosensitizer, phthalocyanine, which converts 
ambient oxygen to an excited form of O2, singlet oxygen, upon illumination at 680 
nm. Like other excited molecules, singlet oxygen has a limited lifetime prior to 
returning to ground state. Within its 4μsec half-life, singlet oxygen can diffuse 
approximately 200 nm in solution. If an acceptor bead is within that distance, 
energy is transferred from the singlet oxygen to thioxene derivatives within the 
acceptor bead, resulting in light production. Without the interaction between 
donor and acceptor bead, singlet oxygen falls to ground state and no signal is 
produced. AlphaScreen acceptor beads use rubrene as the final fluorophore, 
emitting light between 520 and 620 nm. AlphaLISA acceptor beads use a 
Europium chelate as the final fluorophore, emitting light in a narrower peak at 615 
nm (Figure 1.10) (Arkin et al., 2004). 
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Figure 1.10. Illustration of AlphaScreen Assay. Binding of biological partners (represented by 
purple and green ovals) brings Donor and Acceptor beads (represented by the large blue and red 
circles) into close proximity (≤200 nm) and thus a fluorescent signal between 520–620 nm is 
produced in the case of AlphaScreen. When there is no binding between biological partners, Donor 
and Acceptor beads are not in close proximity. Singlet oxygen decays and no signal is produced. 
1.5. Human Endonuclease III (hNTH1) and its role in Base Excision 
Repair 
1.5.1. Base Excision Repair Pathway 
The Base Excision Repair (BER) pathway (Figure 1.11) removes small base 
lesions that do not significantly distort the DNA helix structure. Such damage 
typically results from deamination, oxidation, or methylation (Krokan and Bjørås, 
2013). Tomas Lindahl, the 2015 Nobel Prize winner in Chemistry, was the first to 
decipher the fundamental steps in the BER pathway in 1974. The initial step of 
BER is the recognition and removal of the damaged base by DNA glycosylases. 
Base removal generates an abasic site in DNA, which is then further processed by 
the DNA glycosylases themselves in the case of bifunctional enzymes or by an AP 
endonuclease, before de novo synthesis by the DNA polymerase together with a 
DNA ligase to fix the DNA (Figure 1.11). 
There are 11 determined mammalian DNA glycosylases, which are 
responsible for excision of different types of base lesions (Jacobs and Schär, 
2012). The initial recognition by DNA glycosylases occurs by diffusion of the 
enzyme along the DNA. Minor backbone distortions and the H-bond acceptor and 
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donor changes that occur as a result of base damage are recognized at low 
specificity and affinity, which is followed by base flipping to generate a high-
specificity and -affinity complex. DNA glycosylases are divided into two groups 
according to their catalytic activities. Monofunctional DNA glycosylases cleave 
the N-glycosidic bond between the damaged base and the deoxyribose sugar and 
release the substrate base by creating an apurinic/aprimidinic (AP) site. After 
excision of the damaged base by a monofunctional DNA glycosylase, an AP 
endonuclease (APE1 in humans) cleaves the phosphodiester backbone on the 5' 
side of the AP site via a hydrolytic mechanism (Madhusudan et al., 2005). 
Bifunctional DNA glycosylases, besides their glycosylase activity, have AP-lyase 
activity. After removal of the base lesion, they cleave the DNA strand 3' to the AP 
site by β-elimination or β/δ-elimination leaving ends that require end processing 
before subsequent repair. The end products of the β-elimination are an unsaturated 
hydroxyaldehyde linked to the 3' end (3'-dRP) and 5'-P, which can be processed 
by APE1 generating a 3'-OH end. β/δ-elimination releases an unsaturated 
deoxyribose as trans-4-hydroxy-2,4-pentadienal generating a one-nucleotide gap 
surrounded by 3'-P and 5'-P ends. The 3'-P can be removed by polynucleotide 
kinase/phosphatase (PNKP), preparing the intermediate for the polymerase step. 
The action of APE1 on an AP site generates a single-strand break with a 3'-
hydroxyl terminus, which can prime DNA repair synthesis, and a 5'-deoxyribose 
phosphate (5'dRp) terminus. The 5'dRp residue must be removed in order for the 
repair process to be completed. This task is accomplished by the dRp lyase 
domain present in DNA polymerase β, the enzyme that also performs the task of 
filling in the single base gap thus formed (Prasad et al., 1998; Beard et al., 2006). 
Repair is then completed by ligation of the nick, which is generally catalysed by 
DNA ligase III in association with its binding partner XRCC1. This pathway has 
been termed ‘short patch’ BER. In some types of short-patch BER, 
poly(ADPribose) polymerase I (PARP1) also participates.  
The long-patch BER pathway involves strand displacement repair synthesis 
of at least two nucleotides and the excision of the 5'-dRP residue as part of a flap 
oligonucleotide released by the FEN1 nuclease with the help of PCNA (Klungland 
and Lindahl, 1997). Strand elongation is then performed by DNA polymerase δ/ε, 
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which is expressed in proliferating cells (Akbari et al., 2009).  
Human NTH1 is a bifunctional DNA glycosylase, responsible for the 
removal of oxidized pyrimidines together with two other DNA glycosylases, the 
endonuclease VIII-like (NEIL) enzymes NEIL1 and NEIL2 (Dizdaroglu, 2005). 
These enzymes possess an AP-lyase activity with β/δ-elimination and a 5'- 
phosphodiesterase activity that removes the 5'-dRP residue. They also excise 4,6- 
diamino-5-formamidopyrimidine (FapyAde) lesion (Aamann et al., 2014). 
The choice between ‘short patch’ and ‘long patch’ repair pathways is 
defined by the initiating DNA glycosylase, the cell type and availability of BER 
factors (Krokan and Bjørås, 2013). 
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Figure 1.11. Schematic diagram illustrating the various steps and enzymes involved in Base 
Excision Repair. Taken from Krokan and Bjørås, 2013. 
 BER and its closely associated pathways play key roles in prevention of 
cancer, neurodegeneration, aging and resistance to anticancer agents. The 
cytotoxic effects of anticancer drugs, which introduce base modifications and in 
particular base oxidation and alkylation, can be reduced by the efficient repair of 
DNA by the BER pathway. Because of its necessity for cell survival, several BER 
proteins such as APE1 or PARP1 are targets of therapeutic drugs (Madhusudan et 
al., 2005; Malyuchenko et al., 2015).  
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1.5.2. Human Endonuclease III (hNTH1) 
Human NTH1, a homologue of Escherichia coli endonuclease III (Nth), was 
first purified and identified from calf thymus (Hilbert et al., 1996). The hnth1 
gene is localized on chromosome 16p13.2-.3. It encodes a 34kDa protein, which 
consists of a catalytic domain composed of two -helical subdomains containing 
an helix-hairpin-helix motif and a [4Fe-4S] cluster loop, and an additional 
mammalian-specific N-terminal domain, or NTD (Figure 1.12) (Ikeda et al., 
1998).  
Escherichia coli Endonuclease III (EndoIII) is a bifunctional DNA 
glycosylase/AP lyase, which repairs a series of structurally diverse toxic or 
mutagenic oxidized pyrimidines. This enzyme was first identified not on the basis 
of its DNA glycosylase activity, but rather because it nicked UV-irradiated DNA. 
For this reason it was termed an endonuclease, because it was thought that nicking 
resulted from enzyme-catalyzed hydrolysis of internucleotide phosphodiester 
bonds at sites of DNA damage (Hilbert et al., 1996). It has since been determined 
that the enzyme nicks DNA not via hydrolysis, but by catalyzing β-elimination of 
the 3'-P group at the AP site formed as a result of the enzyme’s DNA glycosylase 
activity (Mazumder et al., 1991). The modified base that was enzymatically 
released from UV-irradiated DNA proved to be cytosine and/or uracil hydrate 
(Boorstein et al., 1989). Enzymes that catalyse both base release and strand 
cleavage via β-elimination are now termed DNA glycosylase/AP lyases (Hilbert et 
al., 1997).  
	 
Figure 1.12. Schematic diagram of hNTH1 domain organization. 
The 3D structure of hNHT1 is unknown, but several structures of its 
homologs from bacteria have been reported (Thayer et al., 1995; Fromme and 
Verdine, 2003; Sarre et al., 2015) (Figure 1.13). These structures, however, only 
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correspond to the catalytic domain, which is highly conserved from bacteria to 
humans (~30% sequence identity). 
                        	 
Figure 1.13. The 3D structure of EndoIII-1 from Deinococcus radiadurans (Sarre et al., 2015) 
illustrated in rainbow colours (dark blue: N-terminus; Red: C-terminus). EndoIII enzymes are 
composed of two domains separated by a DNA-binding cleft in which are located the two 
canonical catalytic residues: Lysine and Aspartate. A [4Fe-4S] cluster is present at the C-terminus. 
E. coli EndoIII displays a broader substrate specificity than hNTH1. The 
substrate specificity of hNTH1 protein is similar to that of Schizosaccharomyces 
pombe Nth protein (Dizdaroglu et al., 2000) (Figure 1.14).  
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Figure 1.14. Pyrimidine-derived lesions excised by hNTH1. Base modifications are encircled with 
red colour. Adapted from Dizdaroglu et al., 1999. 
 hNTH1’s catalytic activity is tightly regulated and several mechanisms are 
involved in this process (Liu et al., 2003) (Figure 1.15). It has been shown that its 
N-terminal tail (NTD) plays an auto-inhibitory role, which could explain the low 
activity of hNTH1 compared to that of its E. coli homologue (Liu and Roy, 2002). 
The hNTH1 dimer was detected in vivo and in vitro at high protein concentrations. 
The dimerization of hNTH1 occurs via NTD interactions and masks the inhibitory 
effect of this tail (Liu et al., 2003).  
hNTH1 also has several interaction partners, which regulate its enzymatic 
reaction (Figure 1.15). The nucleotide excision repair enzyme XPG binds directly 
to hNTH1 and enhances its binding to damaged DNA. The stimulation of hNTH1 
activity by XPG does not require XPG’s catalytic activity in nucleotide excision 
repair (Bessho, 1999; Klungland et al., 1999). It has been reported that APE1 also 
stimulates hNTH1’s glycosylase activity against Tg:A -containing 2'-deoxyribose 
oligonucleotide duplex and increases hNTH1’s lyase activity against Tg:A -
containing substrate (Marenstein et al., 2003). As mentioned before, the direct 
interaction of hNTH1 with YB-1 has been shown to enhance the lyase activity of 
hNTH1 (Marenstein et al., 2001). 
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Figure 1.15. Schematic illustration of the bifunctional reaction mechanism catalyzed by hNTH1 
and the effect of XPG, APE1, and YB-1 on the regulation of its activity. In the case of coupled 
bifunctional activities, the enzyme and the substrate (E+DNAox) generate an enzyme-substrate 
complex (E*DNAox), which leads to the removal of the oxidized base and the formation of an 
enzyme-abasic site complex (E*DNAAP). In turn, this complex is further processed by the lyase 
activity to an enzyme-nicked DNA complex (E*DNAn) and finally, the fully processed DNA 
product after β-elimination is released from the enzyme (E+DNAn). In case the two reaction steps 
are uncoupled, the enzyme dissociates from the abasic site DNA (E+DNAAP) after the glycosylase 
reaction, thereby creating a mixture of DNA substrates containing either abasic sites or oxidized 
bases. The enzyme can then engage in either one of the two sub-pathways: (i) a new round of 
DNA glycosylase activity on DNAox or (ii) AP-lyase activity on DNAAP. The relative engagement 
into one or the other pathway depends on the concentrations of the various species (E, DNAox, 
DNAAP and DNAn) in the reaction. Various factors as indicated act at different reaction steps to 
regulate the hNTH1 activity.  → and ⊣ denote stimulation and inhibition, respectively. Adapted 
from Liu et al., 2003. 
Other DNA glycosylases’ repair activities are also regulated by co-factors. 
The 8-Oxoguanine DNA glycosylase 1, which is responsible for the repair of the 
most frequent oxidized DNA lesion pre-mutagenic 8-oxo-7,8-dihydroguanine (8-
oxoG), is controlled by APE1, XRCC1, and PARP1 (Ba and Boldogh, 2018). 
NEIL1 and NEIL2 are stimulated by Cockayne Syndrome group B protein 
(Muftuoglu et al., 2009; Aamann et al., 2014). 
The knockdown of a gene is one of the methods to study the physiological 
importance of proteins. Knocking-down NTH1 alone (Nth1−/−) did not cause 
significant consequences in mice. However, targeted deletion of hNTH1 and 
NEIL1 (Nth1−/−Neil1−/−) results in increased tumorigenesis in comparison to 
Nth1−/− or Neil1−/− mice, which is the first demonstration of the carcinogenicity of 
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oxidative damage to DNA other than 8-oxoG and highlights the importance of 
hNTH1 (Chan et al., 2009). 
1.6. Preliminary data obtained for the study of YB-1/hNTH1 complex 
Before my arrival in Dr. Timmins’ team, some activity and interaction 
experiments had already been performed to characterise the YB-1/hNTH1 
complex, which are described below. The glycosylase and lyase activities of 
hNTH1 were measured on specific oligonucleotide substrates containing thymine 
glycol (a commonly used EndoIII substrate) paired with adenine in the absence 
and presence of YB-1 (Figure 1.16). YB-1 did not appear to affect the DNA 
glycosylase activity of hNTH1, but instead was found to specifically stimulate 
(27% increase) the rate of AP lyase activity of hNTH1, as reported in the literature 
(Figure 1.16; Marenstein et al., 2001). 
	 
Figure 1.16. Stimulation of hNTH1 AP-lyase activity by YB-1. (A) DNA substrate used in this 
work: a 35 mer dsDNA containing thymine glycol (Tg) in position 14 and a fluorescein labelled 
DNA strand for detection on gel and representative gel of hNTH1 activity reaction. (B) Time 
course experiments of the DNA glycosylase (dotted line) and lyase activities (full line) of 3 nM 
hNTH1 on 75 nM DNA substrate in the absence (black) and presence (red) of 30 nM YB-1.  
 AlphaScreen assays were also performed to characterize the interaction 
between YB-1 and hNTH1 (Figure 1.17). For this, His-tagged hNTH1 was bound 
to Anti-His coated acceptor beads and biotinylated YB-1 was bound to 
streptavidin-coated donor beads. By combining different constructs of hNTH1 and 
YB-1 in such an assay, Dr. J. Timmins’ team could show that the NTD of hNTH1 
is critical for interaction with YB-1 and the C-terminal region of YB-1, which is 
missing in the nuclear form of YB-1, is dispensable for this interaction. The C-
 
 
 
 
39 
terminal residues of YB-1 between 182 and 219 may also play a role in the 
interaction between YB-1 and hNTH1, since the slightly shorter construct (YB1-
C182) showed reduced AlphaScreen signal compared to the nuclear form (YB1-
C219, later referred to as YB-1C).  
	 
Figure 1.17. AlphaScreen binding assays of YB-1 and hNTH1. (A) AlphaScreen measurements 
obtained from a titration of increasing amounts (0, 1, 5, 10 and 50 nM) of YB-1 (wild-type, WT; 
residues 1-182, YB1-C182; residues 1-219, YB1-C219) into reactions containing 100 nM His-
tagged hNTH1. The binding profiles are typical of specific binding. The reduced signal obtained at 
the highest concentration of YB1 is due to a saturation of the binding sites on the streptavidin 
coated donor beads. (B) AlphaScreen measurements obtained from a titration of increasing 
amounts (0, 25, 100, 250 and 1000 nM) of hNTH1 (wild-type, WT; residues 90-326, hNTH1-
ND89; residues 1-89, hNTH1-Ntail) into reactions containing 10 nM biotinylated YB1-C219, 
which was the concentration producing the best signal in (A). (C) AlphaScreen competition assay. 
Increasing concentrations of hNTH1 (without His-tag) were added to an AlphaScreen reaction 
containing 10 nM biotinylated YB1-C219 and 100 nM His-hNTH1. The untagged hNTH1 replaces 
the His-tagged hNTH1 in the complex leading to a decrease in the Alpha Screen signal. The IC50 
derived from this data provides us with an estimate of the binding affinity of the YB-1/hNTH1 
complex and was found to be ~0.5 µM. 
1.7. DNA topoisomerase I as an anticancer drug target 
DNA topoisomerase I is a member of the DNA topoisomerase enzyme 
family. These are essential enzymes, which are responsible for regulating the 
topology of DNA in cells. They are involved in vital cellular functions such as 
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replication, transcription, recombination and DNA repair. These enzymes catalyze 
the conformational changes in DNA topology by generating the concerted 
breakage and rejoining of DNA strands without changing the chemical structure 
of DNA (Champoux, 2001; Wang, 2002). Because of their crucial role in 
proliferating cells, they are targets of anticancer drugs.  
1.7.1. DNA Topology 
In cells, DNA is packed into the nucleus. Supercoiling of the genomic DNA 
is essential and helps to pack the genome into a small volume to fit into the 
nucleus. Topological forms of DNA result from its structure composed of two 
DNA strands that are repeatedly intertwined. Opening these two strands, which 
occurs in all major genetic processes like replication and transcription may cause 
a torsional stress on DNA. If this stress is not taken care of, it can result in DNA 
double-strand breaks (Wang, 2002). To maintain genome integrity, DNA 
topoisomerases avoid this stress by changing the topology of DNA. 
Supercoiling can occur when DNA ends are not able to perform free 
rotation, as is the case inside living cells. Closed circular DNAs like plasmids, 
bacterial chromosomes, genomes of mitochondria and chloroplasts are good 
examples of supercoiling because they have no DNA ends. Although eukaryotic 
chromosomes consist of linear DNA, they are organized into constrained domains 
or loops attached to proteins and nuclear matrix, which block free rotation during 
strand separation (Mirkin, 2001). 
The fundamental topological parameter of a constrained DNA molecule or 
domain is called the linking number (Lk). The linking number is defined as the 
number of times that one DNA strand crosses an imaginary surface, which is 
formed by the other DNA strand. The only way to change Lk is to introduce a 
break in one or both DNA strands, rotate the two DNA strands relative to each 
other and seal the break. There are two geometrical functions in closed circular 
DNA: the twist (Tw) represents the total number of helical repeats by describing 
how the individual strands of DNA wrap around the axis of the DNA helix, and 
the writhe (Wr) is a measure of the coiling of the helix axis in space. Linking 
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number is the sum of Tw and Wr. The shape of the DNA called ‘supercoiled’ is a 
higher helix formation with normal double-stranded DNA. In living cells, the 
characteristic organization of the DNA is a negative supercoil, in which the Wr is 
increased and Tw is lowered compared to a relaxed DNA and has the same Lk 
(Bates and Maxwell, DNA Topology, 2005) (Figure 1.18). 
	 
Figure 1.18. Illustration of the different DNA topologies. Example of a torsionally relaxed DNA 
molecule with a length of 210 base pairs containing 20 turns (10.5 bp/turn) or Tw = 20. If the 
DNA were cut and one end was twisted by four turns in the direction opposite to the natural 
helicity of the DNA, and subsequently resealed, the resulting linking number of the DNA would be 
equal to Lk = 20 − 4 = 16. (Right) The upper and lower panels show the topology of the DNA 
molecule when the removal of these turns is at the expense of twist (Tw = 20 − 4 = 16) and writhe 
(Wr = 0 − 4 = −4), respectively. Taken from Koster et al., 2010. 
1.7.2. DNA Topoisomerases 
DNA topoisomerases catalyze topological changes by generating controlled 
transient strand breakage on DNA (Pommier et al., 2016). The first DNA 
topoisomerase was discovered in 1971 in Escherichia coli by James Wang who 
was studying the supercoiling of E. coli DNA (Wang, 1971).  
DNA topoisomerases carry out the strand breakage by the tyrosine residue in 
their active site. This key residue attacks the phosphodiester bond of DNA leading 
to the formation of a covalent bond by a transesterification reaction (Champoux, 
2001). Topoisomerases are divided into two major classes: type I, which cleave 
single-stranded DNA, and type II, which cleave double-stranded DNA. Type I 
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topoisomerases are further subdivided into two mechanistically different 
subgroups: type IA, which attach the single-strand break to the 5'-phosphate, and 
type IB enzymes, which bind the 3'-phosphate at the break site (Table 1.1) (Nitiss 
et al., 2012). 
Table 1.1. Classification of human DNA topoisomerases and their properties, 
activities, and mechanisms. rel: relaxation activity, -: negative supercoils,            
+: positive supercoils, cat/decat: catenation and decatenation activity. 
Type Name DNA Cleavage Polarity 
Size (kDa) 
Composition 
Activity Mechanism 
IA 
Top3α 
Top3β 
Single 
strand 
5' 
112 
Monomer 
rel - Strand passage 
IB 
Top1 
Top1mt 
Single 
strand 
3' 
91 
Monomer 
rel - + Rotation 
II 
Top2α 
Top2β 
Double 
strand 
5' 
174 
Homodimer 
rel - + 
cat/decat 
Strand passage 
ATPase 
Type I topoisomerases mainly catalyse relaxation of supercoiled DNA, but 
in some cases, they can also perform knotting/unknotting and duplex formation 
with single-stranded DNA, and catenation/decatenation of nicked circular DNAs. 
Type II topoisomerases can catalyse relaxation/supercoiling, knotting/unknotting, 
and catenation/decatenation reactions by generating double-strand breaks using 
ATP. The reactions performed by type I and type II topoisomerases are 
summarized in Figure 1.19.  
Type IA topoisomerases can only relax negatively supercoiled DNA 
reducing one linking number at each reaction by a strand passage mechanism. In 
contrast, type IB topoisomerases can relax both positively and negatively 
supercoiled DNA by controlled rotation allowing to reduce more than one linking 
number for each reaction. Type II topoisomerases possess an ATPase activity to 
perform strand passage of double-stranded DNA between double-strand breaks.  
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Figure 1.19. Reactions of Type I (A) and Type II (B) topoisomerases. Taken from (DNA 
Topology, 2005). 
Because of their essential roles in cellular processes, topoisomerases are 
well-defined anticancer drug targets. Overexpression of topoisomerases in tumour 
cells provides selectivity for drugs. There are two types of topoisomerase 
inhibitors that differ in their mechanism of actions: (i) trapping of topoisomerase-
DNA complexes and (ii) catalytic inhibition of topoisomerases (Topcu, 2001; 
Pommier, 2014).  
CPT, an alkaloid from Camptotheca acuminata, is one of the most known 
hTopoI targeting anticancer drug. Camptothecin derivatives, such as Topotecan 
and Irinotecan are the only FDA-approved hTopoI-targeted anticancer drugs 
(Pommier, 2014). CPT blocks hTopoI’s rejoining step of the cleavage/religation 
reaction, resulting in accumulation of hTopoI-cleavable complex (Figure 1.20 A) 
(Liu et al., 2000). Accumulation of hTopoI-cleavable complex impairs several 
important cellular processes such as replication and transcription which are 
blocked by the torsional stress on the DNA and leads to the formation of cytotoxic 
strand breaks (Figure 1.20 B) (Koster et al., 2007). 
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Figure 1.20. Mechanism of Human Topoisomerase I targeting drugs. (A) Two possible modes of 
formation of hTopoI-cleavable complex by either drug intercalation into DNA (like Campthotecin) 
or drug binding to DNA (like Nogalamycin). Taken from Liu et al., 2000. (B) Cytotoxic effect of 
CPT stabilized hTopoI-cleavable complex. A replication fork creates positive supercoils, which 
are removed (pink arrow) by hTopoI (blue). When CPT stabilizes hTopoI-cleavable complex in 
the DNA, DNA breaks can occur as a result of the accumulation of positive supercoils (left). 
Another possibility is the collision of the replication fork with CPT stabilized hTopoI-cleavable 
complex, and the formation of DNA breaks at the end (right). Taken from Koster et al., 2007.  
hTopoI-mediated DNA damage can be repaired by reversal of hTopoI-
cleavable complex, by Tyrosyl-DNA-phoshodiesterase (Tdp1) and endonucleases 
(Pommier et al., 2006).  
1.7.3. Human Topoisomerase I (hTopoI) 
Human Topoisomerase I (hTopoI) is a Type IB topoisomerase (Wang, 
2002) and solves the topological problems of DNA in replication, transcription 
and other cellular processes by generating reversible single DNA strands 
(Pommier, 2006). hTopoI is encoded by a single copy gene located in 
chromosome region 20q12-13.2 (Juan et al., 1988). 
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hTopoI is a 91kDa monomeric enzyme that forms an asymmetric protein 
clamp, which encircles double-stranded DNA. hTopoI contains four domains: a 
poorly conserved N-terminal domain, a highly conserved core domain, a linker 
domain formed by an extended pair of α-helices, and a conserved C-terminal 
domain (Figure 1.21) (Pommier, 2006). The N-terminal domain is highly charged, 
protease sensitive and contains targeting signals. The core domain contains three 
subdomains: core subdomain I (residues 215–232 and 319–433); core subdomain 
II (residues 233–318); core subdomain III (residues 434–635). The C-terminal and 
core domains are involved in enzymatic activity. The C-terminus contains the 
active site tyrosine described above (Tyr 723 in hTopoI) involved in the catalytic 
reaction illustrated in Figure 1.22. 
	 
Figure 1.21. The structure and domain organization of hTopoI (A) The structure of a C-terminal 
70-kDa fragment of human DNA topoisomerase I (Topo70) in a noncovalent complex with a 22-
base pair DNA duplex. Ribbon diagram of PDB file 1A36 (Stewart et al., 1998), viewed 
perpendicular to helical axis of the DNA duplex (backbone is in orange), the core domain of 
Topo70 forms a protein clamp (shades of blue). The linker domain (purple) extends from the core 
at an oblique angle to the DNA, and the C-terminal domain is in green. The active site Tyr is 
mutated to Phe to render the enzyme inactive for structural studies (indicated in magenta). Taken 
from Wright et al., 2015. (B) Schematic diagram of hTopoI domain organization. NTD: N-
terminal domain. CTD: C-terminal domain. 
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Figure 1.22. Active site of hTopoI and its reaction. In the cleavage reaction, the O-4 atom of the 
active site Tyr723 is shown as the nucleophile that attacks a phosphodiester bond in DNA to 
generate a phosphodiester linkage between itself and the 3' end of the broken strand. The religation 
reaction involves nucleophilic attack by the free 5' hydroxyl group of the broken strand on the 
tyrosine-DNA linkage to restore the phosphodiester bond in the DNA and release the active site 
tyrosine. Taken from (Pommier, 2012). 
hTopoI can relax both negatively and positively supercoiled DNA by a 
controlled rotation mechanism (Figure 1.23). In the strand-breakage reaction, a 
tyrosyl oxygen of the enzyme attacks a DNA phosphorus, forming a covalent 
phosphotyrosine link and breaking a DNA phosphodiester bond at the same time 
(Figure 1.22). Rejoining of the DNA strand occurs by a second transesterification, 
which is basically the reverse of the first — the oxygen of the DNA hydroxyl 
group that is generated in the first reaction attacks the phosphorus of the 
phosphotyrosine link, breaking the covalent bond between the protein and DNA, 
and reforming the DNA backbone bond (Figure 1.22). These reactions create 
transient enzyme-mediated gates in the DNA for the passage of another DNA 
strand. 
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Figure 1.23. hTopoI-mediated DNA relaxation by controlled rotation. Taken from Pommier et al. 
2010. 
The tumour suppressor protein p53 and hTopoI form complexes in vitro and 
in vivo. p53 accumulates in the nucleus and stimulates hTopoI DNA relaxation 
activity in DNA-alkylating agent Mitomycin C-treated MCF7 cells (Gobert et al., 
1996). p53 enhances hTopoI activity by facilitating the clamp structure opening of 
hTopoI in order to release its substrate DNA. Monomeric form of p53 is enough 
to increase the catalytic activity of hTopoI but the tetrameric form of p53 is 
necessary for the stimulation of the topoisomerase I-induced recombination repair 
reaction (Søe and Grosse, 2003). 
Another tumour suppressor, the prostate-specific homeodomain protein 
NKX3.1, also interacts with hTopoI and stimulates its activity by enhancing 
hTopoI-DNA complex formation and increasing its cleavage activity. Down 
regulation of NKX3.1 decreases hTopoI activity in prostates (Bowen et al., 2007). 
It has been shown that the effect of NKX3.1 on hTopoI sensitizes cells to the 
cellular toxicity of CPT. The knockdown of hTopoI had an effect on the DNA 
damage response in PC-3 cells (Song et al., 2013). 
Topo I has been identified as the major non-histone substrate of PARP-1 
and its catalytic activity was inhibited by pADP-ribosylation in vitro (Kasid et al., 
1989). For this reason, using PARP inhibitors in clinical trials enhances the 
cytotoxicity of CPT. It has been shown that subnuclear localization of hTopoI 
changed during PARP inhibitor treatment by live-cell imaging, which was not the 
result of hTopoI/PARP-1 interaction (Das et al., 2016). As mentioned earlier, YB-
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1 has been shown to interact directly with hTopoI and stimulate its relaxation 
activity (Wu et al., 2014). 
There is also some evidence that hTopoI is involved in DNA repair process. 
Decreased expression levels of hTopoI by anti-sense RNA negatively affects the 
ability of cells to induce DNA repair following UV radiation (Mao and Muller, 
2003). The rapid recruitment of hTopoI to UVA-irradiated DNA sites may result 
from its binding to DNA lesions but it may also play additional roles in the repair 
of these lesions (Mielke et al., 2007). Several DNA lesions have been shown to 
trap the hTopoI-cleavable complex (Pourquier et al., 1997; Lesher et al., 2002). 
hTopoI may be required to adjust DNA topology during repair processes or it may 
help to recruit DNA repair proteins to DNA lesions. 
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Objectives 
In the light of the studies presented above, it is clear that YB-1 plays a key 
role in modulating the sensitivity of tumour cells to chemotherapeutic agents via 
its interactions with various proteins, including hNTH1 and hTopoI, as illustrated 
in Figure 1.24. 
	 
Figure 1.24. Schematic illustration of the complex and diverse roles of YB-1 in regulating the 
sensitivity and resistance of tumour cells to chemotherapeutic drugs. (A) The increased abundance 
of nuclear YB-1 in response to genotoxic stress has been shown to lead to enhanced YB1/hNTH1 
complex formation and increased resistance to anticancer therapies, in particular cisplatin, in solid 
tumours. (B) In tumour cells treated with the hTopoI inhibitor, CPT, YB-1 has been shown to 
stimulate hTopoI activity thereby increasing the sensitivity of these cells to the anticancer agent by 
trapping more hTopoI-DNA complexes.  
The first objective of my thesis work was to investigate the formation of 
the YB-1/hNTH1 complex in vitro and in MCF7 cells using FRET approaches 
and to design and optimise a FRET-based biosensor, which could be used for 
high-throughput chemical library screening in order to identify potential inhibitors 
of this complex for use in combined therapy. In addition, a second objective was 
to study YB-1/hTopoI complex in vitro and in various mammalian cell lines using 
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FRET method and to find potent enhancers of this interaction in order to 
potentiate the effects of Campthothecin treatment.  
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Chapter 2. Materials and Methods 
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Summary 
FRENCH 
Les gènes codant pour les protéines d’intérêt utilisées pour des expériences 
de FRET ont été amplifiés par PCR et insérés dans des vecteurs d'expression pour 
cellules mammifères et pour bactéries, soit par des méthodes de clonage classique 
(digestion par enzyme de restriction suivie de ligation), soit par assemblage de 
l’ADN de type Gibson. Toutes les protéines recombinantes utilisées dans ce 
travail ont été surexprimées dans des cellules BL21 (DE3) d'Escherichia coli avec 
une étiquette His clivable en N-terminal ou une étiquette His non-clivable en C-
terminal (pour plusieurs constructions de topoisomérase I humaine). Le protocole 
de purification est composé de trois étapes: (i) chromatographie d'affinité pour le 
nickel, (ii) chromatographie d'affinité pour l'héparine et (iii) chromatographie 
d’exclusion de taille. Les mesures de fluorescence avec des protéines purifiées ont 
été effectuées sur un lecteur de microplaques Clariostar (BMG Labtech) dans des 
plaques à puits à fond plat Corning 384 (Merck) à température ambiante. Nous 
avons optimisé notre Biosenseur 1 pour le criblage de la chimiothèque. Un 
criblage à haut débit (HTS) a été réalisé sur la platforme de Criblage pour des 
Molécules BioActives (CMBA) au CEA de Grenoble. Deux chimiothèques ont été 
criblées: la chimiothèque PPI de Life Chemicals (800 composés) et la 
chimiothèque Prestwick (1280 composés). Les hits potentiels identifiés à partir de 
notre HTS avec le Biosenseur 1 ont été validés avec une autre technique connue 
sous le nom d'AlphaScreen. Des dosages de relaxation du plasmide superenroulé 
ont été réalisés pour étudier l'effet de YB-1 sur hTopoI. Plusieurs lignées 
cellulaires de mammifères ont été utilisées pour des expériences de FRET in vivo. 
Le microscope à épifluorescence sur la plateforme d'imagerie M4D de l'IBS a été 
utilisé pour vérifier la localisation des cellules et l'efficacité de la transfection 
avant les expériences de photoblanchiment accepteur effectuée sur le microscope 
confocal.   
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Özet 
TURKISH 
FRET deneyleri için kullanılan ilgili proteinleri kodlayan genler, PCR ile 
amplifiye edildi ve geleneksel klonlama yöntemleri (restriksiyon enzimi kesimi 
takiben ligasyon) veya Gibson DNA'nın bir araya getirilmesi ile memeli ve 
bakteriyel hücre ekspresyon vektörlerine klonlandı. Bu çalışmada kullanılan tüm 
rekombinant proteinler, ya uzaklaştırılabilir bir N-terminal His-etiketi ya da 
ayrılmaz bir C-terminal His-etiketi (birkaç insan Topoizomeraz I için) ile 
Escherichia coli BL21 (DE3) hücrelerinde aşırı eksprese edilmiştir. Saflaştırma 
protokolü üç aşamadan oluşur: (i) nikel afinite kromatografisi, (ii) heparin afinite 
kromatografisi ve (iii) boyut dışlama kromatografisi. Saflaştırılmış proteinlerle 
floresans ölçümleri, oda sıcaklığında siyah düz tabanlı Corning 384 kuyucuklu 
plakalarda (Merck) bir Clariostar (BMG Labtech) mikroplaka okuyucusu üzerinde 
gerçekleştirilmiştir. Kimyasal kütüphane taraması için Biyosensör 1 optimize 
edilmiştir. Yüksek verimli kimyasal kütüphane taraması (HTS), CEA, 
Grenoble'da BioAktif Molekül Taraması (CMBA) platformunda gerçekleştirildi. 
İki kimyasal kütüphane taranmıştır: Life Chemicals PPI kütüphanesi (800 bileşik) 
ve Prestwick kütüphanesi (1280 bileşik). HTS'mizden Biosensör 1 ile tanımlanan 
potansiyel inhibitörler, AlphaScreen olarak bilinen başka bir teknikle daha da 
doğrulanmıştır. YB-1'in hTopoI üzerindeki etkisini araştırmak için süper sarmal 
plasmid relaksasyon deneyleri gerçekleştirilmiştir. Çeşitli memeli hücre hatları in 
vivo FRET deneyleri için kullanılmıştır. IBS'nin M4D görüntüleme 
platformundaki epifloresans mikroskobunda  hücreler, akseptör foto-ağartma 
deneylerinden önce protein lokalizasyonunu ve transfeksiyon etkinliğini kontrol 
etmek için gözlenmişlerdir. Akseptör foto-ağartma deneyleri için, IBS'nin M4D 
görüntüleme platformunda bir FRAPPA cihazı ile donatılmış bir Olympus IX81 
konfokal mikroskobu kullanılmıştır. 
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2.1. Cloning 
 The cDNAs encoding human YB1, NTH1 and TopoI were codon optimized 
for expression in both bacteria and mammalian cells (in particular, removal of rare 
codons) and were synthesized by Eurofins MWG (see Annex for original and 
optimized sequences) (Figure 2.1). 
	 
Figure 2.1. Illustration of the domain organisation of YB1, hNTH1 and hTopoI and their various 
constructs used in this study. 
The optimized cDNAs of hnth1 and yb1 were provided as cloned fragments 
in the pEX-A2 plasmid. For htopoI the cDNA was delivered as three fragments of 
equal size (766 bp for each, cloned into pEX-A2 plasmid). Two strategies were 
used to assemble these three parts into the full-length gene using the NEBuilder 
HiFi DNA Assembly kit (New England Biolabs; NEB). First, we tried to assemble 
the three htopoI fragments for further amplification by PCR (Figure 2.2 A). 
Second, we created a pEX-A2 plasmid containing the full-length gene by direct 
assembly of the plasmid and the three fragments with overlapping sequences 
(Figure 2.2 B). The second strategy was successful, and we obtained full-length 
htopoI gene and confirmed this construct by DNA sequencing (Genewiz). 
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Figure 2.2. Strategies used to assemble the complete hTopoI gene using the three fragments 
obtained from Eurofins MWG. (A) Assembly of three linear hTopoI fragments for PCR 
amplification. (B) Assembly of three fragments into pEX-A2 plasmid. 
 PCR reactions were performed using Phusion® High-Fidelity PCR Master 
Mix (Thermo Scientific) (100 ng template DNA, 500 nM forward/reverse primers, 
2 X Phusion Master Mix in a total volume of 40 μl) with the following reaction 
conditions: 
Step Temperature Time 
Initial Denaturation 98°C 30 seconds 
30 Cycles 
98°C 
50-65°C 
72°C 
5-10 seconds 
10-30 seconds 
15-30 seconds per kb 
Final Extension 72°C 5-10 minutes (min) 
Hold 4°C  
After amplification, 6 X DNA loading dye (Thermo Scientific) was added to 
PCR reactions before electrophoresis on a 1% agarose gel containing GelGreen 
(Biotium) in 1xTBE buffer (89 mM Tris-borate, pH 8.0, 2mM EDTA). GeneRuler 
1 kb DNA ladder (Thermo Scientific) was used for comparison. The gel was 
visualized on a Chemidoc MP Gel Imaging System (Biorad). PCR products were 
excised and recovered from the agarose with the NucleoSpin® Gel and PCR 
Clean-up kits (Macherey-Nagel). 
PCR products and plasmids were then incubated with appropriate restriction 
enzymes (obtained from NEB) at 37oC for 1 hour. To insert restriction-digested 
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fragments into plasmids, T4 DNA ligase (Fermentas) was used. Ligation was 
carried out at room temperature (RT) for 1 hour using the Rapid Ligation kit 
(Fermentas). 
E. coli DH5α competent cells (NEB) were transformed with 2 μl ligation 
reaction mixture using the heat shock method. After transformation, the cells were 
transferred to LB-agar plates containing an appropriate antibiotic (100 μg/μl 
Ampicillin or 50 μg/μl Kanamycin) and incubated at 37oC overnight (o/n). 
Liquid cultures (5 ml) in LB containing appropriate antibiotic were started 
from colonies obtained after transformation for plasmid DNA purification using 
NucleoSpin® Plasmid QuickPure (Macherey-Nagel). Purified plasmids were 
controlled by restriction enzyme digestion. Positive clones were verified by DNA 
sequencing (Genewiz). The verified clones were used for further experiments. 
PCR primers used for cloning all constructs and cloning fragments are provided in 
the Annex. 
2.1.1. Mammalian Expression Vector 
 For in vivo FRET measurements, all genes were cloned into mammalian 
expression vectors derived from either pEGFP-C1 or pEGFP-N1 (Figure 2.3 A 
and B). 
	 
Figure 2.3. Maps of pEGFP-C1 (A) and N-1 (B) mammalian expression vectors that were 
modified in this study to replace eGFP by either sYFP2 or mTQ2 for in vivo FRET experiments. 
 
 
 
 
60 
The EGFP gene was replaced with sYFP2 or mTQ2 genes (kindly provided 
by J.P. Kleman from the M4D imaging platform at IBS) to create pmTQ2-C1/N1 
and psYFP2-C1/N1 vectors. Then the hnth1 gene was cloned into pmTQ2-C1 and 
N1 vectors and the yb1C gene was cloned into psYFP2-C1 and N1 vectors. To 
overcome low transfection efficiency, we decided to fuse the two protein 
constructs sYFP2-YB1C and hNTH1-mTQ2 with a 10 amino acid long linker 
SGGGASGGGT. The NheI restriction site was added in the middle of the linker 
to facilitate the cloning. 
The htopoI gene was also cloned into mammalian expression vectors 
pmTQ2-C1 by ligation and pmTQ2-N1 by DNA assembly using NEBuilder® 
HiFi DNA Assembly kit (NEB). We additionally created a co-expression plasmid 
with a self-cleaving Foot-and-mouth disease virus (FMDV) 2A peptide (Kim et 
al., 2011). For this, we amplified the mTQ2-hTopoI and the YB1ΔC-sYFP2 
constructs with overlapping regions encoding the 2A peptide and then assembled 
these two fragments by NEBuilder® HiFi DNA Assembly kit to create the 
YB1ΔC-sYFP2-2A-mTQ2-hTopoI construct. 
2.1.2. Bacterial Expression Vector 
 For expression in E. coli we also cloned target genes of interest into 
bacterial expression vectors pProEX HTb and pET21d (Figure 2.4 A and B). 
	 
Figure 2.4. Maps of bacterial expression vectors used for protein expressions. (A) pProEX-HTb, 
and (B) pET21d vectors. 
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 The optimized cDNAs encoding for hNTH1, YB1 and hTopoI were cloned 
into pProEX-HTb (Invitrogen) plasmid and placed under the control of an 
isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible pTrc promoter. In 
addition, the pProEX-HTb vector introduces a hexa-histidine (6x His) affinity tag 
followed by a highly specific tobacco etch virus (TEV) protease cleavage site at 
the amino (N-) terminus of the expressed protein (Figure 2.4 A). To obtain a 
carboxy-(C-)terminal 6x His-tagged form, the htopoI gene was cloned into 
pET21d (Novagen) plasmid under the control of a T7/Lac operon with NcoI and 
XhoI restriction enzymes (Figure 2.4 B). Both bacterial expression vectors contain 
an ampicillin resistance gene. 
2.1.2.1. Fluorescent Protein Coupled Constructs 
To express and purify fluorescent protein coupled proteins in E. coli, 
sYFP2-YB1∆C and hNTH1-mTQ2 were amplified from psYFP2-C1-YB1∆C and 
pmTQ2-N1-hNTH1 constructs, respectively and subcloned into pProEX-HTb 
plasmid. To create the new individual constructs by changing the position of 
fluorescent proteins (YB1∆C-sYFP2 and mTQ2-hNTH1), YB1∆C and hNTH1 
were ligated into digested pProEX-HTb-sYFP2 and pProEX-HTb-mTQ2, 
respectively. To determine the interaction domains of hNTH1, we created two 
different hNTH1 constructs (NtailhNTH1 and ND89hNTH1) fused with mTQ2 
(Figure 2.1). 
For bacterial protein expression, fluorescent protein coupled hTopoI 
constructs (mTQ2-hTopoI and hTopoI-mTQ2) were subcloned from pmTQ2-C1-
hTopoI and pmTQ2-N1-hTopoI into pProEX-HTb and pET21d plasmids, 
respectively. 
2.1.2.2. Biosensor constructs 
For bacterial expression of the Biosensor 1 (sYFP2-YB1∆C-hNTH1-mTQ2) 
construct, sYFP2-YB1∆C (~1360 bp) and hNTH1-mTQ2 (~1660 bp) were 
amplified by PCR using respectively psYFP2-C1-YB1 and pmTQ2-N1-hNTH1 as 
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templates. A 3-piece ligation was set up with digested PCR products sYFP2-
YB1∆C, mTQ2-hNTH1 and digested pProEX-HTb plasmid.  
For making the Biosensor 2 (sYFP2-YB1∆C-NtailhNTH1-mTQ2) and 
Biosensor 3 (sYFP2-YB1∆C-ND89hNTH1-mTQ2) constructs, NtailhNTH1-
mTQ2 and ND89hNTH1-mTQ2 were amplified by PCR using pmTQ2-N1-
hNTH1-Ntail and pmTQ2-N1-ND89hNTH1 as templates, respectively. Then both 
of them were ligated into digested pProEX-HTb-sYFP2-YB1∆C.  
To create the Biosensor 4 (sYFP2-YB1∆C-drEndoIII2-mTQ2) construct, 
drEndoIII2 (~675 bp) was amplified by PCR using Deinococcus radiodurans 
genomic DNA as a template. It was ligated into digested pProEX-HTb-mTQ2. 
Then drEndoIII2-mTQ2 (~1400bp) was ligated with digested pProEX-HTb -
sYFP2-YB1∆C. 
For making the Biosensor 5 (sYFP2-YB1∆C-mTQ2) and Biosensor 6 
(sYFP2- hNTH1-mTQ2) constructs, mTQ2 and sYFP2 were amplified by PCR 
using pProEX-HTb-mTQ2 and pProEX-HTb-sYFP2 as templates, respectively. 
Then both of them were ligated into digested pProEX-HTb-sYFP2-YB1∆C and 
pProEX-HTb-hNTH1-mTQ2, respectively.  
To create the Biosensor 7 (mTQ2-hNTH1-YB1∆C-sYFP2) construct, 
mTQ2-hNTH1 (~1660 bp) and YB1∆C-sYFP2 (~1360 bp) were amplified by 
PCR using psYFP2-N1-YB1 and pmTQ2-C1-hNTH1 as templates, respectively 
and cloned using the same strategy as Biosensor 1. 
To create the Biosensor 9 (mTQ2-hTopoI-YB1∆C-sYFP2) construct, 
mTQ2-hTopoI (~3000 bp), YB1∆C-sYFP2 (~1360 bp) and pET21d plasmid 
(~5500 bp) were amplified by PCR using pProEX-HTb mTQ2-hTopoI, psYFP2-
N1-YB1 and pET21d-hTopoI as templates, respectively. A 3-piece DNA 
assembly was performed with PCR products mTQ2-hTopoI, sYFP2-YB1∆C and 
pET21d by NEBuilder HiFi DNA Assembly kit. 
A list of all the constructs prepared in this work is provided in the Annex. 
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2.2. Protein expression and purification 
All recombinant proteins used in this work were overexpressed in 
Escherichia coli (E.coli) BL21 (DE3) cells with either a cleavable N-terminal His-
tag or an uncleavable C-terminal His-tag (for several human Topoisomerase I 
constructs). Bacterial cultures were grown in LB medium (Sigma) containing 100 
µg/ml Ampicillin at 37oC until they reached OD600 between 1.0 - 1.3. The cultures 
were then induced with 1 mM IPTG. 
2.2.1. Expression and purification of fluorescent proteins 
 All fluorescent proteins (mTQ2, sYFP2 and sYFP2-mTQ2 fusion) were 
overexpressed in BL21 (DE3) cells with a cleavable N-terminal His-tag. 1 liter (L) 
cell cultures were induced with 1 mM IPTG at 20oC with agitation o/n. The cell 
pellets were resuspended in 20 mL/liter Lysis Buffer containing 50 mM Tris pH 
8.0, 200 mM NaCl, 2 mM MgCl2, 0.5 mM EDTA, 0.02 % Triton. After lysis by 
sonication, the lysates were then centrifuged (30 min, 20000 rpm, 4oC) to remove 
cell debris. The supernatant was loaded on a 2 ml Ni-IDA sepharose and purified 
by gravity-flow on bench. The fractions containing fluorescent proteins eluted 
from the Ni-IDA with buffer containing 250 mM imidazole were pooled and 
concentrated using Millipore Amicon® Ultra centrifugal filter concentrators 
(Merck) before injection onto a Superdex 75 10/300 GL gel filtration column 
equilibrated in a 50 mM Tris pH 8.0, 200 mM NaCl. After determination of the 
protein concentration, aliquots of the proteins were flash-frozen in liquid nitrogen 
and then stored at -20oC.  
2.2.2. Expression and purification of fluorescent protein fusion 
proteins, Biosensor constructs and human Topoisomerase I (hTopoI) 
 1 or 2 L cell cultures of YB-1∆C and hNTH1 fusion proteins were induced 
with 1 mM IPTG at 20oC with agitation o/n. The cell pellets obtained after 
centrifugation (20 min, 6000 rpm, 4oC) were resuspended in 20 mL/liter Lysis 
Buffer containing 50 mM Tris pH 8.0, 2 M NaCl, 2 mM MgCl2, 0.5 mM EDTA, 
0.02 % Triton and 10 % Sucrose, supplemented with EDTA-free complete 
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protease inhibitor tablets (1 tablet for 2 L culture; Roche). We flash froze pellets 
in liquid nitrogen and stored them at -80oC.  
 6 or 12 L cell cultures of N- or C-terminally his-tagged hTopoI were 
induced with 1mM IPTG at 18oC o/n. The cell pellets were resuspended in 10 
mL/liter Lysis Buffer composed of 50 mM Tris pH 8.0, 1 M NaCl, 2 mM MgCl2, 
0.5 mM EDTA supplemented with EDTA-free complete protease inhibitor tablets 
(1 tablet for 2 L culture; Roche). hTopoI cell pellets were used directly for lysis 
without freezing. 
 Before cell lysis, we added a few mg lysozyme and DNaseI (Roche) into 
thawed pellets and incubated for 5 min on ice before continuing. We also added 
PMSF and β-mercaptoethanol (ME) at final concentration of 1mM. For 
constructs containing YB1∆C, we added 20 μl S7 nuclease (1mg/ml stock 
solution, Roche) to further eliminate nucleic acid contamination. The cell lysis 
was performed by sonication (Pulse ON 10 sec_Pulse OFF 30 sec_Time 
2:00_Amp 70%). For constructs containing YB1∆C, we added 1 M Urea to the 
sonicated lysates to facilitate the release of nucleic acids from proteins. The 
lysates were then centrifuged (30 min, 20000 rpm, 4oC) to remove cell debris.  
 For testing the interaction between two proteins, it is essential to have a 
sufficient amount of high quality protein that is stable and can be reproducibly 
prepared. Therefore, we optimized the purification protocols for each of our target 
proteins (Figure 2.5). 
!	 
Figure 2.5. Illustration of the purification protocol steps used in our various protein purifications. 
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 The first step of the purification was performed on a 5 ml HisTrap FF 
affinity column (GE Healthcare) on an ÄKTA Purifier FPLC (Fast Protein Liquid 
Chromatography) system (GE Healthcare) controlled by the Unicorn software. 
The column was equilibrated with Ni Buffer A (50 mM Tris pH 8.0, 0.5 M NaCl, 
2 mM MgCl2, 0.5 mM EDTA, 0.02 % Triton, 10 % Glycerol, 1 mM ME). All 
buffers used for FPLC were filtered and degased. The supernatant obtained from 
the lysis was loaded onto the column manually using a syringe and the column 
was then connected to the FPLC and washed extensively to elute weakly bound 
contaminants. The first wash was done with Ni Buffer A. Then other washes were 
performed with Ni Buffer A supplemented with 10 mM (2 % Ni Buffer B = Ni 
Buffer A with 500 mM imidazole) and 50 mM (10 % Ni Buffer B) imidazole. The 
protein was eluted with Ni Buffer A and a gradient of imidazole (100 % Ni Buffer 
B, during 50 min) and collected in 1.5 ml fractions in 96-well plates. After 
analysing fractions from chromatogram peaks on 10 or 12 % TGX Stain-Free 
Gels (Biorad), sample-containing fractions were pooled and centrifuged (13000 
rpm at 4°C for 5 min) to remove the precipitated protein. The TGX Stain-Free 
Gels contain unique trihalo compounds, which in the presence of UV-light react 
with tryptophan residues producing fluorescence that allow rapid fluorescent 
detection of proteins using the Chemidoc MP Gel Imaging System (Biorad). The 
protein concentration was determined by Bio-Rad protein assay using BSA as a 
standard following the manufacturer’s procedures. The nickel column was able to 
remove most cellular contaminants.  
 The second step of the purification was a Heparin affinity chromatography 
for eliminating nucleic acid contamination. The structure and negative charge of 
heparin enable it to mimic DNA in its overall binding properties so it is useful for 
purification of DNA binding proteins. Prior to loading onto Heparin columns, 
samples were diluted to lower the NaCl concentration to 200 mM. The protein 
was then loaded on a 5 ml HiTrap Heparin HP column (GE Healthcare), which 
was equilibrated with Heparin Buffer A (50 mM Tris pH 8.0, 100 mM NaCl, 0.5 
mM EDTA, 10 % Glycerol). First, the column was washed with 5 column 
volumes (CV) Heparin Buffer A, then the proteins were eluted with a linear NaCl 
gradient (0 to 100% Heparin Buffer B=Heparin Buffer A with 1 M NaCl, during 
60 min) and collected in 1 ml fractions. Ntail-hNTH1-mTQ2 construct was not 
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contaminated with nucleic acids so we performed an ion-exchange 
chromatography instead of a heparin affinity purification. The sample was diluted 
to 50 mM NaCl for loading onto a HiTrapQ FF column (GE Healthcare) and 
eluted with a NaCl gradient using the same buffers as for the Heparin 
chromatography. The protein containing samples were identified by 10 or 12 % 
TGX Stain-Free Gel (Biorad) analysis and were pooled. TEV (Tobacco Etch 
Virus) protease produced inhouse was added to the protein at a ratio of 1 mg to 20 
mg protein for cleavage of N-terminally His-tagged pProEX-HTb constructs. 
Cleavage was performed overnight at 4oC.  
 The final purification step was a size-exclusion chromatography. This 
chromatography serves as a quality control of our proteins. The sample was 
concentrated using Millipore Amicon® Ultra centrifugal filter concentrators 
(Merck). PMSF was added to the protein samples prior to injection onto a 
Superdex 200 10/300 GL column (GE Healthcare) or a SEC650 (BioRad) column 
equilibrated in a buffer containing 20 mM Tris pH 8.0, 1 M NaCl, 0.2 mM EDTA, 
1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 10 % glycerol (GF 
Buffer). 0.5 ml fractions were collected. This size-exclusion step was then 
repeated, this time with a GF Buffer containing 500 mM NaCl instead of 1 M 
NaCl. hNTH1 and hTopoI constructs were injected onto a Superdex 200 10/300 
GL gel filtration column equilibrated in a GF Buffer containing 200 mM NaCl. 
The elution peak containing the sample was pooled after checking on 10 or 12 % 
TGX Stain-Free Gel. The protein was concentrated and the final protein 
concentrations were measured using ultraviolet absorbance at 280 nm and the 
theoretical molar extinction coefficients of each construct on a NanoPhotometer 
TM UV/Vis Spectrophotometer (Implen). The molar extinction coefficients of the 
various proteins were calculated using the ProtParam tool on the ExPASy 
Proteomics Server (http://ca.expasy.org/tools/protparam.html), which bases its 
calculation on protein amino acid composition in conjunction with the molar 
extinction coefficients of tyrosine, tryptophan, and cystine (see Annex for details 
of all protein constructs). After determination of the protein concentration, 
aliquots of the proteins were flash-frozen in liquid nitrogen and then stored at -
80oC.  
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2.2.3. Large-scale purification of Biosensor 1 for chemical library 
screening  
 To obtain large amounts of Biosensor 1 for use in chemical library 
screening, 6 L of bacterial culture were prepared. The supernatant containing 
Biosensor 1 was obtained as described above. Four sequential Nickel column 
purifications were carried out. Biosensor constructs were eluted with a 150 mM 
imidazole step based on the elution profiles observed previously using gradient 
elution. Sample-containing fractions were pooled, and their salt concentrations 
were adjusted to 200 mM in order to perform three sequential Heparin column 
purifications. After eliminating DNA contamination, we performed several gel 
filtration purifications with SEC650 column first equilibrated in a GF Buffer 
containing 1 M NaCl, then equilibrated in a GF Buffer containing 500 mM NaCl.  
The elution peak containing the Biosensor 1 was pooled after checking on 10 % 
TGX Stain-Free Gel. Only highly pure fractions were conserved to minimise 
contamination by degradation products of Biosensor 1, which could interfere with 
FRET measurements. The protein concentration was measured on a 
NanoPhotometer TM UV/Vis Spectrophotometer (Implen). Aliquots of the 
proteins (1 ml / 0.5 ml) were flash-frozen in liquid nitrogen and then stored at -
80oC.  
2.2.4. Preparation of proteins for AlphaScreen Assay 
 For AlphaScreen measurements (see section 2.5), we used hNTH1 with its 
N-terminal His-tag (no cleavage with the TEV protease) and biotinylated YB1∆C. 
To biotinylate YB1∆C, we first used a 5 ml HiTrap Desalting column (GE 
Healthcare) to transfer 0.5mg YB1∆C into a phosphate buffer (20 mM 
NaPhosphate pH 8.0, 0.5 M NaCl, 1 mM MgCl2, 5 % glycerol, 0.005 % Triton X-
100 and 1 mM ME) instead of the Tris-based GF buffer, since the NHS-Biotin 
(Sigma) reacts with amine groups. YB1∆C was then incubated with 0.25 mM 
NHS-Biotin at 25ºC for 2 hours before the reaction was stopped by the addition of 
50 mM Tris pH 8.0. The excess of NHS-Biotin was then removed by a second run 
on the desalting column equilibrated this time in Tris GF buffer. Fractions 
containing biotinylated YB1∆C were pooled, aliquoted and stored at -80ºC. 
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2.3. In vitro Fluorescence Resonance Energy Transfer (FRET) 
measurements 
 FRET involves a non-radiative transfer of energy from an excited donor 
fluorophore to an adjacent acceptor fluorophore. Due to the nature of the 
transition dipole interaction between the two fluorophores, energy transfer is more 
efficient when they are in close proximity than when they are further apart, 
allowing one to measure relative distances of up to 10 nm between donor and 
acceptor, making FRET extremely sensitive to small changes in distance (Piston 
and Kremers, 2007). The donor molecules typically emit at shorter wavelengths, 
which overlap with the absorption spectrum of the acceptor. We used CFP (Cyan 
Fluorescent Protein) and YFP (Yellow Fluorescent Protein) variants 
(mTurquoise2 and sYFP2), two colour variants of GFP (Green Fluorescent 
Protein), as donor and acceptor fluorophores (Figure 2.6). All proteins used for 
FRET measurements were expressed as fusions with either of these two 
fluorescent proteins. In Biosensor constructs containing both sYFP2 and mTQ2, 
we measured intramolecular FRET. 
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Figure 2.6. Excitation (full line) and emission (dashed line) spectra of mTQ2 (cyan) and sYFP2 
(yellow) fluorescent proteins used in this study. The emission of mTQ2 overlaps extensively 
(grey) with the excitation spectrum of sYFP2. Vertical cyan and yellow full lines indicate the 
excitation wavelengths used for mTQ2, and sYP2, respectively. Vertical cyan and yellow dashed 
lines indicate the emission wavelengths used for mTQ2, and sYP2, respectively. 
  Fluorescence measurements were carried out on a Clariostar (BMG 
Labtech) microplate reader in black flat bottom Corning 384 well plates (Merck) 
at room temperature. Reaction mixtures were prepared in 50 μl final volume in 
GF buffer (20 mM Tris pH 8.0, 0.2 mM EDTA, 1 mM TCEP, 10 % glycerol) 
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containing different concentrations of NaCl or urea (6 M). Protein concentrations 
in protein mixes with hNTH1 constructs were at 5 μM final concentration for each 
protein. Protein mixes with hTopoI constructs were prepared at 1μM final 
concentration for each protein. Analysis of all biosensors was performed at 1 μM 
final concentration. All in vitro FRET measurements were performed in triplicate. 
 FRET efficiencies were calculated by performing three different 
measurements (Figure 2.7). First, the donor molecule (mTQ2) was excited at its 
absorption wavelength (435/15 nm) and the fluorescence intensity of mTQ2 was 
recorded at its emission wavelength (477/20 nm). The measurement corresponds 
to the donor channel, which we refer to as IDD. Second, the acceptor molecule 
(sYFP2) was excited at its absorption wavelength (485/15 nm) and the 
fluorescence intensity of sYFP2 was measured at its emission wavelength (528/20 
nm) (Figure 2.7 A). This measurement corresponds to the acceptor channel, 
referred to as IAA. Finally, a third measurement was performed in which mTQ2 
was excited at 435/15 nm, and the fluorescence intensity at sYFP2’s emission 
wavelength was recorded. We called this filter combination the FRET channel or 
IDA. If two fluorescent proteins are close enough to FRET, a decrease of mTQ2 
fluorescence intensity and an increase of sYFP2 fluorescence intensity will be 
observed in the FRET channel (Figure 2.7 B).  
	 
Figure 2.7. Schematic representation of the FRET measurements performed in order to calculate 
the FRET efficiency. (A) Fluorescence spectra of donor only (blue) and acceptor only (yellow) 
samples recorded using respectively donor and acceptor channels. (B) Fluorescence spectra of 
donor alone (blue) and of mixed donor and acceptor labeled samples (red) using the FRET 
channel. Ext.: Excitation, Em. max: Emmission maximum. 
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 Ratiometric FRET efficiency calculations were performed using various 
correction factors (Roszik et al., 2009). These spill-over factors reflect spectral 
crosstalk between the donor, the acceptor and the FRET channel and were 
calculated with donor only and acceptor only samples (Figure 2.8). S1 is the 
contribution of the donor alone to the FRET signal (IDA/IDD) and was calculated to 
be 0.42 for mTQ2. S2 is the contribution of the acceptor alone to the FRET signal 
(IDA/IAA) and was calculated to be 0.04 for sYFP2. S3 is the contribution of the 
donor alone to the acceptor signal (IAA/IDD) and was calculated to be 0.04 for 
mTQ2. 
	 
Figure 2.8. Fluorescence spectra showed spill-over factors between channels. (A) The 
fluorescence intensity contribution of donor only sample in the FRET and acceptor channels (S1 
and S3). (B) The fluorescence intensity contribution of acceptor only sample in the FRET channel 
(S2). 
 The FRET efficiency is the quantum yield of the energy transfer transition. 
The rate of relative detection sensitivity of the excited acceptor compared to the 
excited donor is described by the alpha factor (α), which was determined to be 
1.37 for our mTQ2/sYFP2 FRET pair (Nagy et al., 1998) (Table 2.1).  
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Table 2.1. Alpha Factor calculation with mTQ2 and sYFP2 fluorescent proteins 
alone.  
efr1 = ExC2 at max Å~ QY3 at donor excitation. 
  ExC at 
max  
QYmax at acceptor 
excitation 
QY at donor 
excitation 
ExC at donor 
Excitation 
Donor mTQ2 6055.82 n.a. 0.9300 5631.91 
Acceptor sYFP2 23466.86 0.68 0.0312 732.21 
    Ratio efr 7.69 
Alpha factor: IDA(acceptor alone)* efr / IDD(donor alone) 
1 efr: FRET efficiency, 2 ExC: extinction coefficient, 3 QY: quantum yield  
 The FRET efficiency (E) is calculated by the following formula: 
E =
A
1 + A
 
with A =
1
α
 × 
IDA − (IDD × S1) − (IAA × S2) + (IDD × S2 × S3)
IDD
  
2.4. In vitro high-throughput screening with Biosensor 1 
2.4.1. Optimization of Biosensor 1 FRET measurements 
 To investigate the effect of DMSO, FRET measurements were performed on 
0.2 µM Fusion and Biosensor 1 proteins in 50 mM NaCl GF buffer containing 
various concentrations of DMSO (0.5-5 % DMSO). To evaluate the stability of 
the biosensor, FRET measurements of 0.2 μM Biosensor 1 in presence of DMSO 
(0.5 and 1.3 %) were repeated every 10 minutes for 2 hours. A dose response 
curve was prepared with 12nt THF dsDNA oligonucleotide (see Annex for 
sequence) to find the concentration needed for inhibition of the interaction in 
order to use as our positive control for our assay. Minimal FRET values were 
obtained by adding 0.5 μM 12nt THF dsDNA oligonucleotide to the reactions.  
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 We performed high-throughput screening with 0.2 µM Biosensor 1 in GF 
buffer containing 50 mM NaCl (20 mM Tris pH 8.0, 50 mM NaCl, 0.2 mM 
EDTA, 1 mM TCEP, 10 % glycerol). The final reaction volume was 50 µl. The 
FRET efficiency was determined by measuring the emission of excited mTQ2 and 
sYFP2 (excitation filter at 435/15 nm for mTQ2 and at 485/15 nm for sYFP2) at 
their maximal emission wavelengths (emission filter at 477/20 nm for mTQ2 and 
528/20 nm for sYFP2) (endpoint measurements). FRET efficiencies were 
calculated as described above. FRET efficiencies of Prestwick Chemical Library 
second screening were calculated after subtraction of the fluorescence values of 
the compounds alone.     
 For a reliable screening assay, there must be a significant separation 
between the "Max" and "Min" signals. The Z' factor can be used to evaluate this 
signal separation. We performed a Z' factor assay with 30 samples with 0.2 μM 
Biosensor 1 in 50 mM NaCl (our “Max” signal) and 30 samples with 0.2 μM 
Biosensor 1 in 50 mM NaCl in the presence of 0.5 μM 12nt THF dsDNA 
oligonucleotide (our “Min” signal). The FRET measurements were performed on 
both the Clariostar and the TECAN microplate reader to determine the Z' factors 
for both plate readers.  
2.4.2. Chemical library screening at CMBA platform 
High-throughput chemical library screening was performed on the Center 
for the screening for BioActive Molecules (CMBA) platform at the CEA, 
Grenoble. Two chemical libraries were screened: the PPI library from Life 
Chemicals (800 compounds) and the Prestwick library (1280 compounds). All 
chemical compounds used in our chemical screens were dissolved in 100 % 
DMSO. Test compounds from Life Chemicals and Prestwick Chemicals were 
delivered at 3.8 mM and 10 mM, respectively in 100 % DMSO. For the screening, 
reactions were carried out in 50μl final volume in GF buffer containing 50 mM 
NaCl. First, 40 μl 0.25 μM Biosensor 1 was added to the wells of Corning 384 
well plates, then 10 μl of 5 times concentrated compound stock solution was 
added to Biosensor 1. After mixing by pipetting, emission wavelengths of excited 
mTQ2 and sYFP2 were measured on a TECAN microplate reader at different time 
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points after mixing: 15, 30 and 60 min. All reactions were performed in triplicate 
at 50 μM final concentration of inhibitor for the first screening, and then 30 
selected test compounds were further tested in a secondary screen in triplicate at 
50, 10 and 1 μM final concentrations. All assay plates contained multiple negative 
(Biosensor 1 without test compounds) and positive controls (Biosensor 1 with 
12nt THF oligonucleotide, 5 M NaCl or 2.5 M NaCl)  (Figure 2.9).  
	 
Figure 2.9. Illustration of screening plates. (A) 96-well plate containing 5x stock solutions. Green 
wells: 2.5 % DMSO in buffer containing 50 mM NaCl. Red wells: Total 80 compounds at 250 µM 
concentration for each plate. Blue wells: Positive controls; from top to bottom 2.5 µM 12nt THF 
oligonucleotide in 50 mM NaCl, 5 M NaCl, and 2.5 M NaCl respectively. (B) 384-well plate used 
for screening every test compounds in triplicate. 
A large batch of Biosensor 1 was purified, so that all the tests and screens 
were performed with the same protein stock. For Life Chemicals PPI fragment 
library first screening, 3.2 mg Biosensor 1 (110 ml at 0.25 µM concentration), 20 
µl at 50 µM concentration 12nt THF oligonucleotide, and 10 Corning 384-well 
plates were used. For Prestwick Chemicals first screening, 5.4 mg Biosensor 1 
(175 ml, at 0.25 µM concentration), 28 µl at 50 µM concentration 12nt THF 
oligonucleotide, and 16 Corning 384-well plates were used. For second screenings 
of 30 selected compounds, 0.4 mg Biosensor 1 (14 ml, at 0.25 µM concentration), 
7.5 µl at 50 µM concentration 12nt THF oligonucleotide, and 1 Corning 384-well 
plates were used. 
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 The FRET efficiencies of all compounds were calculated and compared to 
the maximal FRET control to determine the percent inhibition for each compound 
with the following formula: 
% inhibition = 100 × [ 1 −
(Χ − MIN)
(MAX − MIN)
] 
 Various validation tests were performed on selected compounds displaying 
significant FRET inhibition in our secondary screens. Powders were purchased 
from Sigma and were solubilized in 100 % DMSO before storing them at -20ºC or 
4ºC. We checked the fluorescence of these compounds by measuring their 
fluorescence at 435 and 528 nm after dilution in GF buffer containing 50 mM 
NaCl. To evaluate the effects of these compounds on our Fusion construct 
(sYFP2-mTQ2), 40 μl 0.25 μM Fusion was mixed with 10 μl of test compounds 
(at 250 µM) prior to fluorescence reading. 
 Selected compounds were further tested on the Biosensor 1 with dose 
response experiments, in which increasing concentrations of compounds (all 
prepared at a final DMSO concentration of 1%) were added to Biosensor 1. The 
various compound concentrations were prepared by serial (1:2) dilutions of 500 
µM stock solution. The data points corresponding to the means of triplicate 
measurements were fitted to a standard sigmoidal inhibition model in GraphPad 
Prism 6 using the following formula: 
Y = Bottom +
(Top − Bottom)
(1 + 10(LogIC50−Log (X))× H)
 
 
X: Compound concentration 
Y: Response, decreasing as X increases 
Top and Bottom: Plateaus in same units as Y 
IC50: Concentration of compound causing half maximal inhibition 
H: Hill slope. 
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2.5. AlphaScreen Assay 
Potential hits identified from our HTS with Biosensor 1 were further 
validated with another technique known as AlphaScreen. We used donor beads 
coated with streptavidin and AlphaLisa acceptor beads coated with anti-His 
antibodies. These beads were used to bind biotinylated YB1C and His-tagged 
hNTH1, respectively. AlphaScreen assays were performed in white, flat-bottom, 
small volume 384-well plates (Perkin Elmer). The final reaction volume was 20 
µl. All reagents were diluted in AlphaScreen buffer (AS buffer) composed of 20 
mM Tris pH 7.5, 150 mM NaCl, 0.01 % Triton X-100, 0.01 % Tween 20, 0.5 mM 
EDTA, 1 mM ME and 0.1 mg/ml BSA. First, 8 µl of the compounds diluted in 
AS buffer supplemented with 2.5 % DMSO (or the buffer alone for controls 
without compounds) were transferred to the wells. Then 2 µl of biotinylated 
YB1C at 100 nM (10 nM final concentration) and 2 µl of His-tagged full-length 
hNTH1 at 1 µM (100 nM final concentration) were added to the wells. After a 30 
min incubation at room temperature, 4 µl of anti-His AlphaLisa acceptor beads 
diluted to 0.1 mg/ml in AS buffer were added to the wells and the reaction was 
left to incubate for a further 45 min at room temperature and protected from light 
with aluminium foil. Finally, 4 µl of streptavidin-coated donor beads diluted to 
0.1 mg/ml in AS buffer were added to the wells and after 45-60 min incubation, 
the plate was read on the Clariostar plate-reader fitted with an aperture spoon (to 
avoid excitation of neighbouring wells) and the appropriate filters (excitation filter 
at 680/40 nm and emission filter at 570/100 nm). Reactions were prepared in 
triplicate. The data points corresponding to the means of triplicate measurements 
were fitted in GraphPad Prism 6 to the same sigmoidal inhibition model as 
described above. 
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2.6. DNA relaxation activity assays 
 Supercoiled plasmid relaxation assays were carried out in 10 μl final volume 
containing 1μl purified hTopoI enzyme, 250 ng supercoiled pUC19 plasmid in 
reaction buffer (20 mM Tris pH 8.0, 72 mM KCl, 5 mM MgCl2, 0.1 % BSA). 
Reactions were started by addition of the enzyme. The reaction mixture was 
incubated at 37oC for 30 min. Reactions were terminated with one volume of stop 
buffer (0.1 M EDTA, 4 % SDS, 0.1 % bromophenol blue, 30 % glycerol) and 
relaxation products were separated on 0.8 % agarose gel in 1xTBE buffer (89 mM 
Tris-borate, pH 8.0, 2 mM EDTA) in a horizontal electrophoresis apparatus (5 
V/cm) at 4ºC and photographed under UV light after staining in water containing 
Gel Green (Biotium) for 20 min. The TopoI inhibitor, CPT was used as a control 
in our reactions (Beidler and Cheng, 1995). To check the stimulation of hTopoI 
relaxation activity by YB1C protein, hTopoI and YB1C were preincubated at 
room temperature for 10 minutes before starting the relaxation reactions (Osheroff 
and Bjornsti, 2001; Senarisoy et al., 2013). 
 Substrate plasmid DNA pUC19 was purified from E. coli using a Qiagen 
Plasmid Maxi Kit. The purified plasmid was free of contaminating protein and 
was primarily composed of negatively supercoiled covalently closed circular 
DNA molecules (form I DNA), with nicked circles (form II DNA) representing no 
more than 20 % of the total DNA (Figure 2.10) (Bjornsti and Osheroff, 1999). 
	 
Figure 2.10. Representative agarose gel image to show the mobility of the supercoiled substrate 
(form I), the nicked circles (form II), and the relaxed topoisomers (form I relaxed). 
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2.7. Maintenance and transfection of mammalian cells 
We used the MCF7 cell line to investigate the interaction of YB1ΔC and 
hNTH1. MCF7 cells were maintained as subconfluent monolayer cultures in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with Glutamax-I (Life 
Technologies) supplemented with 10 % fetal bovine serum, 100 units/ml 
penicillin, and 100 μg/ml streptomycin, 0.1 mM non-essential amino acids, 1 mM 
sodium pyruvate at 37oC under a humidified 5 % CO2 atmosphere. For passage, 
cell layers were detached by trypsinization and reseeded upon dilution (1:6). 
 To detect the interaction of YB1ΔC and hTopoI, we used HeLa, MCF7 
and PC3 cells. HeLa cells were grown in 35 mm dishes using DMEM (Life 
Technologies) supplemented with 10 % fetal bovine serum, 100 units/ml 
penicillin, and 100 μg/ml streptomycin and the cells were maintained in a 37oC 
incubator supplied with 5 % CO2. PC-3 cell line was obtained from the European 
Collection of Authenticated Cell Cultures (ECACC). PC3 cells were maintained 
in Coon's Modification of Ham's F-12 (Sigma) supplemented with 10 % fetal 
bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37oC under 
a humidified 5 % CO2 atmosphere. For passage, cell layers were detached by 
trypsinization and reseeded upon dilution (1:10). 
 For all three cell lines, 24 h before transfection a monolayer culture 
covering 80 % of the substratum (i.e. 80 % confluent) was divided 1:3 into 35 mm 
dishes containing two microscope coverslips. Cells were transfected with 1 μg 
plasmid DNAs using FuGENE HD transfection reagent (Promega) in accordance 
with the manufacturer’s instructions. Cells were grown on microscope coverslips 
for 24 h post transfection before being washed in PBS, fixed in 2 % 
paraformaldehyde in PBS (37°C, 15 min) and then washed again three times for 5 
min in PBS. Slides were finally mounted in DABCO, and immediately inspected 
under the microscope. 
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2.8. FRET measurements in mammalian cells 
Fluorescence microscopy – particularly exploiting genetically expressed 
fluorescent proteins – can be applied directly to map and quantify protein 
interactions in live or fixed cells and preserve information concerning the 
inhomogeneous cellular distribution of molecules, with typical spatial resolution 
below 0.5 μm (Jares-Erijman and Jovin, 2006). 
The epifluorescence microscope on the M4D imaging platform of IBS was 
used to check for cell localisation and transfection efficiency before acceptor 
photobleaching experiments. For acceptor photobleaching experiments, the cells 
were monitored after fixation using an Olympus IX81 confocal spinning disk 
microscope equipped with a FRAPPA device on the M4D imaging platform of 
IBS (Figure 2.11). The images were acquired with a 60x objective and with 
appropriate filter sets for the two channels (CFP and YFP). Exposure times were 
typically of 100ms and laser powers of CFP (445 nm) and YFP (515 nm) were 80 
%, and 5 %, respectively. 
	
 
Figure 2.11. Illustration of the confocal, spinning disk microscopy platform setup used for the 
acceptor photobleaching experiments on fixed cells. 
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 Acceptor photobleaching is a one of the methods for detecting FRET in 
cells. In FRET, the acceptor fluorophore quenches the donor fluorescence by 
taking its energy. Photobleaching the acceptor fluorophore releases this quenching 
and in case of FRET, the donor fluorescence increases when the acceptor is 
bleached. For acceptor photobleaching experiments, we acquired 50 sequential 
images (100 ms exposure time, laser 445 nm for CFP with 80 % power and laser 
515 nm for YFP with 5 % power). After 10 acquired images, the acceptor was 
gradually photobleached (100 ms exposure time, laser 515 nm and 1-3 % power) 
in a selected area of the nucleus. The imaging scans were acquired with a laser 
power attenuated to 0.1 – 1 % of the bleach intensity. For quantitative acceptor 
photobleaching analysis, fluorescence intensities of the bleached region (ROI 1), 
the entire cell nucleus (ROI 2) and background (ROI 3) were measured at each 
time point. Data were corrected for extracellular background intensity and for the 
overall loss in total intensity as a result of the bleach pulse itself and the imaging 
scans. Images were analysed with Volocity software and the FRET efficiency was 
calculated using the acceptor photobleaching (donor dequenching) method 
described in Roszik et al., 2013 which is independent of the donor-to-acceptor 
ratio.  
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Summary 
FRENCH 
Partie I. Complexe de YB-1/hNTH1 
Du signal FRET a été détecté en utilisant la technique de photoblanchiment 
de l’accepteur dans des cellules MCF7 transfectées de manière stable avec 
hNTHl-mTQ2 et exprimant de manière transitoire YB-1ΔC-sYFP2. Afin de 
surmonter la faible efficacité de co-transfection et d'étudier les conditions dans 
lesquelles interagissent hNTH1 et YB-1, nous avons créé une seule chaine 
polypeptidique, qui contient les protéines sYFP2, YB-1ΔC, hNTH1 et mTQ2 
reliées par des liaisons d’acides aminés (entre 5 et 10). Nous n'avons pas observé 
de signal FRET significatif avec les cellules MCF7 exprimant le Biosenseur 1 
nucléaire. 
Toutes les protéines utilisées pour des expériences de FRET in vitro ont été 
purifiées avec succès. Le signal FRET a pu être détecté lors du mélange de 
protéines individuelles à une concentration de protéine de 5 μM dans du tampon 
contenant 50 mM de NaCl. A cette concentration de NaCl, l'efficacité de FRET du 
Biosenseur 1 est également très élevée (39%) et comparable à celle obtenue avec 
notre construction Fusion dans laquelle sYFP2 et mTQ2 sont associées en une 
même chaine polypeptidique (~ 40%). Nous avons effectué des mesures FRET sur 
les 7 constructions de Biosenseur à différentes concentrations de NaCl (50 mM - 1 
M), indiquant que l'interaction entre YB-1ΔC et hNTH1 est spécifique, mais 
semble être très sensible au sel. Toutes les constructions de Biosenseur ont montré 
des efficacités de FRET minimales similaires en présence d'urée 6 M. Nous avons 
effectué des mesures de FRET en présence d’un substrat ADN non clivable de 
hNTH1. Nous avons observé un effet similaire à celui du sel. Lorsque la 
concentration d'oligonucléotide augmente, l'efficacité de FRET diminue. Nous 
avons également effectué les mesures FRET dans du NaCl 50 mM à différentes 
concentrations de protéines du Biosenseur 1 (allant de 0,01 à 2 μM). Nous avons 
observé que l'efficacité de FRET du Biosenseur 1 diminuait rapidement lorsque la 
concentration était inférieure à 0,2 μM. 
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La caractérisation des différentes constructions de Biosensor et de nos 
expériences d'optimisation de tampon a clairement indiqué que notre Biosenseur 
était un outil approprié pour examiner l'interaction de hNTH1-YB-1 et également 
pour cribler les inhibiteurs potentiels de cette interaction. Le DMSO n'a pas 
affecté significativement les niveaux de FRET du Biosenseur. Pour tester la 
robustesse de notre test, nous avons effectué un test de facteur Z' sur 30 
échantillons en l'absence et la présence d’oligonucléotide dsDNA 12nt THF. Les 
valeurs du facteur Z' issues des mesures effectuées dans notre laboratoire sur le 
lecteur de plaques Clariostar et sur la plateforme CMBA sont respectivement de 
0,83 et 0,90, ce qui montre que notre Biosenseur 1 est un outil très fiable pour 
détecter les inhibiteurs potentiels de l’intéraction YB-1ΔC/hNTH1. Nous avons 
utilisé notre Biosenseur 1 pour réaliser un criblage à haut débit de la chimiothèque 
Life Chemicals PPI (Interactions protéine-protéine) et de la chimiothèque 
Prestwick Chemical sur la plateforme CMBA en collaboration avec Dr. Caroline 
Barette. Le premier criblage à haut débit a été effectué avec 0,2 μM de Biosenseur 
1 et une concentration de composé fixée à 50µM en triplicatas dans un volume 
final de 50 μl. Après ce premier HTS, 30 composés sélectionnés présentant des 
taux réduits de FRET ont été testés à trois concentrations différentes (50, 10 et 1 
μM). Nous avons trouvé trois composés de la chimiothèque Life Chemicals PPI 
qui présentaient une inhibition de 30-60% à une concentration de 50 μM et 
avaient toujours un effet inhibiteur à une concentration de 1 μM. 8 composés de la 
chimiothèque de Prestwick se sont avérés être des inhibiteurs potentiels affichant 
une inhibition claire et dépendante de la concentration sur le signal FRET. Les 
composés de la chimiothèque Life Chemicals PPI ont montré une fluorescence 
intrinsèque. Les inhibiteurs potentiels de la chimiothèque Prestwick ont été 
sélectionnés parmi ceux qui ne présentaient pas de signal de fluorescence 
intrinsèque. Les 7 composés Prestwick n'ont eu aucun effet sur le signal FRET de 
la fusion, alors que les composés Life Chemicals ont réduit le signal FRET de 6 à 
9%, indiquant que leur fluorescence intrinsèque, relativement élevée, peut 
interférer avec le processus de FRET. L'efficacité réduite de FRET peut ainsi 
résulter de la fluorescence intrinsèque du composé et non de l'inhibition de 
l'interaction hNTH1/YB-1. Trois composés d'essai identifiés à partir de la 
chimiothèque Life Chemicals PPI semblent donc être des faux positifs. Nos 
expériences de validation des composés Prestwick à partir de poudre achetés chez 
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Sigma suggèrent que plusieurs composés obtenus à partir de la plate-forme 
CMBA pourraient être dégradés ou modifiés en raison de la congélation-
décongélation répétée avant utilisation dans le criblage haut débit. Leur effet 
inhibiteur sur l'interaction hNTH1/YB-1ΔC peut donc être le résultat de leur 
dégradation ou altération. Des expériences AlphaScreen ont validé l'effet 
inhibiteur de certains composés Prestwick. 
Partie II. Complexe de YB-1/hTopoI 
Nous avons exprimé et purifié deux formes de la topoisomérase I humaine : 
hTopoI-FL et hTopoI-70 à partir de la purification de l'hTopoI marquée par His à 
l'extrémité C-terminale. Les activités de relaxation de hTopoI-FL et de hTopoI-70 
étaient similaires. Campthotécin a montré un effet inhibiteur similaire sur l'activité 
de hTopoI-FL et hTopoI-70 avec des IC50 dans la gamme de 5-10 μM. YB-1ΔC 
stimule clairement l'activité de hTopoI-FL et de hTopoI-70, très probablement par 
une interaction directe, ce qui suggère que le domaine N-terminal de hTopoI n'est 
pas essentiel pour l'interaction avec YB-1ΔC. 
Les constructions de fusion de hTopoI ont été purifiées avec de faibles 
rendements. Nous avons réussi à mesurer du signal de FRET avec des 
constructions de fusion hTopoI à une concentration finale de seulement 1 μM de 
protéine dans du tampon contenant 50 mM de NaCl. Le signal le plus élevé a été 
obtenu quand à la fois mTQ2 et sYFP2 ont été fusionnés aux extrémités C-
terminales de hTopoI et YB-1ΔC. Les efficacités de FRET étaient plus faibles 
dans le cas de hTopoI-70, mais significativement plus élevées qu'avec le contrôle 
négatif (mTQ2 seul), indiquant que la région N-terminale est importante, mais pas 
essentielle pour l'interaction avec YB-1ΔC, en accord avec nos mesures d'activité 
de relaxation qui ont montré que YB-1ΔC pouvait également stimuler hTopoI-70. 
Nous avons observé que des quantités accrues de sel conduisent à des efficacités 
de FRET réduites en affectant l'interaction.  
Nous avons ensuite étudié l'interaction entre YB-1 et hNTH1 dans plusieurs 
lignées cellulaires (HeLa, MCF7 et PC-3). Nous avons détecté un faible signal de 
FRET avec les cellules MCF7 et PC-3 co-transfectées avec mTQ2-hTopoI et YB-
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1ΔC-sYFP2, mais des études plus approfondies seront nécessaires pour confirmer 
ces résultats préliminaires.  
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Özet 
TURKISH 
Bölüm I. YB-1/hNTH1 kompleksi 
FRET sinyali, hNTH1-mTQ2 proteinini stabil olarak eksprese eden ve 
YB-1∆C-sYFP2 ile geçici olarak transfekte edilmiş MCF7 hücrelerinde akseptör 
foto-ağartma tekniği kullanılarak tespit edilmiştir. Düşük ko-transfeksiyon 
etkinliğinin üstesinden gelmek ve hNTH1 ve YB-1'in etkileştiği koşulları 
araştırmak için, kısa amino asitlerle bağlanan sYFP2, YB-1∆C, hNTH1 ve mTQ2 
proteinlerini içeren tek bir polipeptit yapısı olan Biyosensör 1 oluşturuldu. 
Biyosensör 1’i nükleuslarında eksprese eden MCF7 hücreleri ile anlamlı bir FRET 
sinyali gözlemlenmemiştir. 
In vitro FRET deneylerinde kullanılacak olan tüm rekombinant proteinler 
başarıyla saflaştırılmıştır. FRET sinyali, 50 mM NaCI içeren tampon içinde 5 μM 
protein konsantrasyonunda proteinlerin karıştırılmasıyla tespit edilebilmiştir. 
Biyosensör 1'in FRET etkinliği 50 mM'lik bir tuz konsantrasyonunda çok 
yüksektir (% 39) ve FRET kontrolü olan sYFP2-mTQ2 Füzyon proteinimizle (% 
40) elde edilen değere yakındır. Oluşturduğumuz 7 farklı biyosensör yapısıyla 
artan tuz konsantrasyonlarında (50 mM NaCl-1 M NaCl) FRET ölçümleri 
gerçekleştirilmiş ve YB-1∆C ile hNTH1 arasındaki etkileşimin yüksek tuz 
konsantrasyonlarına duyarlı olduğu görülmüştür. Tüm biyosensör yapıları, 6 M 
üre varlığında benzer minimal FRET verimliliği göstermiştir. FRET ölçümleri, 
hNTH1'in hidrolize edilemeyen substratı (12nt THF dsDNA oligo) varlığında 
gerçekleştirilmiş ve tuz konsantrasyonuna benzer bir etki gözlemlenmiştir. 
Oligonükleotid konsantrasyonu arttığında FRET verimliliği azalmaktatır. Aynı 
zamanda FRET ölçümleri farklı Biyosensör 1 protein konsantrasyonlarında (0.01 
ila 2 μM arasında) 50 mM NaCl içeren tamponda gerçekleştirilmiştir. Biosensor 
1'in FRET verimliliğinin, 0.2 μM'nin altındaki konsantrasyonlarında hızla 
düştüğünü gözlemlenmiştir. 
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Farklı biyosensör yapılarının karakterizasyonu ve tampon optimizasyon 
deneylerimiz, biyosensörümüzün hNTH1-YB-1 etkileşimini araştırmak ve aynı 
zamanda bu etkileşimin potansiyel inhibitörlerini taramak için uygun bir araç 
olduğunu açıkça göstermektetir. Kimyasal kütüphanelerindeki bileşiklerde 
kullanılan DMSO, Biyosensörün FRET seviyelerini önemli ölçüde etkilememiştir. 
Tarama testinin güvenilirliğini test etmek için, pozitif kontrolümüz olan 12nt THF 
küt uçlu çift iplikli DNA oligonükleotidin yokluğunda ve varlığında 30’ar örnek 
üzerinden bir Z' faktör testi gerçekleştirilmiştir. Laboratuvarımızda Clariostar 
microplaka okuyucu ve CMBA platformu üzerinde yapılan ölçümlerden elde 
edilen Z' faktör değerleri, sırasıyla 0.83 ve 0.90'dır. 1’e yakın olan bu değerler, 
Biyoensör l'in YB-1ΔC/hNTH1 etkileşiminin potansiyel inhibitörlerini tespit 
etmek için güvenilir bir araç olduğunu göstermektedir. Life Chemicals Protein-
protein Etkileşimleri (PPI) kimyasal kütüphanesinin ve Prestwick Chemical 
kimyasal kütüphanesinin CMBA platformunda yüksek verimli taramasını 
gerçekleştirmek için Biyosensör 1'i kullandık. İlk yüksek verimli tarama (HTS), 
50 μl'lik son hacimde, üç tekrar şeklinde 0.2 μM Biyosensör 1 ve 50 μM bileşik 
konsantrasyonu ile gerçekleştirilmiştir. Bu ilk HTS'den sonra, azaltılmış FRET 
seviyeleri gösteren 30 seçilmiş bileşik, üç farklı konsantrasyonda (50, 10 ve 1 
μM) tekrar test edilmiştir. Life Chemicals PPI kimyasal kütüphanesinden 50 μM 
konsantrasyonunda % 30-60 inhibisyon gösteren ve 1 μM konsantrasyonunda hala 
inhibitör etki gösteren üç bileşik bulunmuştur. Prestwick Chemical kimyasal 
kütüphanesinden 8 bileşik, FRET sinyalini konsantrasyona bağlı bir inhibe 
edebilen potansiyel inhibitörler olarak belirlenmiştir. 
Life Chemicals PPI kimyasal kütüphane isabetleri içsel bir floresan 
göstermiştir. Prestwick Kütüphanesi'nden potansiyel isabetler, içsel bir floresan 
sinyali göstermeyenler arasından seçilmiştir. 7 Prestwick bileşiğinin Füzyon’un 
FRET sinyali üzerinde hiçbir etkisi bulunmamaktadır, ancak Life Chemicals 
bileşikleri FRET sinyalini % 6 ila 9 oranında düşürmüştür; bu, nispeten yüksek 
içsel floresansın FRET sürecine müdahale edebileceğini göstermiştir. Dolayısıyla, 
azaltılmış FRET verimliliği, hNTH1/YB-1 etkileşiminin inhibisyonundan değil, 
bileşiğin içsel floresansından kaynaklanabilir. Life Chemicals PPI kimyasal 
kütüphanesinden tanımlanan üç test bileşiği yanlış pozitif gibi görünmektedir. 
Elde ettiğimiz sonuçlar, CMBA platformundan elde edilen birkaç bileşiğin 
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kimyasal taramada kullanılmadan önce tekrarlanan donma-çözülme nedeniyle 
bozulabileceğini veya modifiye olabileceğini göstermektedir. Bu nedenle, 
hNTH1/YB-1ΔC etkileşimi üzerindeki inhibitör etkileri, bozulmalarının veya 
değiştirilmelerinin bir sonucu olabilir. AlphaScreen deneyleri bazı Prestwick 
bileşiklerinin inhibitör etkisini doğrulamıştır. 
Bölüm II. YB-1/hTopoI kompleksi 
C-terminal His-etiketli hTopoI'nin saflaştırılmasından iki protein formu 
hTopoI-FL ve hTopoI-70 elde edilmiştir. hTopoI-FL ve hTopoI-70'in relaksasyon 
aktiviteleri benzer çıkmıştır. Campthotecin, 5-10 μM aralığında IC50 değerleri ile 
hTopoI-FL ve hTopoI-70'in aktivitesi üzerinde benzer bir inhibitör etki 
göstermiştir. YB-1ΔC, hTopoI-FL ve hTopoI-70'in aktivitesini, büyük olasılıkla 
doğrudan etkileşim yoluyla benzer şekilde uyarmaktadır; bu da, hTopoI'nin N-
terminal alanının YB-1ΔC ile etkileşim için tek bölge olmadığını düşündürmüştür. 
Floresan proteinlerle füzyon hTopoI proteinleri, düşük verimle 
saflaştırılmıştır. FRET sinyali, 50 mM NaCl içeren tamponda sadece 1 μM protein 
konsantrasyonunda floresan proteinlerle füzyon olan hTopoI ve YB-1ΔC 
proteinleri ile ölçülebilmiştir. En yüksek sinyal, hem mTQ2 hem de sYFP2’nin, 
hTopoI ve YB-1ΔC'nin C terminallerine füzyonundan elde edilmiştir. FRET 
verimliliği hTopoI-70-mTQ2 durumunda azalmış, ancak yine de negatif kontrol 
(mTQ2) ile karşılaştırıldığında anlamlı olarak daha yüksek çıkmıştır. Bu N-
terminal bölgesinin önemli olduğunu, ancak hTopoI-70'in de YB-1 ile 
uyarılabildiğini gösteren relaksasyon aktivite ölçümleri ile uyumlu olarak 
etkileşim için zorunlu olmadığını göstermiştir. Artan tuz konsantrasyonlarının, 
etkileşimi etkileyerek düşük FRET verimliliğine yol açtığı gözlemlenmiştir. 
YB-1 ve hTopoI arasındaki etkileşim, birçok hücre hattında (HeLa, MCF7 
ve PC-3) araştırılmıştır. mTQ2-hTopoI ve YB-1∆C-sYFP2 ile birlikte transfekte 
edilmiş MCF7 ve PC-3 hücreleri ile bir miktar FRET sinyali saptanmıştır ancak 
bu ön sonuçları doğrulamak için daha ileri çalışmalara ihtiyaç duyulmaktadır. 
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Part I. YB-1/hNTH1 complex 
Before my arrival in Grenoble, Dr. J. Timmins’ team had shown that 
hNTH1 and YB-1 interact in vitro (AlphaScreen assay) as described in the 
“Introduction”. Moreover, using in vitro DNA repair activity measurements using 
purified hNTH1 and YB-1, YB-1 had been shown to specifically stimulate the 
lyase activity of hNTH1, but not the glycosylase activity. The objectives of my 
work were to further investigate the YB-1/hNTH1 complex formation in vivo and 
to design and optimise a FRET-based biosensor to detect the interaction of 
hNTH1 with YB-1, which could be used for high-throughput chemical library 
screening for potential inhibitors of the YB-1/hNTH1 complex in order to use for 
sensitizing cisplatin-resistant mammalian cells. 
3.1. YB-1/hNTH1 interaction in mammalian cells 
YB-1 and hNTH1 had previously been shown to interact in MCF7 breast 
cancer cells (Guay et al., 2008). We thus set out to further study this interaction in 
cells using the FRET method. First, we prepared mammalian expression vectors, 
encoding for either hNTH1 fused to the cyan fluorescent protein, mTurquoise2 
(mTQ2) (Goedhart et al., 2012) or YB-1 fused to the yellow fluorescent protein, 
sYFP2 (Kremers et al., 2006). mTQ2 and sYFP2 are high brilliance, FRET-
compatible fluorescent proteins (Kremers et al., 2006) (see Annex for list of 
constructs). Two constructs of YB-1 were prepared: one of them corresponding to 
the intact protein, and the other one corresponding to the nuclear form of YB-1 
that is missing the C-terminal region (YB-1C). We checked the expression and 
cellular localisation of these constructs after transfection into the breast cancer cell 
line, MCF7 (Figure 3.1). As expected, hNTH1 and the truncated YB-1 (YB-1C) 
were found to localise to the nucleus, while the full-length YB-1 mostly localised 
to the cytoplasm (Figure 3.1). For subsequent experiments, we thus used only the 
nuclear form of YB-1, which is more relevant for the study of its interaction with 
hNTH1. 
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Figure 3.1. MCF7 cells transfected with hNTH1-mTQ2 (A), YB-1-sYFP2 (B) and YB-1ΔC-
sYFP2 (C). 
For in vivo FRET assays, MCF7 cells were transfected with both hNTH1 
fused to mTQ2 and YB-1C fused to sYFP2. However, the co-transfection 
efficiency was very low (<1 %) and it was difficult to find cells expressing both 
constructs. To overcome this problem, we developed two strategies in parallel, 
which are described below. First, we established a stable MCF7 cell line, which 
expressed hNTH1-mTQ2 and could be used for transfection with YB-1∆C fused 
to sYFP2. Second, we designed a Biosensor construct encoding sYFP2, YB-1∆C, 
hNTH1 and mTQ2 proteins in a single polypeptide chain connected by short 
amino acid linkers.  
3.1.1. FRET measurements in hNTH1-mTQ2 expressing MCF7 cells 
We created a stable MCF7 cell line, which ubiquitously expresses hNTH1-
mTQ2. To perform in vivo FRET assays, we transiently transfected this stable cell 
line with either sYFP2 alone, sYFP2-YB-1ΔC or YB-1ΔC-sYFP2. Cells were 
fixed one day after transfection and the FRET signal was detected by performing 
gradual acceptor photobleaching using a FRAPPA device (Van Munster et al., 
2005). In this procedure, the acceptor (sYFP2) is bleached, causing the donor 
(mTQ2) signal to increase in case of FRET. The increase in mTQ2 intensity upon 
acceptor (sYFP2) photobleaching is visible by eye in these cells (Figure 3.2). 
Expression levels of YB-1ΔC constructs were variable. We only detected clear 
FRET signal in MCF7 cells, which overexpressed the YB-1ΔC protein. The FRET 
efficiencies measured on MCF7 cells stably transfected with hNTH1-mTQ2 and 
transiently expressing sYFP2 alone, sYFP2-YB-1ΔC or YB-1ΔC-sYFP2 were 1.3 
%, 15.4 % and 22.0 % respectively (Figure 3.2 D). The strongest FRET signal was 
 
 
 
 
93 
obtained from stably transfected MCF7 cells transiently expressing YB-1ΔC-
sYFP2 in which both mTQ2 and sYFP2 were fused to the C-termini of hNTH1 
and YB-1ΔC, respectively. In this configuration, the FRET efficiency was 
significantly higher than that of the negative control (transiently transfected with 
sYFP2-NLS, a nuclear form of sYFP2), and clearly indicated that hNTH1 and 
YB-1C interact in the nuclei of MCF7 cells. 
	 
Figure 3.2. hNTH1-YB-1 FRET measurements in transfected MCF7 cells. MCF7 stable cell line-
expressing hNTH1-mTQ2 and transfected with sYFP2 alone (A), sYFP2-YB-1ΔC (B) and YB-
1ΔC- sYFP2 (C). mTQ2 is seen in the CFP channel (blue). sYFP2 is seen in the YFP channel 
(green). The white rectangle indicates the area of the nucleus that was photobleached. Scale bar: 
10 µm. (D) FRET efficiencies in the MCF7 stable cell line expressing hNTH1-mTQ2 and 
transfected with sYFP2-NLS, sYFP2-YB-1ΔC and YB-1ΔC- sYFP2. The presented data are the 
mean of at least three replicates. 
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3.1.2. Design of Biosensor construct 
 In order to overcome the low co-transfection efficiency and to investigate 
the conditions under which hNTH1 and YB-1 interact, we created a single 
polypeptide construct, which contains sYFP2, YB-1∆C, hNTH1 and mTQ2 
proteins connected by short amino acid linkers (Figure 3.3). 
SYFP2 YB1 hNTH1 mTQ2 
A 
YB1 
hNTH1 
445 nm 
540 nm 
YB1 
hNTH1 
445 nm 
465 nm B 
DNA damage? Stress? 
FRET 
Figure 3: (A) Design of the single-molecule biosensor probe in order to express 
SYFP2, YB1, hNTH1 and mTurquoise2 as a single polypeptide chain. (B) 
Schematic representation of the YB1-hNTH1 biosensor. Upon interaction of 
hNTH1 with YB1, the two FRET partners will come into close proximity to one 
another allowing for FRET to occur. This system will allow us to probe for the 
conditions under which hNTH1 and YB1 interact and will be used to test for 
inhibitor efficiency in cellulo. 
Inhibitors 
!	 
Figure 3.3. Biosensor design. The yellow and blue cylinders represent sYFP2 and mTQ2 proteins, 
respectively. Upon interaction of hNTH1 with YB-1, mTQ2 and sYFP2 come close together and 
FRET signal c n be measured. 
The Biosensor 1 construct was cloned into a mammalian expression vector 
and transfected into MCF7 cells. Only a subset of cells showed nuclear expression 
of the Biosensor (i.e. both mTQ2 and sYFP2 were expressed in the nucleus). A 
majority of cells showed cytoplasmic expression of the biosensor and some cells 
also showed differential expression of mTQ2 and sYFP2 in different cell 
compartments, suggesting the Biosensor 1 had been cleaved in vivo. We 
nonetheless performed acceptor photobleaching experiments on selected MCF7 
cells expressing nuclear Biosensor 1 and the FRET efficiency was found as ~7% 
in these cells (Figure 3.4). This relatively low FRET efficiency compared to that 
obtained with our stably transfected MCF7 cell line (Figure 3.2) could be due to 
the orientation of the proteins in the Biosensor 1 construct. Our in vivo FRET 
experiments using the individual constructs indicated that FRET was more 
efficient when both fluorescent proteins were fused to the C-termini of hNTH1 
and YB-1. Also, little is known concerning the stoichiometry of the hNTH1/YB-1 
complex; a one to one hNTH1:YB-1C ratio as is the case in the Biosensor may 
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not be enough for efficient complex assembly. To verify this, we thus decided to 
further characterise the Biosensor 1 in vitro. 
!	 
Figure 3.4. Example of a hNTH1-YB-1 FRET measurement in MCF7 cells transfected with 
Biosensor 1. mTQ2 is seen in the CFP channel (blue). sYFP2 is seen in the YFP channel (green). 
The white rectangle indicates the area of the nucleus that was photobleached. Scale bar: 10µm.  
3.2. YB-1ΔC/hNTH1 interaction in vitro 
3.2.1. Purification of fluorescent protein fusion constructs 
3.2.1.1. Fluorescent proteins 
	 
Figure 3.5. Illustration of fluorescent proteins used in our work. Red: N-terminal, cleavable His-
tag. Grey: short linker sequences. 
sYFP2, mTQ2, and Fusion (sYFP2-mTQ2) constructs (Figure 3.5) were 
successfully expressed in E. coli BL21 cells with cleavable N-terminal His-tags 
and were purified with Ni-IDA sepharose column followed by gel filtration 
(Figure 3.6). 
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Figure 3.6. Example of Stain-Free gel image of fluorescent proteins. M: Biorad SDS-PAGE broad 
range protein marker, 1-3: sYFP2 (28 kDa), mTQ2 (28 kDa), Fusion (57 kDa), respectively. 
3.2.1.2. YB-1∆C fusion constructs 
	 
Figure 3.7. Illustration of YB-1∆C constructs fused to sYFP2 used in our work. Red: N-terminal, 
cleavable His-tag. Grey: short linker sequences. 
sYFP2-YB-1∆C and YB-1∆C-sYFP2 constructs (Figure 3.7) were cloned 
into pProEX-HTb for expression in E. coli BL21 cells with cleavable N-terminal 
His-tags and were purified using three chromatographic steps: a nickel affinity 
column, a heparin column and a size-exclusion chromatography. Although the 
proteins were relatively free of other protein contaminants after the Nickel 
column, they were highly contaminated with nucleic acids. We thus used a 
heparin column and a first size-exclusion chromatography in high salt (1 M NaCl) 
to remove this nucleic acid contamination (Figure 3.8). In the end, we recovered 
between 1.5 and 2.5 mg/L of pure sYFP2-YB-1∆C and YB-1∆C-sYFP2 proteins, 
which was sufficient for further experiments. 
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Figure 3.8. Illustration of the different chromatographic steps used to purify YB-1∆C fusion 
constructs (53 kDa). Curly brackets indicate the pooled fractions. (A) Chromatogram and Stain-
Free gel of nickel purification; (B) Chromatogram and Stain-Free gel of heparin purification; (C) 
Chromatograms and Stain-Free gel of gel filtration at 1 M NaCl and 0.5 M NaCl. 
3.2.1.3. hNTH1 fusion constructs 
	 
Figure 3.9. Illustration of hNTH1 constructs fused to mTQ2 used in our work. Red: N-terminal, 
cleavable His-tag. Grey: short linker sequences. 
All hNTH1 fusion constructs (Figure 3.9) were cloned into pProEX-HTb for 
expression in E. coli BL21 cells with cleavable N-terminal His-tags and were 
purified using three chromatographic steps. All constructs produced similar 
chromatographic profiles on His-Trap columns (Figure 3.10). Since hNTH1 
possesses a [4Fe-4S] cluster and absorbs at 410 nm, we used this wavelength for 
tracking our protein (Ikeda et al., 1998). 
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Figure 3.10. Illustration of the different chromatographic steps used to purify hNTH1 fusion 
constructs. Curly brackets indicate the pooled fractions. (A) Chromatogram and Stain-Free gel of 
nickel purification; (B) Chromatogram and Stain-Free gel of heparin purification; (C) 
Chromatogram and Stain-Free gel of gel filtration. 
For hNTH1-mTQ2 and ND89hNTH1-mTQ2, we performed a heparin 
affinity chromatography step to remove contaminating DNA. NtailhNTH1 
construct was not contaminated with DNA therefore we exchanged the Heparin 
affinity purification step with an ion-exchange chromatography to eliminate other 
contaminants (Figure 3.11). As a last purification step, all hNTH1 constructs were 
loaded on a Superdex 75 size exclusion column equilibrated in a buffer containing 
200 mM NaCl (Figure 3.10). In the end, we recovered pure hNTH1 fusion 
constructs at a sufficient concentration for further experiments (Table 3.1). 
	 
Figure 3.11. NtailhNTH1-mTQ2 ion-exchange chromatography. Chromatogram of HiTrapQ FF 
column with 50mM NaCl and 10% Stain-Free gel analysis of fractions. Curly bracket shows the 
pooled fractions. 
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Table 3.1.  Properties of purified hNTH1 fusion proteins. 
Name of proteins Size (kDa) 
Purification Yield/L 
culture (mg) 
Concentration 
(mg/ml) 
hNTH1-mTQ2 63 1 0.9 
mTQ2-hNTH1 63 3.5 7 
NtailhNTH1-mTQ2 38.5 0.5 2 
ND89hNTH1-mTQ2 54 1.4 4.2 
3.2.1.4. Biosensor constructs 
Figure 3.12 illustrates all the Biosensor constructs that we prepared and used 
for in vitro FRET measurements. As for the individual constructs, the Biosensor 
constructs were cloned into pProEX-HTb vector for expression in E. coli BL21 
cells with a cleavable N-terminal His-Tag. Cloning of these constructs was 
facilitated by introducing a NdeI restriction site within the central linker sequence 
between YB-1C and hNTH1.  
	 
Figure 3.12. Illustration of the Biosensor constructs used in our work. Red: N-terminal, cleavable 
His-tag. Grey: short linker sequences. 
The Biosensor constructs were overproduced with a His-tag allowing us to 
purify them by a nickel affinity column. All of the biosensors showed similar 
chromatographic profiles. Despite previous treatments eluted Biosensors from 
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nickel affinity column were heavily contaminated with nucleic acids. We 
performed a heparin affinity purification and a gel filtration with 1 M NaCl 
containing GF buffer to eliminate nucleic acid contamination. In order to reduce 
the salt concentration in the final sample for further analysis, we used a second gel 
filtration column equilibrated in a GF Buffer containing 500 mM NaCl (Figure 
3.13). In the end, we recovered pure Biosensor proteins (Figure 3.14) at a 
sufficient concentration for further experiments (Table 3.2). 
	 
Figure 3.13. Representative gels and chromatograms of Biosensor 1 (116 kDa) purification. Curly 
brackets indicate the pooled fractions. (A) Chromatogram and Stain-Free gel of nickel purification; 
(B) Chromatogram and Stain-Free gel of heparin purification; (C) Chromatograms at 1 M NaCl 
and 0.5 M NaCl and Stain-Free gel of gel filtration. 
	 
Figure 3.14. Stain-free gel analysis of purified Biosensor constructs. M: Biorad Precision Plus 
unstained protein marker, 1-6: Biosensor 1 (116 kDa), Biosensor 2 (91 kDa), Biosensor 3 (106 
kDa), Biosensor 5 (80 kDa), Biosensor 6 (91 kDA), Biosensor 7 (116 kDA), respectively. 
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Table 3.2.  Properties of purified Biosensor proteins. 
Name of proteins Size (kDa) 
Purification Yield/L 
culture (mg) 
Concentration 
(mg/ml) 
Biosensor 1 116 2 2.6 
Biosensor 2 91 1 1.9 
Biosensor 3 106 0.9 1.5 
Biosensor 4 105 0.15 5 
Biosensor 5 80 1.4 3 
Biosensor 6 91 4.5 3 
Biosensor 7 116 1.5 5.5 
3.2.2. FRET measurements  
3.2.2.1. Mixture of individual proteins 
We used the fluorescent proteins alone (sYFP2 and mTQ2) as negative 
controls and the sYFP2-mTQ2 Fusion as a positive control (Figure 3.15) 
throughout our FRET measurements. These measurements were also used for our 
calculations of the FRET efficiency (see Chapter 2 Materials & Methods). 
	 
Figure 3.15. mTQ2 and sYFP2 spectra of the sYFP2 and mTQ2 alone and mixed in a 1:1 ratio, 
and sYFP2-mTQ2 fusion construct at 1.5µM in 200mM NaCl GF buffer. (A) Emission spectra 
obtained after exciting mTQ2 at 435nm. (B) Emission spectra obtained after exciting sYFP2 at 
485nm. 
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We did not observe any FRET signal when mixing the individual 
fluorescent proteins sYFP2 and mTQ2 (FRET efficiency ~ 0 %), but the 
fluorescent protein Fusion construct had a significant FRET signal (FRET 
efficiency ~ 40 %). When measuring FRET after mixing individual hNTH1 and 
YB-1C proteins fused to mTQ2 and sYFP2, respectively no significant FRET 
signal was detected using a protein concentration of 1.5 µM and buffer containing 
200 mM NaCl. Since high salt concentrations are known to interfere with ionic 
interactions, we tried to decrease the salt concentration, and also tried to increase 
the protein concentration to make sure that we were above the estimated Kd value 
(~0.5 µM) determined previously in the laboratory. Finally, FRET signal could be 
detected when mixing individual proteins at 5 µM protein concentration in 50 mM 
NaCl buffer (Figure 3.16 A). 
	 
Figure 3.16. FRET efficiencies of individual protein mixes of hNTH1 and YB-1C constructs. 
(A) FRET efficiencies of protein mixtures containing mTQ2 alone, mTQ2-hNTH1 or hNTH1-
mTQ2 mixed with sYFP2-YB-1C or YB-1C-sYFP2 at 5µM final concentration in 50mM NaCl 
GF buffer. The highest FRET signal was obtained with the fluorescent proteins fused to the C-
termini of hNTH1 and YB-1C. (B) FRET efficiencies of YB-1C-sYFP2 mixed with various 
constructs of hNTH1 fused to mTQ2 at 5µM in 50mM NaCl GF buffer. The highest FRET 
efficiency was obtained with full-length hNTH1 fused to the N-terminus of mTQ2. 
As in our in vivo FRET measurements (Figure 3.3), the highest signal was 
obtained when both mTQ2 and sYFP2 were fused to the C-termini of hNTH1 and 
YB-1ΔC, respectively. We also evaluated other constructs of hNTH1 (Ntail and 
ND89) with YB-1ΔC-sYFP2, but these truncated forms of hNTH1 did not show 
any significant FRET signal (Figure 3.16 B).  
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3.2.2.2. Biosensors 
We then set out to determine the optimal buffer conditions for FRET with 
our Biosensor 1 construct. We changed the NaCl concentration (500 mM NaCl, 
250 mM NaCl, 100 mM NaCl, and 50 mM NaCl) and evaluated its effect on the 
FRET signal (Figure 3.17 A). When we decreased the salt, we observed an 
increase in the FRET signal, illustrated by the increase in emission at 525 nm 
(corresponding to the sYFP2 peak) as a result of energy transfer from the donor to 
the acceptor. The interaction between YB-1∆C and hNTH1 thus appears to be 
highly salt-sensitive. At a salt concentration of 50 mM, however, the FRET 
efficiency is very high (39 %) and comparable to that obtained with our Fusion 
construct (~40 %) (Figure 3.17 B). 
	 
Figure 3.17. FRET measurements of Biosensor 1 and its comparison with Fusion construct. (A) 
mTQ2 spectra of 1µM Biosensor 1 at different NaCl (50, 100, 250, and 500 mM) concentrations. 
The highest FRET signal of Biosensor 1 was obtained in buffer containing 50 mM NaCl (B) 
mTQ2 spectra of 1µM Fusion and Biosensor 1 in buffer containing 50mM NaCl. Fusion and 
Biosensor 1 showed similar FRET efficiencies in buffer containing 50 mM NaCl. 
Then we carried out FRET measurements on all 7 Biosensor constructs at 
different concentrations of salt (50 mM NaCl-1 M NaCl) in order to observe the 
difference between the constructs (Figure 3.18 A). Since the biosensor is a single 
polypeptide chain, all constructs show a basal FRET signal of ~10 %. The relative 
change in FRET efficiency (FRET efficiency) when going from 500 mM NaCl 
to 50mM NaCl is thus a better measure of the interaction than the absolute FRET 
measurement (Figure 3.18 B). 
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Figure 3.18. FRET measurements of all Biosensors and Fusion construct at different NaCl 
concentrations. (A) FRET efficiencies of Biosensor constructs at different NaCl concentrations (50 
mM NaCl - 1 M NaCl). All Biosensor constructs had a basal FRET signal. Biosensors 1 and 7 
showed a considerable change between salt concentrations of 50 mM and 500 mM. (B) 
Comparison of the FRET efficiencies of Biosensor constructs at 50 mM and 500 mM NaCl 
concentrations. 
There was a small effect of salt on our positive control (Fusion of sYFP2-
mTQ2). We observed a slight decrease (5 %), which could be due to changes in 
the chromophore conformation or non-specific interactions between fluorescent 
proteins. Salt concentration considerably affects the FRET efficiencies of the 
Biosensor 1 and 7, suggesting that it specifically interferes with the interaction 
between hNTH1 and YB-1.  
Compared to Biosensors 1 and 7, the other Biosensor constructs (Biosensors 
2-6) showed either reduced FRET signals at low salt and/or increased FRET 
signals at high salt concentration, resulting in overall reduced FRET efficiencies. 
This indicates that the interaction between YB-1 and hNTH1 is largely lost when 
truncated forms of hNTH1 or the bacterial homologue of hNTH1 (Deinococcus 
radiodurans EndoIII2 protein) are used. These findings are in agreement with our 
FRET measurements performed on the individual constructs (Fig. 3.16). 
Biosensors 5 and 6, which are missing one of the two protein partners (hNTH1 in 
Biosensor 5 and YB-1∆C in Biosensor 6), also displayed significantly reduced 
FRET efficiency. A high FRET efficiency is thus a strong indication that 
hNTH1 and YB-1 interact within the biosensor constructs 
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To determine the minimal FRET level for each Biosensor construct, we 
performed our FRET measurements in the presence of 6 M urea that efficiently 
denatures hNTH1 and YB-1, but not the fluorescent proteins (Figure 3.19) as 
judged by their unaffected fluorescent intensity. All Biosensor constructs showed 
similar minimal FRET efficiencies. Interestingly, we noticed that the FRET 
efficiency of the Fusion is also reduced in comparison with the 40 % FRET 
efficiency in 50 mM NaCl, even though the fluorescence intensity measurements 
were unchanged. 
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Figure 3.19. FRET efficiencies of Fusion and Biosensor constructs at 1 μM concentration in 50 
mM NaCl in the presence of 6 M urea. All Biosensor constructs showed similar minimal FRET 
efficiencies. 
Previous experiments in our laboratory showed that hNTH1 binds with high 
affinity (Kd ~2 nM) a 12 mer double-stranded oligonucleotide containing a 
tetrahydrofuran (THF) synthetic AP site paired with guanine (G) (Figure 3.20 A). 
We thus performed FRET measurements in the presence of this uncleavable 
substrate of hNTH1 (Figure 3.20 B). We observed a similar effect as with NaCl. 
When the concentration of oligonucleotide increased, the FRET efficiency 
decreased (Figure 3.20 C). But unlike NaCl concentration, there was no effect on 
the Fusion. This suggests that the FRET signal results from a specific interaction 
between hNTH1 and YB-1 that has been disrupted by binding of hNTH1 to its 
DNA substrate. 
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Figure 3.20. FRET measurements in order to find a potential competitor of YB-1/hNTH1 
interaction for Biosensor 1 construct. (A) hNTH1 affinity to different oligonucleotides containing 
a stable THF abasic site paired with either guanine (G) or adenine (A). hNTH1 showed a higher 
affinity to the oligonucleotide containing a stable THF abasic site paired with guanine (B) mTQ2 
spectra of 1 μM Biosensor 1 in 50 mM NaCl in the presence of increasing concentrations of 12nt 
THF blunt dsDNA oligonucleotide. Increasing concentrations of 12nt THF blunt dsDNA 
oligonucleotide decreased the FRET signal of Biosensor 1. (C) FRET efficiencies of Fusion and 
Biosensor 1 at 1 μM concentration in 50mM NaCl as a function of 12nt THF blunt dsDNA 
oligonucleotide concentration (0-2 µM). 12nt THF blunt dsDNA oligonucleotide did not decrease 
the FRET signal of Fusion construct. 
We also performed the FRET measurements in 50 mM NaCl at different 
Biosensor 1 protein concentrations (ranging from 0.01 to 2 µM) to check whether 
this had any influence on the FRET efficiency (Figure 3.21). We observed that the 
FRET efficiency of the Biosensor 1 rapidly dropped when lowering the 
concentration below 0.2 µM. This was not the case with the Fusion protein, which 
exhibited a constant FRET efficiency irrespective of its concentration, as expected 
for intramolecular FRET. 
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Figure 3.21. FRET measurements of Fusion and Biosensor constructs at different protein 
concentrations in buffer containing 50mM NaCl. The FRET signal of Fusion did not change 
according to protein concentrations. However, the FRET signal of Biosensor 1 decreased below 
0.2 µM protein concentration. 
3.3. High-throughput chemical library screening with Biosensor 1  
 Protein-protein interactions (PPI) are important in most cellular processes 
and, as such, are the focus of many probe- and drug-discovery programs (Roche 
and Morelli, 2010). However, it has been difficult to identify small molecule or 
peptide inhibitors of PPI that bind stoichiometrically to a single site on the protein 
surface. In the absence of high-resolution structures of targeted proteins, in silico 
drug design and approaches based on molecular docking to find protein-protein 
interaction inhibitors (2P2I) are not suitable. In such cases, FRET can be a useful 
method high-throughput screening for protein-protein interaction inhibitors (Song 
et al., 2011; Rogers et al., 2012; Schaap et al., 2013). 
 The characterisation of the different Biosensor constructs and our buffer 
optimisation experiments clearly indicated that our Biosensor was a suitable tool 
for probing the hNTH1-YB-1 interaction and also for screening potential 
inhibitors of this interaction. We chose Biosensor 1 construct for the subsequent 
screening experiments because this construct was more stable and robust 
compared to Biosensor 7 and could be produced at high yields. The robotic 
chemical screening assay was performed in collaboration with Caroline 
BARETTE from the Center for the screening for BioActive Molecules (CMBA) 
platform, located at the Biosciences and Biotechnology Institute of Grenoble 
(BIG). 
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 We checked the quality and reliability of our FRET-based assay before 
starting the chemical library screening. 
3.3.1. Optimization of Biosensor 1 
Compounds in chemical libraries are typically dissolved in DMSO 
(Dimethyl sulfoxide). We thus evaluated the FRET levels of the Biosensor in the 
presence of a range of DMSO concentrations to ensure that it didn’t significantly 
affect our assay (Figure 3.22). We observed only a slight decrease (- 5 %) in the 
FRET efficiency at the highest DMSO concentrations indicating that low 
concentrations of DMSO were compatible with our assay. 
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Figure 3.22. Stability of FRET signal of 0.2 µM Fusion and Biosensor 1 construct in presence of 
increasing amounts of DMSO  (0.5, 1, 1.5, 2, and 5 %).  A slight decrease (-5 %) in the FRET 
efficiency of Biosensor 1 was observed at 5 % DMSO concentration. 
Before performing high-throughput chemical library screening, several 
quality control analyses had to be done to assess the reliability of our assay. First, 
based on our experiments presented in Figure 3.21, we decreased the Biosensor 1 
concentration to 0.2 μM in order to screen more chemicals with a minimal amount 
of protein. At this concentration, the FRET efficiency of Biosensor 1 was close to 
30 %. Then we performed a dose response assay (Figure 3.23) with the 12nt THF 
blunt dsDNA oligonucleotide, which we planned to use as a positive control for 
inhibition in our screening experiments. We found the IC50 value of the 12nt THF 
dsDNA oligonucleotide to be 0.13 μM. We thus chose to fix the concentration of 
the oligo at 0.5 μM which produces the minimal FRET level (~ 10 %). 
 
 
 
 
109 
0.01 0.10 1
5
10
15
20
25
30
35
[12nt THF oligo] mM
F
R
E
T
 e
ff
ic
ie
n
c
y
 (
%
)
	 
Figure 3.23. Inhibition of Biosensor 1 FRET by addition of hNTH1 DNA substrate. Dose 
response of 12nt THF blunt dsDNA oligonucleotide (at 0.01, 0.03, 0.06, 0.13, 0.25, 0.5, 1, and 
2μM) on 0.2μM Biosensor 1 in buffer containing 50mM NaCl. The data points corresponding to 
the means of triplicate measurements were fitted to a standard sigmoidal inhibition model in 
GraphPad Prism. 
Finally, we checked the stability of the Biosensor 1 and the FRET signal 
over a 2-hour period (Figure 3.24). We compared the stability of the Biosensor in 
its optimal buffer, in the presence of DMSO (0.5 % and 1.3 %) and in the 
presence of 0.5 μM 12nt THF blunt dsDNA oligonucleotide. The FRET signal of 
Biosensor 1 was relatively stable at 0.2 μM in 50 mM NaCl. A slight decrease in 
the signal is observed, but a significant and reproducible difference in FRET 
efficiency for Biosensor 1 was detected in the absence and presence of 0.5 μM 
12nt THF blunt dsDNA oligonucleotide. Again addition of DMSO did not 
significantly affect the FRET signal. 
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Figure 3.24. Stability of FRET signal of Biosensor 1 construct during 2 hours. The FRET 
efficiency of Biosensor 1 was monitored over a 2 hour period in 50 mM GF buffer (blue), 
supplemented with either 0.5 % DMSO (red), 1.3 % DMSO (green) or 0.5 µM 12nt THF oligo 
(purple). 
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 Our maximum (Max) FRET values detected for 0.2 µM Biosensor 1 in GF 
buffer containing 50 mM NaCl were found to be ~ 30 % on the Clariostar 
fluorescence plate reader and ~ 40 % on the TECAN microplate reader present on 
the CMBA screening platform. Our minimum (Min) FRET values obtained with 
0.2 µM Biosensor 1 in GF buffer containing 50 mM NaCl in the presence of 0.5 
µM 12nt THF oligonucleotide were found to be ~ 10 % on the Clariostar and ~ 18 
% on the TECAN microplate reader. On both plate readers, the ∆FRET efficiency 
(Max – Min) was thus very similar and close to 20 %. 
To test the robustness of our screening assay, we performed a Z' factor test 
on 30 samples in the absence and presence of 12nt THF blunt dsDNA 
oligonucleotide. The Z' factor is a statistical parameter to determine the suitability 
of an assay for high-throughput screening (Zhang et al., 1999). The equation we 
used for the determination of the Z' factor and the categorization of our screening 
assay is given in Figure 3.25. 
	 
σ : standard deviation, µ : mean, c+ : positive control, c- : negative control 
	 
Figure 3.25. Equation of Z' factor and categorization of screening assay by the value of the Z' 
factor (Zhang et al., 1999).  
The Z' factor values derived from measurements performed in our 
laboratory on the Clariostar plate reader and on the CMBA platform are presented 
in Table 3.3. 
Table 3.3. Z' factor values obtained for our Biosensor 1 assay. 
Plate reader, Laboratory Z' factor 
Clariostar, IBS 0.83 
TECAN, CMBA platform 0.90 
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As seen in Figure 3.25, the value of the Z' factor is expected to be between 
0.5 and 1 in a robust assay. Our results show that our Biosensor 1 is a very reliable 
tool to detect the potential inhibitors of the YB-1ΔC/hNTH1 interaction. 
3.3.2. Life Chemicals Protein-Protein Interaction Fragment Library 
We used our Biosensor 1 to perform a high-throughput screen of the Life 
Chemicals Protein-protein Interactions (PPI) library on the CMBA platform. This 
chemical library contains 800 compounds that have been specifically selected to 
target protein-protein interactions. All stock compounds in this library were 
provided at 3.8 mM in 100 % DMSO. 
The first high-throughput screening was performed with 0.2 μM Biosensor 1 and 
50 μM compound concentration in triplicate in a final volume of 50 μl. The 12nt 
THF oligonucleotide at 0.5 μM final concentration was used as a positive control 
(Figure 3.26). The percentage inhibition of the compounds was calculated by 
comparing the Biosensor 1 FRET efficiencies in the absence and presence of 12nt 
THF oligonucleotide (see Material and Methods for detailed description of 
calculation). 
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Figure 3.26. Overall results obtained from the first HTS of Life Chemicals PPI library. The FRET 
of Biosensor 1 in DMSO (green dots) was set to 0% inhibition, while the FRET of Biosensor 1 in 
the presence of 12nt THF oligonucleotide (blue dots) was set to 100% inhibition. Test compounds 
from ten 384-well plates are shown as red dots in the graph. The values presented are the mean of 
triplicate measurements recorded 1h after mixing the Biosensor 1 with the compounds. 
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Due to an error in the calculation of the required Biosensor 1 volume, the 
robot pipetted the wrong volumes of Biosensor 1 in the 8th plate and as a result 
FRET calculations derived from these measurements are highly variable and 
unreliable. After this first HTS, 30 selected compounds exhibiting reduced FRET 
levels (> 25 % inhibition) were further tested at three different concentrations (50, 
10 and 1 μM) (Figure 3.27). Of these 30 compounds, 22 of them were from plate 
8 in order to repeat them correctly, and 8 of them showed reduced FRET signal 
with a small standard deviation. 
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Figure 3.27. Overall results obtained from the second HTS of Life Chemicals PPI library with 
selected 30 compounds. Inhibition percentages of Biosensor 1 in presence of 30 selected Life 
Chemicals compounds at 50, 10 and 1 μM (three columns of the same colour side by side, 
respectively). Horizontal dashed line represents 25 % inhibition on Biosensor 1.  Selected 
compounds used in further validation tests are marked with an asterisk (*). 
We found three compounds, which showed 30-60 % inhibition at 50 μM 
concentration and had still an inhibitory effect at 10 μM concentration (Figure 
3.27 and 3.28 D). Two of these display similar chemical structures (Figure 3.28 B, 
C). 
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Figure 3.28. Potential hits identified in Life Chemicals PPI library. (A-C) Chemical structures and 
names of three potential hits identified from the high-throughput screening of the Life Chemical 
PPI library (D) FRET efficiencies of three potential hits identified from the Life Chemicals PPI 
library with Biosensor 1. Blue: Biosensor 1 + 1.3 % DMSO; Red: Biosensor 1 + 0.5 µM 12nt THF 
DNA; Green: Biosensor 1 + 50 µM compounds.  
3.3.3. Prestwick Chemical Library 
Next, we performed a second HTS on the CMBA platform using the 
Prestwick Chemical Library. This library is a unique collection composed of 1280 
small molecules, 95 % approved drugs (FDA, EMA and other agencies). All stock 
compounds in this library were at 10 mM in 100% DMSO. As before, the screen 
was performed with 0.2 µM Biosensor 1 and 50 µM compound in triplicate. 
After this first high-throughput screening (Figure 3.29), we found 20 
compounds showing higher than 50 % inhibition. Some of them also increased the 
FRET signal, but a majority of compounds did not show any significant effect on 
Biosensor 1. 
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Figure 3.29. Overall results obtained from the first HTS of Prestwick Chemical library. The FRET 
of Biosensor 1 in DMSO (green dots) was set to 0% inhibition, while the FRET of Biosensor 1 in 
the presence of 12nt THF oligonucleotide (blue dots) was set to 100% inhibition. Test compounds 
from 16 384-well plates are shown as red dots in the graph. The values presented are the mean of 
triplicate measurements recorded 1h after mixing the Biosensor 1 with the compounds.  
30 compounds were selected for a second screening at three different 
concentrations (50, 10 and 1 μM). Of these, 28 compounds showed higher than 30 
% inhibition in the primary screen, with 3 compounds reducing the FRET levels 
of the Biosensor more severely than the 12nt THF oligonucleotide (and hence 
appear as >100 % inhibition in Figure 3.29), while two of them increased the 
FRET efficiency of Biosensor 1 (negative inhibition in Figure 3.29). Several of 
these compounds strongly affected the measured fluorescence intensities. Two of 
them showed 15 times higher mTQ2 signal, which indicates that the compounds 
themselves may emit strong fluorescence at 477 nm. Half of them showed similar 
effects on fluorescence intensities of mTQ2 and sYFP2. The rest of them 
decreased both fluorescence intensities of mTQ2 and sYFP2. In this second 
screening, we therefore, decided to include wells corresponding to the test 
compounds alone diluted in the Biosensor buffer to check for the intrinsic 
fluorescence of the compounds. The results of the secondary screen are shown in 
Figure 3.30.  
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Figure 3.30. Overall results obtained from the secondary HTS of Prestwick Chemical library with 
30 selected compounds. Inhibition percentages of Biosensor 1 in presence of 30 selected Life 
Chemicals compounds at 50, 10 and 1 μM (three columns of the same colour side by side, 
respectively). Horizontal dashed line represents 50 % inhibition of Biosensor 1. Selected 
compounds used in further validation tests are marked with an asterisk (*). F indicates the 
compounds, which showed high intrinsic fluorescence signal alone. Q indicates the compounds 
that quench the fluorescence signal. 
8 compounds from the Prestwick Chemical Library were found to be 
potential inhibitors displaying a clear, concentration-dependent inhibition of the 
FRET signal (Figure 3.31). 
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Figure 3.31. Characterisation of the top 8 hits identified from the Prestwick chemical library. 
Extent of Biosensor FRET inhibition by 8 Prestwick compounds (at 50, 10 and 1 µM) identified in 
the secondary screening on the CMBA platform. The values are derived from the 1h measurement. 
The names, properties and molecular structures of these 8 compounds from 
the Prestwick Chemical Library are given in Table 3.4.  
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Table 3.4. List of compounds from Prestwick Chemical Library after second 
screening. 
Cpd 
id 
Chemical name Formula 
Molecular 
weight 
(g/mol) 
Molecular Structure 
410 
Amphotericin 
B 
C47H73NO17 924 
O
O
O OO
O
NH
2
OH
OH
OH
OH
OH
OH
OH OH
OH
OH
CH
3
OH
CH
3
CH
3
CH
3
H
Chiral
	 
489 
Ceftazidime 
pentahydrate 
C22H32N6O12S2 637 N
N
NS
N
N
+
S
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O
OO
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OH
CH
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OH
2 OH2
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814 
Cefsulodin 
sodium salt 
C22H19N4NaO8S2 555 
NS
N
S
N
+
O
O
O O
O
OO
O
NH
2
H H
Na
+
	 
456 
Meclocycline 
sulfosalicylate 
C29H27ClN2O14S 695 
	 
307 
Oxytetracycline 
dihydrate 
C22H28N2O11 497 
	 
819 
Moxalactam 
disodium salt 
C20H18N6Na2O9S 564 
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385 
Mitoxantrone 
dihydrochloride 
C22H30Cl2N4O6 517 
	 
139 
Cefotaxime 
sodium salt 
C16H16N5NaO7S2 478 
	 
Amphotericin B is a polyene antifungal antibiotic produced by Streptomyces 
nodosus, with antifungal activity. Ceftazidime pentahydrate, Cefsulodin sodium, 
Moxalactam disodium and Cefotaxime sodium are beta-lactams and 
cephalosporin antibiotics with bactericidal activity. Meclocycline sulfosalicylate 
and Oxytetracycline are tetracycline derivative antibiotics. Mitoxantrone is an 
anthracenedione antibiotic with antineoplastic activity and a topoisomerase II 
inhibitor.  
3.4. Validation of hits from screening 
In order to validate these initial hits, we ordered the powders corresponding 
to the three hits from Life Chemicals (F0380-0013, F2359-0017 and F2359-0607) 
and to seven of the eight Prestwick compounds (Amphotericin B, Meclocycline 
sulfosalicylate, Moxalactam disodium, Cefsulodin sodium, Mitoxantrone, 
Ceftazidime and Oxytetracycline) from Sigma for further analyses. We did not 
purchase the 8th compound (Cefotaxime) for the first validation tests because it 
was the least effective of the four beta-lactam antibiotics.  
3.4.1. Autofluorescence of compounds 
First, we checked the fluorescence spectra of the compounds identified in 
the Life Chemicals PPI library alone in buffer. The test compound that showed the 
highest inhibition (F0380-0013) showed a high level of fluorescence in the mTQ2 
channel, which if uncorrected, largely affected the FRET efficiency calculation 
making it appear as a false positive result. The other two compounds showed low 
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levels of intrinsic fluorescence. Potential hits from the Prestwick Library were 
selected from those that did not show intrinsic fluorescence signal (Table 3.5). 
Table 3.5. The level of intrinsic fluorescence of potential hits from Life 
Chemicals and Prestwick Chemical Library at 50μM concentration. 
Name of compounds 
mTQ2 channel 
(ex 435/em 477) 
sYFP2 channel 
(ex 485/em 528) 
F0380-0013 15112 354 
F2359-0017 1364 28 
F2359-0607 3078 20 
Amphotericin B 75 57 
Meclocycline  266 16 
Moxalactam 16 10 
Cefsulodin 100 26 
Mitoxantrone -2 22 
Ceftazidime 23 11 
Oxytetracycline 122 13 
 3.4.2. Effect of compounds on the FRET signal of the Fusion construct 
We then tested the effect of our selected compounds on the FRET signal of 
0.2 μM Fusion (Figure 3.32) to verify that their effects on Biosensor 1 were not 
due to an interference with the FRET process itself. In these new measurements 
performed with the purchased compounds from Sigma, the FRET efficiencies 
were calculated after correcting for the intrinsic fluorescence of the test 
compounds. The 7 Prestwick compounds had no effect on the FRET signal of the 
Fusion, whereas the Life Chemical compounds reduced FRET signal by 6 to 9 % 
indicating that their intrinsic fluorescence, which is relatively high, may interfere 
with the FRET process. 
 
 
 
 
119 
We also performed the same experiments with Prestwick compounds 
obtained from the CMBA platform and after storage at 4oC during 2 days and 3 
months. The results did not change indicating Prestwick compounds do not 
interfere with the FRET process. 
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Figure 3.32. Effect of selected compounds on the FRET efficiency of the Fusion construct. FRET 
efficiencies of 0.2 μM Fusion in the absence (blue) and presence (red) 12nt THF-DNA and 50 µM 
test compounds (green). Reduced FRET signal of Fusion was observed in the presence of Life 
Chemicals compounds. No significant change was detected on Fusion FRET signal in the presence 
of Prestwick compounds.  
3.4.3. Effect of compounds on the FRET signal of Biosensor 1 
Next, we tested the inhibitory effects of these identified compounds on 
the FRET signal of 0.2 μM Biosensor 1. Life Chemicals compounds 
prepared from powders were tested at two different concentrations (50 μM 
and 10 μM) (Figure 3.33). 
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Figure 3.33. Inhibition of Biosensor 1 FRET by Life Chemicals test compounds. (A) FRET 
efficiencies of Biosensor 1 at 0.2μM concentration in buffer containing 50mM NaCl in the 
presence of DMSO alone (blue), 12nt THF oligonucleotide (red) and either 10 (purple) or 50 µM 
(green) of Life Chemicals test compounds. (B) Extent of inhibition of Life Chemicals test 
compounds at 10 (purple) or 50 µM (green). Horizontal dashed lines indicate 10, 30, and 50 % 
values, respectively. 
Compounds F2359-0017 and F2359-0607 had little effect on the FRET 
signal of Biosensor 1. Compound F0380-0013 caused a decrease in Biosensor 1 
FRET similar to that seen with the Fusion construct (Figure 3.32). The reduced 
FRET efficiency may thus result from the intrinsic fluorescence of the compound 
and not from inhibition of the hNTH1/YB-1 interaction. These three test 
compounds identified from the Life Chemicals PPI library thus appear to be false-
positives. 
We then tested the seven selected compounds from the Prestwick Chemical 
library freshly prepared from Sigma powders on 0.2 μM Biosensor 1 (Figure 
3.34). Initial measurements were performed at a single compound concentration 
of 50 µM. 
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Figure 3.34. Inhibition of Biosensor 1 FRET by seven Prestwick compounds. (A) FRET 
efficiencies of Biosensor 1 at 0.2μM concentration in buffer containing 50mM NaCl in the 
presence of DMSO alone (blue), 12nt THF oligonucleotide (red) or 50 µM Prestwick test 
compounds. (B) Inhibition percentages of Prestwick test compounds at 50 µM. Horizontal dashed 
lines indicate 10, 30, and 50 % values, respectively. 
The results obtained for Cefsulodin and Mitoxantrone ordered from Sigma 
showed similar inhibitory effects to those seen in our second screening on the 
CMBA platform. However, the other compounds showed little or no effects. We 
repeated these measurements after a few days and to our surprise the effects of the 
compounds were different indicating that the solubility of the compounds may be 
an issue. To verify this, Caroline Barette from the CMBA platform also kindly 
provided us with a small volume of the compound stock solutions used in the 
robotic screens allowing us to test these compounds stocks on our Biosensor 
construct in parallel. We performed these comparative measurements on the 7 of 
Prestwick compounds (Figure 3.35).  
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Figure 3.35. Comparison of the extent of inhibition of seven selected Prestwick compounds from 
different sources.  Extent of inhibition of Prestwick compounds at 50 µM, either freshly prepared 
from powders (blue), stored at 4ºC for 2 days after preparation (red) or for 3 months (green), and 
provided by the CMBA platform as a 10mM stock solution (purple). Storage at 4ºC for three 
months improved their ability to inhibit the Biosensor FRET levels even more potently than 
compounds provided by the CMBA platform. Horizontal dashed lines indicate 10, 40, 60, 90, and 
100 % values, respectively. 
Cefsulodin and Mitoxantrone were found to be potent inhibitors irrespective 
of their source and mode of preparation and storage with inhibitions of ~ 65 and ~ 
45 % respectively. Meclocycline and Oxytetracycline ordered from Sigma did not 
show any significant inhibition using freshly prepared solutions and after storage 
of these chemicals at 4oC for 2 days. This is in marked contrast with the effect of 
these compounds provided by the CMBA platform, which caused around 90 % 
inhibition. Interestingly, after storage of the solubilized compounds at 4oC for 
three months, we observed an even stronger inhibition effect with these two 
compounds, which surpassed the inhibitory effect of the 12nt THF oligonucleotide 
(> 100 % inhibition). In the case of Amphotericin B and Moxalactam, storing the 
compounds at 4ºC significantly improved their ability to inhibit the Biosensor 
FRET levels. Storage at 4ºC for three months improved their inhibitory potential 
to levels beyond those obtained with the compounds provided by the CMBA 
platform. A similar behaviour was seen for Ceftazidime, even though its 
inhibitory potential was quite strong already using freshly prepared solutions (40 
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%). These measurements confirm that all seven of these compounds strongly 
inhibit the Biosensor 1 FRET signal as seen in our primary and secondary HTS, 
but this effect may be caused by degraded or altered compounds.  
In view of these differences in inhibition depending on the source and 
storage conditions of the compounds, we decided to check the UV/Vis absorbance 
spectra of our various compounds (Figure 3.36). 
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Figure 3.36. Spectral analysis of Prestwick compounds. Comparison of spectra of seven selected 
Prestwick compounds freshly prepared from Sigma powders (blue), stored at 4ºC for 2 days after 
preparation (red) or for 3 months (green) and provided by the CMBA platform (purple). 
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Here again, these absorbance spectra reveal some clear differences between 
Prestwick compounds freshly prepared from powder (blue lines) and those 
obtained from CMBA platform (purple lines) or stored at 4ºC for 3 months (green 
lines). Interestingly, there are similarities between the spectra obtained from the 
Prestwick compounds provided by the CMBA platform (purple lines) and those 
prepared from Sigma powder and stored at 4oC for 3 months (green lines), which 
clearly suggests that several of the compounds are unstable and no longer 
correspond to the initial solubilized compound. 
Finally, we performed dose response assays with the seven Prestwick hits. 
We used the freshly prepared solutions after 2 days of storage at 4ºC for 
Cefsulodin and Mitoxantrone and used solutions stored at 4ºC for 3 months for the 
other compounds (Figure 3.37). 
	 
Figure 3.37. Dose response curves of selected Prestwick hits ordered from Sigma, dissolved in 
DMSO and stored at 4ºC for 2 days or 3 months prior to measurements. The data points 
corresponding to the means of triplicate measurements were fitted to a standard sigmoidal 
inhibition model in GraphPad Prism. (A) Cefsulodin and mitoxantrone (2 days at 4ºC), (B) 
Amphotericin B, Meclocycline and Moxalactam, (C) Ceftazidime and Oxytetracycline. 
IC50 values of Prestwick hits ordered from Sigma are given in Table 3.6. 
Amphotericin B, Ceftazidime, Oxytetracycline and Cefsulodin were found to be 
the more potent inhibitors of the hNTH1/YB-1∆C interaction with IC50 values 
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between 8 and 14 µM. Meclocyline is also a potential inhibitor with an IC50 of 16 
µM. Mitoxantrone and Moxlactam exhibit higher IC50 values (> 40 µM) and 
appear to be poorer inhibitors. 
Table 3.6. IC50 values of Prestwick hits ordered from Sigma. 
 
Ampho- 
tericin B 
Meclo- 
cycline 
Moxa-
lactam 
Cefsu-
lodin 
Mitoxan-
trone 
Ceftazi- 
dime 
Oxytetra-
cycline 
IC50 (µM) 8.91 16.26 41.50 10.47 44.67 13.93 13.34 
R2 of fits 0.99 0.99 0.92 0.99 0.97 0.96 0.98 
Lastly, for comparison we performed limited dose response assays with the 
small amounts of compounds provided by the CMBA platform (Figure 3.38).  
	 
Figure 3.38. Dose response curves of seven Prestwick hits provided by CMBA platform. (A) 
Amphotericin B, Meclocycline, Moxalactam and Cefsulodin, (B) Mitoxantrone, Ceftazidime, and 
Oxytetracycline. The data points corresponding to the means of triplicate measurements were 
fitted to a standard sigmoidal inhibition model in GraphPad Prism. 
IC50 values of the seven Prestwick hits provided by CMBA platform are 
given in Table 3.7. These data confirm that Mitoxantrone and Moxalactam are 
less potent as Biosensor 1 FRET inhibitors, while the other compounds have IC50 
values between 9 and 18 µM.  
Table 3.7. IC50 values of Prestwick hits provided by CMBA platform. 
 
Ampho- 
tericin B 
Meclo- 
cycline 
Moxa-
lactam 
Cefsu-
lodin 
Mitoxan-
trone 
Ceftazi- 
dime 
Oxytetra-
cycline 
IC50 (µM) 14.16 9.58 128.83 18.20 92.26 12.79 10.97 
R2 of fits 0.98 0.97 0.83 0.94 0.91 0.98 0.96 
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Amphotericin B, Meclocycline, Ceftazidime and Oxytetracycline from 
Sigma and the CMBA platform inhibited the interaction in the similar range 9 to 
16 µM. Moxalactam showed a higher inhibitory effect after incubation at 4ºC for 
3 months than obtained from the CMBA platform (Table 3.6 and 3.7), confirming 
our previous results (Figure 3.35). Cefsulodin and in particular Mitoxantrone 
provided by the CMBA platform showed significantly reduced inhibitory effect 
than Sigma powders, suggesting the fresh solutions of these compounds in 
contrast with other Prestwick chemicals are more potent inhibitors (Table 3.6 and 
3.7). 
Our results suggest that several compounds obtained from the CMBA 
platform may be degraded or modified due to repeated freeze-thawing prior to use 
in chemical screening. Their inhibitory effect on hNTH1/YB-1C interaction may 
therefore be the result of their degradation or alteration. 
3.4.4. AlphaScreen Assay 
To further validate these initial hits, we tested the effects of five of these 
compounds using an alternative protein-protein interaction assay that had 
previously been used to study the hNTH1/YB-1 interaction in the laboratory, 
namely the AlphaScreen technology, which is a bead-based luminescence assay. 
Dose-response measurements were performed for compounds Amphotericin B, 
Meclocycline, Moxalactam, Mitoxantrone and Cefsulodin prepared from Sigma 
powders and stored at 4ºC for 2 days (Figure 3.39). Mitoxantrone, which is a 
darkly coloured compound, was found to significantly quench the luminescence 
signal produced by the AlphaScreen beads and could therefore not be evaluated 
using this technique. The other four compounds showed dose-dependent 
inhibition of the hNTH1/YB-1C interaction with IC50 values between 30 and 160 
µM, which are a little higher but in the similar range to those determined using 
our FRET-based Biosensor 1 (Table 3.8). 
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Figure 3.39. Dose response curves of selected Prestwick hits ordered from Sigma and stored at 
4ºC for 2 days determined by AlphaScreen assay. The data points corresponding to the means of 
triplicate measurements were fitted to a standard sigmoidal inhibition model in GraphPad Prism. 
Table 3.8. IC50 values of Prestwick hits determined by AlphaScreen assay. 
 Amphotericin B Cefsulodin Meclocycline Moxalactam 
IC50 (µM) 160.9 55.48 30.77 49.66 
R2 of fits 0.74 0.97 0.96 0.93 
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Part II. YB-1-hTopoI complex 
In addition to its interaction with hNTH1, YB-1 has also been shown to 
interact with hTopoI and to function as an endogenous regulator of hTopoI-
dependent DNA relaxation. In particular, YB-1 is able to interact with hTopoI 
during CPT-induced oxidative stress and this process increases cellular sensitivity 
to this drug in PC-3 cells (Wu et al., 2014). The objective of my work was thus to 
investigate and further characterise the interaction between hTopoI and YB-1 in 
vitro and in diverse mammalian cell lines using FRET to evaluate its potential as 
an anticancer drug target. 
3.5.  YB-1-hTopoI interaction in vitro  
3.5.1. Expression and purification of human Topoisomerase I (hTopoI) 
Initially the complete hTopoI and two N-terminally truncated forms of 
hTopoI were cloned into pProEX-HTb for expression in E. coli BL21 cells with 
cleavable N-terminal His-tags (Figure 3.40 and see Annex). The two truncated 
forms showed no expression and for the intact hTopoI protein, it was successfully 
expressed, but partially degraded and two forms of hTopoI were recovered. The 
first pool contained a degraded form of hTopoI, while the second pool contained 
mostly full-length hTopoI. In both cases, the protein yield was very low and the 
protein concentration could not be determined reliably, but the protein could 
nonetheless be used to perform initial relaxation activity tests. To overcome these 
difficulties, we decided to tag the protein at its C-terminus with a non-cleavable 
hexa-histidine tag (Figure 3.40). 
	 
Figure 3.40. Illustration of hTopoI constructs used in our work. Red: His-tag. Grey: short linker 
sequences. 
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For this C-terminally His-tagged hTopoI, we also observed partial 
degradation of the protein after the first Ni-affinity purification, but the protein 
yield was much higher (Figure 3.41). A major band ~70 kDa (hTopoI-70) was 
eluted in the 50 mM imidazole wash and full-length hTopoI (hTopoI-FL) was 
eluted mostly during the imidazole gradient. 
	 
Figure 3.41. Purification of hTopoI-FL and hTopoI-70. Illustration of the various 
chromatographic steps involved in the purification of C-terminally His-tagged hTopoI full-length 
and hTopoI-70 from bacterial cell lysates. 
Both forms were collected separately for further purifications. We tried to 
separate contaminants from the hTopoI-FL using a Heparin column, but this step 
was unsuccessful. Instead, we found that performing a second Nickel affinity 
column with a long (8-10 CV) 50 mM imidazole wash to separate hTopoI-70 and 
hTopoI-FL was successful. This way we achieved to largely separate the two 
forms of hTopoI. For the last purification step, the samples were loaded on a 
Biorad SEC 650 size exclusion column and hTopoI-FL and hTopoI-70 were 
eluted with GF buffer containing 200 mM NaCl. In the end, we recovered pure 
hTopoI-70 and hTopoI-FL at 3.5 mg/ml and 0.75 mg/ml protein concentrations, 
respectively starting from a 6 L culture. The yield was low (Table 3.9), but 
significantly higher than with the N-terminallly His-tagged hTopoI.  
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We characterised the purified hTopoI-FL and hTopoI-70 by mass 
spectrometry analysis. hTopoI-FL displayed the expected mass for the full-length 
protein (91.8 kDa) and we determined that hTopoI-70 (71.2 kDa) is an N-
terminally truncated form of hTopoI (missing residues 1-172) (Figure 3.42).  
	 
Figure 3.42. Mass spectrometry analysis of hTopoI-FL and hTopoI-70 fractions. 
To attempt to reduce this degradation, we designed a mutant in which K172 
was mutated to alanine. However, hTopoI-FL-K172A showed a similar 
purification and degradation profile as wild-type protein. 
Table 3.9.  Properties of purified hTopoI proteins. 
Name of proteins 
Size 
(kDa) 
Purification Yield/ L 
culture (mg) 
Concentration 
(mg/ml) 
His-hTopoI-FL 93.5 - - 
hTopoI-FL-His 92 0.009 0.75 
hTopoI-70-His 71 0.06 3.5 
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3.5.2. DNA relaxation activity assays 
We performed relaxation assays using both hTopoI-FL and hTopoI-70 (with 
C-terminal His-tags) purified from E. coli (Figure 3.43).    
	 
Figure 3.43. DNA relaxation activity of purified hTopoI. Left: Representative agarose gel images 
of relaxation activity of hTopoI-70 and hTopoI-FL on supercoiled pUC19 plasmid (0.1-25 nM). 
Right: Extent of DNA relaxation as a function of hTopoI-70 (black) or hTopoI-FL (red) 
concentration (nM). Experiments were performed in triplicate and the means and standard 
deviations were plotted and fitted to a simple sigmoidal model using GraphPad Prism. 
 The relaxation activities of hTopoI-FL and hTopoI-70 are similar as 
expected and reported previously (Lance Stewart et al., 1996), since both 
constructs possess an intact catalytic domain. We compared the relaxation activity 
of hTopoI-FL wild type (wt) and mutant K172A. There was no difference in their 
relaxation, suggesting that the mutation does not affect hTopoI (Figure 3.44).  
	 
Figure 3.44. DNA relaxation activity of wild-type and K172A hTopoI. Representative agarose gel 
images of the relaxation activity of hTopoI wt and mutant K172A (0.1-20 nM) on supercoiled 
pUC19 plasmid. 
 
 
 
 
132 
We then investigated the effect of the hTopoI poison CPT, on the relaxation 
activity of hTopoI-FL and hTopoI-70. CPT showed a similar inhibitory effect on 
the activity of hTopoI-FL and hTopoI-70 with IC50 values in the range of 5-10 µM 
(Figure 3.45). 
	 
 
Figure 3.45. Inhibition of the DNA relaxation activity of hTopoI by CPT. Left: Representative 
agarose gel images of relaxation activity of 20 nM hTopoI-70 and hTopoI-FL on supercoiled 
pUC19 plasmid in the presence of increasing concentrations of CPT (0-2 mM). Right: Extent of 
DNA relaxation by 20 nM hTopoI-70 (black) and hTopoI-FL (red) in the presence of increasing 
CPT concentrations (0-2 mM). Experiments were performed in triplicate and the means and 
standard deviations were plotted and fitted to a simple inhibition model using GraphPad Prism. 
3.5.3. Stimulation of hTopoI’s relaxation activity by YB-1 
 We chose to investigate the effect of YB-1 on the hTopoI relaxation activity 
using a hTopoI concentration of 0.5 nM, which relaxes ~ 10-20 % of supercoiled 
plasmid. We checked the effect of the nuclear form of YB-1, YB-1∆C, on the 
relaxation activity of hTopoI-FL and hTopoI-70 by pre-incubating the proteins 
together before adding them to the supercoiled DNA reaction mix (Figure 3.46). 
YB-1ΔC clearly stimulates the activity of both hTopoI-FL and hTopoI-70, most 
likely through a direct interaction, which suggests that the N-terminal domain of 
hTopoI is not essential for the interaction with YB-1ΔC. To further explore this, 
we thus performed interaction studies using FRET.  
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Figure 3.46. Stimulation of hTopoI DNA relaxation activity by YB-1∆C. Left: Representative 
agarose gel images showing the stimulatory effect of YB-1∆C (8-800 nM) on 0.5 nM hTopoI-FL 
and hTopoI-70 enzymatic activity. Right: Extent of DNA relaxation by 0.5 nM hTopoI-70 (black) 
and hTopoI-FL (red) in the presence of increasing amounts of YB-1∆C. Experiments were 
performed in triplicate and the means and standard deviations were plotted and fitted to a one-
phase association model using GraphPad Prism. 
3.5.4. In vitro FRET measurements  
3.5.4.1. Expression and purification of hTopoI fusion constructs 
To investigate the interaction of hTopoI with YB-1 by FRET, we fused 
hTopoI to mTQ2. As for hTopoI-FL, two constructs were prepared with either the 
His-tag at the N- or the C-terminus (Figure 3.47). After the Ni-affinity purification 
of His-mTQ2-hTopoI, the protein was partially degraded and very low amounts of 
mTQ2-hTopoI were recovered, allowing us to make just one FRET measurement. 
Then we purified the C-terminally His-tagged hTopoI-mTQ2 starting from a 6 L 
bacterial culture. Figure 3.48 summarizes all purification steps. We found that the 
protein was partially degraded during the Ni-affinity purification and as with 
hTopoI-His we ended up purifying two forms of hTopoI: hTopoI-70-mTQ2 and 
hTopoI-FL-mTQ2.   
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Figure 3.47. Illustration of hTopoI fusion constructs used in our work. Red: His-tag, grey: short 
linker sequences, orange: hTopoI, cyan: mTurquoise2 (mTQ2). 
	 
Figure 3.48. Purification of hTopoI-mTQ2. Illustration of the various chromatographic steps 
involved in the purification of C-terminally his-tagged hTopoI-mTQ2 and hTopoI-70-mTQ2.  
After a final gel filtration step, we recovered sufficient hTopoI-70-mTQ2 
protein for FRET measurements and a small amount of hTopoI-FL-mTQ2 
construct (Table 3.10). 
Table 3.10.  Properties of purified hTopoI fused to mTQ2 proteins. 
Name of proteins 
Size 
(kDa) 
Purification Yield/ L 
culture (mg) 
Concentration 
(mg/ml) 
His-mTQ2-hTopoI 122 0.004 1 
TopoI-mTQ2-His 120 0.015 3.0 
TopoI70-mTQ2-His 99 0.500 1.8 
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We tried to create a Biosensor construct containing hTopoI-FL (see Annex). 
We successfully obtained the clone of pProEX-HTb-mTQ2-hTopoI-YB1ΔC-
sYFP2 for overexpression in E.coli BL21 cells, but by gel electrophoresis and 
Western blotting we could not detect a band at ~172 kDa corresponding to our 
intact Biosensor construct. We performed a small-scale purification, which 
revealed that the hTopoI Biosensor construct was degraded in the bacteria. 
3.5.4.2. Mixture of individual proteins 
Purified hTopoI and YB-1ΔC fusion proteins used for FRET measurements 
are shown in Figure 3.49.  
	 
Figure 3.49. Representative gel of the purified proteins for in vitro FRET measurements. M: 
Biorad Precision Plus unstained protein marker, 1-6: hTopoI-mTQ2 (120 kDa), hTopoI-mTQ2 
contaminated (120 kDa), hTopoI-70-mTQ2 (99 kDa), YB-1ΔC-sYFP2 (53 kDa), sYFP2-YB-1ΔC 
(53 kDA), sYFP2 (28 kDA), respectively. 
Despite very low amounts of protein, we succeeded in measuring FRET 
with hTopoI fusion constructs at a final concentration of only 1 µM protein in GF 
buffer containing 50 mM NaCl (Figure 3.50). For comparison, no FRET signal 
was detected for hNTH1 constructs at such low protein concentrations. 
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Figure 3.50. FRET efficiencies of individual protein mixes of hTopoI and YB-1C constructs. (A) 
FRET efficiencies of hTopoI and YB-1ΔC mixtures at 1µM in buffer containing 50mM NaCl. 
*Single measurement (B) FRET efficiencies of individual protein mixtures with YB-1ΔC-sYFP2 
at 1µM in buffer containing 50mM NaCl. 
Our FRET measurements confirmed that hTopoI interacts directly with 
nuclear YB-1ΔC. The highest signal was obtained when both mTQ2 and sYFP2 
were fused to the C-termini of hTopoI and YB-1ΔC. The FRET efficiencies were 
decreased in the case of hTopoI-70, but still significantly higher than with the 
negative control (mTQ2 alone), indicating that the N-terminal region is important, 
but not essential for the interaction with YB-1ΔC, in agreement with our 
relaxation activity measurements that showed that YB-1ΔC could also stimulate 
hTopoI-70. The FRET levels were seen to vary according to the purity of purified 
protein construct. When hTopoI-FL-mTQ2 was contaminated with small amounts 
of hTopoI-70 form (Figure 2.49, lane 2), the FRET efficiency measured for the 
hTopoI-FL-mTQ2 mixture with YB-1ΔC-sYFP2 was reduced compared with that 
obtained using the more pure sample (Figure 2.49, lane 1). 
We investigated the effect of salt concentration on the hTopoI/YB-1 
interaction (Figure 3.51) and observed that increased amounts of salt lead to 
reduced FRET efficiencies by affecting the interaction. 
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Figure 3.51. Effect of salt concentration on YB-1/hTopoI interaction. (A) FRET efficiencies of 
hTopoIFL and YB-1ΔC mixtures at 1µM in buffer containing 50mM, 140mM, and 330mM NaCl. 
*Single measurement (B) FRET efficiencies of hTopoI70 and YB-1ΔC mixtures at 1µM in buffer 
containing 50mM, 140mM, and 330mM NaCl. 
3.6. YB-1/hTopoI interaction in mammalian cells 
After confirming that hTopoI and YB-1 interact directly in vitro, we set out 
to investigate their interaction in vivo, in different human cell lines and several 
fusion constructs were prepared for these experiments (Figure 3.52). 
	 
Figure 3.52. Schematic illustration of mammalian expression vector constructs used for in vivo 
FRET experiments. 
3.6.1. FRET measurements in HeLa cells 
We first evaluated the interaction of YB-1ΔC with hTopoI in HeLa cells. 
Before performing FRET experiments, we checked the expression and cellular 
localisation of mTQ2 fused hTopoI constructs (Figure 3.53).  
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Figure 3.53. Nuclear localisation of hTopoI-mTQ2 in HeLa cells. Representative epifluorescence 
microscopy images of HeLa cells transfected with pmTQ2-NLS (A), pmTQ2-C1-hTopoI (B) and 
pmTQ2-N1-hTopoI (C). Right column, CFP channel; left column, DIC channel overlaid with CFP 
channel.  
We observed expression of both N-terminally and C-terminally mTQ2 
fused hTopoI in HeLa cells, however the transfection efficiencies were very low 
for both constructs. The mTQ2-hTopoI construct showed better transfection 
efficiency and donor fluorescent intensity than the hTopoI-mTQ2 construct. When 
we performed co-transfection experiments with mTQ2-hTopoI and YB-1-sYFP2, 
we were unable to find cells co-expressing both constructs. Moreover, attempts to 
establish a stable HeLa cell line expressing mTQ2-hTopoI failed (surviving cells 
no longer showed any detectable expression of mTQ2-hTopoI), probably due to 
toxicity of hTopoI overexpression. 
To overcome the low co-transfection efficiency, we tried the 2A self-
cleaving peptide based co-expression system (Wang et al., 2015). The Foot-and-
mouth disease virus 2A peptide regulates the simultaneous expression and 
cleavage of multiple gene targets in cells. We inserted the 2A peptide in between 
our YB-1ΔC-sYFP2 and mTQ2-hTopoI sequences to ensure the two constructs 
were expressed at similar levels in vivo. As a negative control, we prepared a 
construct in which sYFP2-YB-1ΔC was replaced by sYFP2-NLS (Figure 3.54).  
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Figure 3.54. Schematic illustration of 2A co-expression constructs used in mammalian cells. 2A -
C is a negative control, missing YB-1C, in which sYFP2-NLS and mTQ2-hTopoI are co-
expressed in the nucleus. 2A NLS is a variant of the 2A construct in which an additional NLS 
signal was added to the C-terminus of sYFP2 to favour the nuclear localisation of YB1-C-sYFP2. 
We transfected our HeLa cells with these co-expression constructs. The 
images of fixed samples were acquired one day after transfection (Figure 3.55).  
	 
Figure 3.55. FRET measurements between YB-1C and hTopoI in HeLa cells. Representative 
epifluorescence microscopy images of HeLa cells transfected with psYFP2-NLS-2A-mTQ2-
hTopoI (A), pYB-1ΔC-sYFP2-2A-mTQ2-hTopoI (B), pYB-1ΔC-sYFP2-NLS-2A-mTQ2-hTopoI 
(C). mTQ2 is seen in the CFP channel (blue). sYFP2 is seen in the YFP channel (green). The 
white rectangle indicates the area of the nucleus that was photobleached. Scale bar: 10µm. (D) 
FRET efficiencies measured in HeLa cells transfected with the various 2A constructs. The 
presented data are the mean of at least eight replicates. 
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We observed co-expression of YB-1ΔC-sYFP2 and mTQ2-hTopoI, but the 
cellular localisation of YB-1ΔC-sYFP2 was variable in these cells. Some cells 
showed nuclear localisation, others showed cytoplasmic staining and some 
showed both of these localisations. In contrast, the sYFP2-NLS and mTQ2-
hTopoI proteins were found to localise correctly in the nucleus. To overcome 
cytoplasmic diffusion of YB-1ΔC-sYFP2, we added a Nuclear Localisation Signal 
(NLS) at the C-terminus of sYFP2 (Figure 3.54). Some cytoplasmic staining was 
still observed even in the presence of an additional NLS sequence (Figure 3.55 C). 
After performing Acceptor Photobleaching, no significant FRET signal could be 
detected with these different 2A constructs in HeLa cells (Figure 3.55 D). 
3.6.2. FRET measurements in MCF7 cells 
We then decided to study the hTopoI/YB-1ΔC interaction in the breast 
cancer cell line, MCF7 cells. We transfected the cells with the 2A co-expression 
constructs and used the acceptor photobleaching method to detect FRET signal 
(Figure 3.56). 
	 
Figure 3.56. FRET measurements between YB-1C and hTopoI in MCF7 cells using the 2A 
constructs. Representative epifluorescence microscopy images of MCF7 cells transfected with 
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psYFP2-NLS-2A-mTQ2-hTopoI (A), pYB-1ΔC-sYFP2-2A-mTQ2-hTopoI  (B), pYB-1ΔC-
sYFP2-NLS-2A-mTQ2-hTopoI (C). mTQ2 is seen in the CFP channel (blue). sYFP2 is seen in the 
YFP channel (green). The white rectangle indicates the area of the nucleus that was 
photobleached. Scale bar: 10µm. (D) FRET efficiencies measured in MCF7 cells transfected with 
the various 2A constructs. The presented data are the mean of at least five replicates. 
In MCF7 cells transfected with the 2A -C negative control, both mTQ2-
hTopoI and sYFP2-NLS were detected in the nuclei (Figure 3.56 A). In MCF7 
cells transfected with 2A constructs containing YB-1ΔC, YB-1ΔC-sYFP2 was 
both in the nucleus and in the cytoplasm (Figure 3.56 B and C). Acceptor 
photobleaching experiments were performed on cells co-expressing nuclear YB-
1C and mTQ2-hTopoI and as in the case of HeLa cells, the FRET levels 
measured were very variable and no significant FRET signal could be detected 
with these 2A constructs in the MCF7 cell line (Figure 3.56 D). 
We also performed co-transfection experiments in MCF7 cells and the co-
transfection efficiency was higher than in HeLa cells, allowing us to perform 
acceptor photobleaching experiments on co-transfected cells (Figure 3.57). This 
allowed us to test different YB-1C and hTopoI constructs to determine whether 
the position of the fluorescent protein influenced the FRET efficiency. A 
significant FRET signal was obtained from MCF7 cells co-transfected with 
mTQ2-hTopoI and YB-1ΔC-sYFP2, when YB-1ΔC-sYFP2 was highly expressed, 
thus indicating that hTopoI and YB-1ΔC can interact in the nuclei of MCF7 cells 
(Figure 3.57 D). In contrast, no FRET was detected when sYFP2 was fused to the 
N-terminus of YB-1C. The orientation of the two fluorescent proteins is thus 
critical for detecting the interaction as was observed in our in vitro measurements 
(Figure 3.50 A). 
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Figure 3.57. FRET measurements in MCF7 cells co-transfected with YB-1C and hTopoI. 
Representative epifluorescence microscopy images of MCF7 cells co-transfected with mTQ2-
hTopoI and with sYFP2-NLS (A), YB-1ΔC- sYFP2 (B) and sYFP2-YB-1ΔC (C). mTQ2 is seen in 
the CFP channel (blue). sYFP2 is seen in the YFP channel (green). The white rectangle indicates 
the area of the nucleus that was photobleached. Scale bar: 10µm. (D) FRET efficiencies measured 
in MCF7 cells co-transfected with mTQ2-hTopoI and sYFP2 fusion constructs. The presented data 
are the mean of at least five replicates. 
3.6.3. FRET measurements in PC-3 cells 
In the literature, the interaction between hTopoI and YB-1 had previously 
been detected in the prostate cancer cell line, PC-3 (Wu et al., 2014). We thus set 
out to investigate whether we could also detect FRET in PC-3 cells co-expressing 
hTopoI and YB-1. First, we transfected our PC-3 cells with 2A constructs. We 
observed co-expression of sYFP2-NLS and mTQ2-hTopoI in the nucleus (Figure 
3.58 A), but all cells transfected with either the 2A or 2A NLS construct 
(containing YB-1C) showed mostly cytoplasmic staining for the sYFP2 (Figure 
3.58 B and C). Therefore, we could not perform acceptor photobleaching 
experiments. 
 
 
 
 
143 
	 
Figure 3.58. Cellular distribution of sYFP2 and mTQ2 signals in PC-3 cells transfected with 2A 
constructs. Representative epifluorescence microscopy images of PC-3 cells transfected with 
psYFP2-NLS-2A-mTQ2-hTopoI (A), pYB-1ΔC-sYFP2-2A-mTQ2-hTopoI  (B), pYB-1ΔC-
sYFP2-NLS-2A-mTQ2-hTopoI (C). mTQ2 is seen in the CFP channel (blue). sYFP2 is seen in the 
YFP channel (green). The last column shows merged images. Scale bar: 10µm.  
We then performed co-transfection and acceptor photobleaching 
experiments with the individual constructs in PC-3 cells (Figure 3.59). The 
expression levels of hTopoI constructs fused with mTQ2 in PC-3 cells were very 
low. 
	 
Figure 3.59. FRET measurements in PC-3 cells co-transfected with YB-1C and hTopoI. 
Representative epifluorescence microscopy images of PC-3 cells co-transfected with mTQ2-
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hTopoI and either sYFP2-NLS (A) or YB-1ΔC-sYFP2 (B). mTQ2 is seen in the CFP channel 
(blue). sYFP2 is seen in the YFP channel (green). The white rectangle indicates the area of the 
nucleus that was photobleached. Scale bar: 10µm. (C) FRET efficiencies measured in PC-3 cells 
co-transfected with mTQ2-hTopoI and sYFP2 fusion constructs. The presented data are the mean 
of at least five replicates.  
Our negative control (PC-3 cells co-transfected with mTQ2-hTopoI and 
sYFP2-NLS) showed a higher FRET efficiency compared to other cell lines. 
However, the PC-3 cells co-transfected with mTQ2-hTopoI and YB-1ΔC-sYFP2 
showed significantly higher FRET efficiency compared to the negative control 
suggesting hTopoI and YB-1ΔC may interact in PC-3 cells (Figure 3.59 C). The 
FRET signal varied a lot from cell to cell, suggesting the interaction may require a 
special condition. We also performed the same experiments in PC-3 cells with the 
hTopoI-mTQ2 construct (with mTQ2 fused to the C-terminus of hTopoI), and 
obtained high FRET efficiencies (around ~54 %) for both the negative control 
(co-transfected with sYFP2-NLS) and the interaction experiment (co-transfected 
with YB-1ΔC-sYFP2). No reliable conclusions could thus be drawn from these 
experiments in PC-3 cells. 
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Summary 
FRENCH 
Partie I. Complexe de YB-1/hNTH1 
La variation d’une cellule à l’autre du signal FRET émanant de l’interaction 
entre hNTH1 et YB-1 dans les cellules MCF7 suggère que certaines cellules sont 
exposées au stress dû au processus de transfection ou à la surexpression YB-1ΔC, 
qui peut influencer la signalisation cellulaire et d'autres processus cellulaires, ce 
qui peut favoriser l'interaction entre YB-1ΔC et hNTH1. Nous avons seulement 
détecté de faibles niveaux de FRET dans les cellules MCF7 exprimant le 
Biosenseur 1 dans le noyau; ceci résulte peut-être du ratio 1:1 des protéines dans 
la construction du Biosenseur 1. Il n'y a aucune information sur la stœchiométrie 
du complexe YB-1/hNTH1, mais peut-être que l'oligomérisation de YB-1 est 
nécessaire pour une liaison efficace à hNTH1, ce qui expliquerait pourquoi le 
signal FRET fort a été détecté seulement dans les cellules MCF7 surexprimant 
YB-1. YB-1 peut fonctionner de manière similaire à p53, qui est connu pour sa 
capacité à adopter différentes formes oligomériques qui stimulent différents 
processus. Contrairement aux expériences de FRET in vivo, le signal FRET 
obtenu en mélangeant des protéines fluorescentes fusionnées à YB-1 et hNTH1 
était stable et reproductible. Des concentrations de sel plus élevées bloquent les 
interactions ioniques entre les surfaces protéine-protéine et l'interaction entre YB-
1 et hNTH1 est sensible à la force ionique du tampon de réaction. En raison de la 
haute sensibilité du FRET et de son aptitude à la spectroscopie et à l'analyse par 
imagerie, de nombreux efforts ont été déployés pour développer des expériences 
quantitatives et des tests de criblage à haut débit (HTS). D'autres techniques, telles 
que le FRET résolu dans le temps et l’AlphaScreen, sont également utilisées pour 
l’HTS. Chaque méthode a ses avantages et ses inconvénients. En l'absence 
d'informations structurelles concernant le complexe YB-1/hNTH1, nous avons 
choisi de développer un test de criblage FRET à haut débit pour rechercher des 
inhibiteurs potentiels du complexe. Bien que l'utilisation d'une quantité réduite de 
Biosenseur 1 nous ait permis de cribler plus de composés avec une quantité 
donnée de protéines, cela a affecté dans une certaine mesure la reproductibilité de 
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notre test. Il est difficile de trouver un bon contrôle positif lors du développement 
d'un test d’activité. Nous avons utilisé un substrat spécifique de hNTH1 pour 
perturber le signal FRET provenant de l'interaction YB-1/hNTH1. L'ajout de 
substrat de hNTH1 (oligonucléotide dsDNA de 12nt THF) réduit les efficacités 
FRET des Biosenseurs, mais n'affecte pas le signal de fusion de sYFP2-mTQ2.  
En HTS, l'obtention d'une seule measure de chaque composé pour le 
criblage primaire est associée à une proportion élevée de faux positifs. Dans notre 
cas, nous avons effectué des mesures une seule concentration de composé (50 
μM) en triplicatas pour minimiser le nombre de faux positifs. Ensuite, au cours du 
criblage secondaire de 30 composés sélectionnés, nous avons réalisé des HTS 
avec des concentrations de composés à 50, 10 et 1 μM afin d'étudier leurs profils 
de dose-réponse pour éliminer les inhibiteurs faibles. Lors de la dernière étape, 
validation des "hits", nous avons rencontré plusieurs problèmes. Les composés 
identifiés comme inhibiteurs de la bibliothèque Life Chemicals ont émis une 
fluorescence à une longueur d'onde similaire à celle du donneur, conduisant à une 
augmentation apparente du signal mTQ2 du Biosenseur 1, qui apparaît comme 
une diminution du taux de FRET. Notre analyse spectrale des composés Prestwick 
inhibiteurs du FRET Biosenseur 1 et la comparaison des effets de ces composés 
provenant de différentes sources ont révélé que ces impacts initiaux identifiés par 
la plateforme CMBA peuvent ne pas correspondre aux composés attendus, mais 
plutôt à des formes dégradées ou modifiées de ces produits chimiques. La perte ou 
l'instabilité du composé pendant le stockage à long terme et plusieurs cycles de 
congélation-décongélation peuvent expliquer pourquoi nous n'avons pas réussi à 
reproduire les effets inhibiteurs de certains des composés Prestwick sélectionnés 
lorsque nous préparions des solutions fraîches à partir de poudres commandées 
chez Sigma. Dans certains cas, le stockage des composés à 4ºC pendant 2 à 3 
jours a amélioré leur effet, ce qui pourrait aussi résulter d'une lente solubilisation 
de ces composés.  
À l'avenir, la nature chimique exacte de ces inhibiteurs potentiels devra être 
déterminée et les valeurs de IC50 de ces composés actifs déterminées avec 
précision en utilisant le test Biosenseur 1, mais aussi avec un test alternatif tel que 
l'AlphaScreen. 
 
 
 
 
149 
Partie II. Complexe de YB-1/hTopoI 
Pour purifier hTopoI, plusieurs systèmes d'expression ont été utilisés, le 
système baculovirus-cellule d'insecte étant le plus largement utilisé pour les 
analyses structurales. Nous avons exprimé hTopoI dans des cellules E. coli BL21 
en utilisant un ADNc optimisé par codon avec des marqueurs His N-terminaux ou 
C-terminaux. Nous avons observé plusieurs formes dégradées après la purification 
par affinité sur résine nickel, avec une forme tronquée majeure avec un poids 
moléculaire proche de 70 kDa. Ces multiples espèces pourraient être expliquées 
par des éléments promoteurs procaryotes et/ou des signaux d'initiation de 
traduction procaryotes conduisant à l'expression et/ou à la traduction de formes 
hTopoI tronquées. Elles peuvent également provenir de la protéolyse de la 
protéine après traduction, bien que notre mutant hTopoI dans lequel K172 a été 
remplacé par de l'alanine a également été soumis à un clivage, ce qui suggère que 
cela ne soit pas la cause principale de la troncation. Notre hTopoI-70 étant 
dépourvue des résidus 1-172, l'obtention de la même activité que hTopoI-FL était 
un résultat attendu et confirme que les 172 résidus N-terminaux sont dispensables 
pour l'activité de relaxation de l'ADN de hTopoI. Dans la littérature, les résidus 
191-206 dans le domaine N-terminal de hTopoI se sont révélés être impliqués 
dans le contrôle de l'étape de rotation des brins de la catalyse et la médiation des 
contacts à l'ADN en aval du site de clivage. Nous avons démontré que la forme 
nucléaire de YB-1, YB-1ΔC, stimule spécifiquement l'activité de relaxation de 
l'ADN de hTopoI-FL et hTopoI-70, indiquant que les 172 premiers résidus du 
domaine N-terminal ne sont pas essentiels pour cette stimulation YB-1ΔC-
dépendante.  
Nous avons démontré une interaction directe de YB-1ΔC avec hTopoI en 
mélangeant des protéines marquées par fluorescence purifiée à une concentration 
de 1μM en utilisant des mesures de FRET in vitro, suggérant que l'affinité de 
l’interaction entre YB-1/hTopoI peut être supérieure à celle de l'interaction YB-
1/hNTH1. Parce que le signal FRET avec hTopoI-70 n'a pas été complètement 
perdu, d'autres régions de hTopoI peuvent également être nécessaires pour 
l'interaction, comme suggéré par nos expériences de relaxation d'ADN dans 
lesquelles hTopoI-70 a également été stimulée par YB-1ΔC.  
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Dans des expériences de co-transfection, un signal FRET considérable a été 
observé dans les cellules MCF7 et PC-3 transfectées avec mTQ2-hTopoI et 
YB1AC-sYFP2 comparées aux cellules témoins négatives transfectées avec 
mTQ2-hTopoI et sYFP2-NLS. Cependant, comme dans le cas de YB-1/hNTH1, la 
surexpression de YB1ΔC-sYFP2 était nécessaire pour détecter un signal FRET 
clair, indiquant que des formes oligomériques supérieures de YB-1 pourraient être 
nécessaires pour interagir avec hTopoI, comme cela a été observé pour p53. 
Il a été montré que PARP-1, un régulateur clé des événements de réparation 
de l'ADN, peut inhiber l'activité de relaxation de hTopoI par pADP-ribosylation in 
vitro. Pour cette raison, les inhibiteurs de PARP sont maintenant utilisés dans des 
essais cliniques pour améliorer la cytotoxicité de la caomptothécin (CPT). La 
stimulation de PARP-1 par YB-1 a également été démontrée récemment et cette 
stimulation diminue la sensibilité des cellules aux inhibiteurs de PARP-1. Si YB-1 
augmente l'activité de PARP-1, ceci pourrait à son tour provoquer une inhibition 
de l'activité catalytique de hTopoI par la ribosylation de pADP. YB-1 semble 
donc jouer un rôle régulateur complexe dans les cellules via ses différents 
partenaires d'interaction, et ces résultats apparemment contradictoires peuvent 
résulter de différents mécanismes régulateurs dans les cellules et/ou différents 
niveaux d'expression des protéines dans différentes cellules tumorales. 
Effectuer des expériences EMSA pour étudier l'effet de YB-1 sur la liaison à 
l'ADN de hTopoI fournira plus d’informations sur l’effet stimulant de YB-1 sur 
l’activité de relaxation de hTopoI. D'autres méthodes biochimiques et 
biophysiques, telles que la résonance plasmonique de surface (SPR), la 
calorimétrie par titration isotherme (ITC) et AlphaScreen, pourraient également 
être utilisées pour étudier davantage l'interaction de YB-1 avec hTopoI. 
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Özet 
TURKISH 
Bölüm I. YB-1/hNTH1 kompleksi 
FRET sinyalinin hücreden hücreye farklılık göstermesinin nedenlerinden 
biri, tüm hücrelerde gerçekleşmezken bazı hücrelerin transfeksiyon sürecine veya 
hücre sinyallerini ve diğer hücresel süreçleri etkileyebilen YB-1ΔC aşırı 
ekspresyonuna bağlı olarak strese maruz kalması, bunların da YB-1ΔC ve hNTH1 
arasındaki etkileşimi desteklemesi olabilir. Biyosensör 1'i hücre çekirdeğinde 
eksprese eden MCF7 hücrelerinde düşük FRET seviyeleri gözlenmiştir. Bu durum 
Biosensor 1’deki proteinlerin bire bir oranında olmasından kaynaklanabilir. YB-
1/hNTH1 kompleksinin stokiyometrisi hakkında herhangi bir bilgi yoktur, fakat 
güçlü FRET sinyalinin sadece YB-1'i aşırı eksprese eden MCF7 hücrelerinde 
tespit edilmesi belki de YB-1'in oligomerizasyonunun, hNTH1'e etkili bağlanma 
için gerekli olduğunu düşündürmektedir. YB-1, farklı süreçleri uyaran farklı 
oligomerik formları olduğu bilinen p53'e benzer bir şekilde işlev görebilir. İn vivo 
FRET deneylerinin aksine, saflaştırılmış floresan proteinlerle füzyon olan hNTH1  
ve YB-1ΔC proteinlerinin karıştırılması ile yapılan FRET ölçümlerinden elde 
edilen FRET sinyali stabil ve tekrarlanabilirdir. Yüksek tuz konsantrasyonları 
protein-protein yüzeyleri arasındaki iyonik etkileşimleri bloke eder bu nedenle 
YB-1 ile hNTH1 arasındaki etkileşim, reaksiyon tamponunun iyonik şiddetine 
duyarlıdır. FRET'in yüksek hassasiyeti ve hem spektroskopi hem de görüntüleme 
analizi için uygunluğu nedeniyle, kantitatif deneyler ve yüksek verimli tarama 
(HTS) analizleri geliştirmek için çokça kullanılmaktadır. Zaman çözümlü FRET 
ve AlphaScreen gibi diğer teknikler de HTS için kullanılmaktadır. Her yöntemin 
avantajları ve dezavantajları vardır. YB-1/hNTH1 kompleksine ilişkin yapısal 
bilgilerin yokluğundan, kompleksin potansiyel inhibitörlerini araştırmak için 
yüksek verimli FRET-bazlı bir tarama testi geliştirilmesi düşünülmüştür. 
Biosensor 1'in düşük konsantrasyonda kullanılması, belirli bir miktarda protein ile 
daha fazla bileşiğin taranmasına izin verse de, çalışmamızın tekrarlanabilirliğini 
bir dereceye kadar etkilemiştir. Bir tarama testi geliştirirken iyi bir pozitif kontrol 
bulmak zordur. YB-1/hNTH1 etkileşiminden gelen FRET sinyalini bozmak için 
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hNTH1'in hidrolize edemediği bir substratı kullanılmıştır. hNTH1 substratının 
(12nt THF dsDNA oligonükleotid) eklenmesi, biyosensörlerin FRET verimini 
azaltırken sYFP2-mTQ2 füzyon proteinin sinyalini etkilemez. 
HTS'de, birincil tarama için her bir bileşiğin tek bir ölçümünün elde 
edilmesi, yüksek oranda yanlış pozitiflerle ilişkilendirilmiştir. Bizim 
durumumuzda, yanlış pozitiflerin sayısını en aza indirmek için tek bir bileşik 
konsantrasyonunun (50µM) ölçümlerini üç kez gerçekleştirdik. Daha sonra, 
seçilen 30 bileşiğin ikincil taraması sırasında, zayıf inhibitörleri elemek amacıyla 
konsantrasyon-cevap profillerini araştırmak için 50, 10 ve 1 μM'lik bileşik 
konsantrasyonları ile HTS gerçekleştirilmiştir. Son adım olan “isabetlerin” 
doğrulanması sırasında birkaç problemle karşılaşılmıştır. Life Chemicals kimyasal 
kütüphanesinden inhibitör olarak tanımlanan bileşikler, donöre benzer bir dalga 
boyunda floresan yaymıştır bu da Biosensor 1'in mTQ2 sinyalinde belirgin bir 
artışa neden olmuştur. Bunun sonucunda da FRET seviyesini azalttıkları 
belirlenmiştir. Biyosensör 1 FRET sinyalini inhibe eden seçilmiş Prestwick 
bileşiklerinin spektral analizleri ve bu bileşiklerin farklı kaynaklardan gelenlerinin 
etkilerinin karşılaştırılması, CMBA platformu tarafından belirlenen bu başlangıç 
isabetlerinin beklenen bileşiklere karşılık gelmediğini, bunun yerine bozulmuş 
veya modifiye olmuş formlarından meydana geldiğini ortaya çıkarmaktadır. Uzun 
süreli depolama ve çoklu donma-çözülme döngüleri sırasında bileşik kaybı veya 
kararsızlığı, Sigma'dan sipariş edilen tozları kullanarak taze çözeltiler 
hazırladığımız zaman, seçilen Prestwick bileşiklerinin bazılarının önleyici 
etkilerini neden yeniden üretemediğimizi açıklayabilir. Bazı durumlarda 
bileşiklerin 4ºC'de 2-3 gün saklanması etkilerini geliştirmiş, bu bileşiklerin yavaş 
çözünmesinden kaynaklanabilmektedir. 
Gelecekte, bu potansiyel inhibitörlerin tam kimyasal yapısı belirlenmeli ve 
bu aktif bileşiklerin IC50 değerleri, Biyosensör 1 testi kullanılarak ve aynı 
zamanda AlphaScreen gibi alternatif bir deneyle de belirlenmelidir. 
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Bölüm II. YB-1/hTopoI kompleksi 
hTopoI'yi saflaştırmak için, çeşitli ekspresyon sistemleri kullanılmıştır ve 
bakulovirüs ekspresyon sistemi, yapısal analizler için gerekli protein eldesi için en 
yaygın olarak kullanılanıdır. E. coli BL21 hücrelerinde, N veya C terminali His-
etiketleriyle kodonu optimize edilmiş cDNA kullanılarak hTopoI’i ifade etmeyi 
başardık. Nikel afinite saflaştırması sonucunda, 70 kDa'ya yakın bir moleküler 
ağırlığa sahip, büyük bir degrade form ile birkaç değişik degrade form 
gözlemlenmiştir. Bu değişik degrade formlar, prokaryotik promoter elementler 
ve/veya prokaryotik translasyon başlatma sinyallerinin bölünmüş hTopoI 
formlarının ekspresyonuna ve/veya translasyonuna yol açması sonucu ortaya 
çıkabilmektedir. Ayrıca bu durum, proteolitik bozunmadan da kaynaklanabilirler. 
Ancak lizin172'nin alanin ile değiştirildiği hTopoI mutantımızın da degradasyona 
maruz kalmasından dolayı bu degradasyonun ana nedeni olmayabileceği 
düşünülmektedir. hTopoI-70'in 1-172 arasındaki amino asit kalıntıları eksiktir, 
ancak hTopoI-FL ile aynı aktiviteyi göstermektedir. Bu literatürde olduğu gibi 
beklenen bir sonuçtur, N-terminal domaininde bulunan 172 amino asit 
kalıntılarının hTopoI’nin DNA relaksasyon aktivitesi için gerekli olmadığını teyit 
etmektedir. Literatürde, hTopoI'nın N-terminal alanındaki 191-206 amino asit 
kalıntılarının, enzimin iplik döndürme adımının kontrol edilmesinde ve kesim 
bölgesinin aşağısındaki DNA'ya temasında rol oynadığı gösterilmiştir. YB-1ΔC, 
YB-1'nin nükleer formu, hem hTopoI-FL'nin hem de hTopoI-70'in DNA 
relaksasyon aktivitesini spesifik olarak uyardığı ve N-terminal domainin ilk 172 
amino asit kalıntısının bu YB-1ΔC bağımlı stimülasyon için gerekli olmadığı 
gösterilmiştir. 
YB-1ΔC'nin hTopoI ile doğrudan etkileşimini, saflaştırılmış floresan 
proteinlerle füzyon olan hTopoI ve YB-1ΔC proteinlerinin  1 μM 
konsantrasyonunda karıştırmak suretiyle FRET ölçümleri ile gösterilmiş ve bu da 
YB-1/hTopoI etkileşim afinitesinin YB-1/hNTH1 etkileşiminden daha yüksek 
olabileceğini düşündürmektedir. hTopoI-70 ile FRET sinyali azalıp ancak 
tamamen kaybolmadığından, hTopoI-70'in de YB-1ΔC tarafından uyarıldığı DNA 
relaksasyon deneyleri tarafından da önerildiği için, etkileşim için başka hTopoI 
bölgeleri de gerekmektedir. 
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Ko-transfeksiyon deneylerinde, mTQ2-hTopoI ve sYFP2-NLS ile transfekte 
edilen negatif kontrol hücreleri ile karşılaştırıldığında mTQ2-hTopoI ve YB1ΔC-
sYFP2 ile transfekte edilen MCF7 ve PC-3 hücrelerinde anlamlı bir FRET sinyali 
gözlenmiştir. Bununla birlikte, YB-1/hNTH1 durumunda olduğu gibi, net bir 
FRET sinyalinin saptanması için YB1C-sYFP2'nin aşırı ekspresyonu gereklidir, 
bu da p53’de gözlemlendiği gibi, hTopoI ile etkileşime girmek için YB-1'in daha 
yüksek oligomerik formlarının gerekli olabileceğini göstermektedir. 
DNA onarım olaylarının anahtar regülatörü olan PARP-1'in, in vitro olarak 
pADP-ribosilasyonu ile hTopoI relaksasyon aktivitesini inhibe ettiği 
gösterilmiştir. Bu nedenle, PARP inhibitörleri CPT'nin sitotoksisitesini artırmak 
için klinik çalışmalarda kullanılmaktadır. PARP-1'in son zamanlarda YB-1 ile 
uyarıldığı gösterilmiştir ve bu uyarım hücrelerin PARP-1 inhibitörlerine olan 
duyarlılığını azaltmaktadır. YB-1, PARP-1'in aktivitesini arttırırsa, bu durum, 
hTopoI'nin katalitik aktivitesinin pADP-ribosilasyonu ile engellenmesine neden 
olabilmektedir. Dolayısıyla YB-1, çeşitli etkileşim partnerleri aracılığıyla 
hücrelerde karmaşık bir düzenleyici rol oynamaktadır ve literatürdeki çelişkili 
bulgular, farklı tümör hücrelerindeki farklı düzenleyici mekanizmalardan ve/veya 
farklı protein ekspresyon seviyelerinden kaynaklanabilmektedir. 
YB-1'in hTopoI'nin DNA bağlanması üzerindeki etkisini araştırmak için EMSA 
deneylerinin yapılması, YB-1'in hTopoI'nin relaksasyon aktivitesi üzerindeki 
uyarıcı etkisi hakkında daha fazla bilgi sağlayacaktır. Yüzey Plazmon Rezonansı 
(SPR), İzotermal titrasyon kalorimetrisi (ITC) ve AlphaScreen gibi diğer 
biyokimyasal ve biyofiziksel yöntemler, YB-1'in hTopoI ile etkileşimini daha 
fazla araştırmak için kullanılabilir. 
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Part I. YB-1/hNTH1 complex 
We successfully demonstrated the YB-1/hNTH1 interaction using FRET 
method in MCF7 cells and in vitro with purified proteins. We created a robust and 
reliable FRET-based assay using our Biosensor 1 construct, for high throughput 
screening in order to find potential inhibitors of the YB-1/hNTH1 complex. We 
identified several promising compounds in the Prestwick Chemical library that 
significantly reduced the FRET signal of our Biosensor 1. 
We obtained a significant FRET signal with a MCF7 stable cell line 
expressing hNTH1-mTQ2 and transfected with YB1ΔC-sYFP2, but only in cells 
in which YB-1ΔC was strongly overexpressed (Figure 3.2). This observation is 
not surprising because YB-1 has been reported to interact and regulate the activity 
of hNTH1 under genotoxic stress conditions, such as cisplatin treatment in the 
MCF7 cells (Guay et al., 2008). During acceptor photobleaching experiments, 
FRET signal varied from cell to cell. It is possible that some cells are exposed to 
stress due to the transfection process or YB-1ΔC overexpression, which can 
influence cell signalling and other cellular processes, which in turn may favour 
the interaction between YB-1ΔC and hNTH1. 
We encountered cellular localisation problems during transfection of MCF7 
cells with the Biosensor 1 construct. A possible reason for this could be that the 
endogenous NLS signals of YB-1ΔC and hNTH1 were no longer accessible when 
the proteins were joined together in the Biosensor construct. Changing the relative 
positions of the proteins within the biosensor construct may overcome this 
problem. In some cases, Biosensor 1 was also degraded and CFP and YFP 
staining were observed in the nucleus and cytoplasm, respectively. This suggests 
that the linkers between the proteins and particularly between YB-1ΔC and 
hNTH1, are protease-sensitive. This could be avoided or minimised by changing 
the sequence of these linker regions. When we performed acceptor 
photobleaching experiments in MCF7 cells expressing the Biosensor 1 in the 
nucleus, we only detected low levels of FRET. This may result from the 1:1 ratio 
of the proteins in the Biosensor 1 construct. There is no information about the 
stoichiometry of the YB-1/hNTH1 complex, but maybe the oligomerization of 
 
 
 
 
156 
YB-1 is needed for efficient binding to hNTH1, which would explain why strong 
FRET signal was only detected in YB-1 overexpressing MCF7 cells. YB-1 maybe 
functions similarly to p53, which is known to adopt different oligomeric forms 
that stimulate different processes (Søe and Grosse, 2003).  
FRET measurements by mixing fluorescent proteins fused to YB-1 and 
hNTH1 confirmed our FRET experiments in MCF7 cells. Contrary to in vivo 
FRET experiments, the obtained FRET signal was stable and reproducible. 
Because FRET is a distance-sensitive method (less than 10 nm), the positions and 
orientations of fluorescent proteins are important in obtaining a FRET signal. The 
FRET efficiencies of mixtures were affected by the position of the fluorescent 
protein, as in the in vivo FRET experiments. The highest FRET signal was 
obtained when both mTQ2 and sYFP2 were fused to the C-termini of hNTH1 and 
YB-1ΔC, respectively. In this condition, a FRET signal of ~ 7% could be 
reproducibly measured which is significantly higher than our negative control 
(YB-1ΔC-sYFP2 mixed with mTQ2 alone) (Figure 3.16). The concentration of 
mixture was also important. Below 5 μM concentration no FRET signal was 
detected. This may reflect the affinity or the stoichiometry of the complex. As we 
observed in MCF7 cells, an excess of YB-1 may be necessary for complex 
formation. Optimal buffer conditions were also critical to detect the FRET signal. 
At NaCl concentrations higher than 50 mM, we could not detect a significant 
FRET signal. This indicates that the interaction between YB-1 and hNTH1 is 
sensitive to the ionic strength of the reaction buffer. Higher salt concentrations 
block ionic interactions between protein-protein surfaces (Dumetz et al., 2007). 
The purity of protein samples is also very important, especially for nucleic acid-
binding proteins. A contamination of RNA and/or DNA can affect the interaction 
of these proteins. For this reason, we performed several chromatographic steps to 
ensure complete elimination of nucleic acid contamination in our purification 
procedure (Figure 2.5). Some biochemical methods for investigation of protein-
protein interaction, like co-immuno precipitation, may give misleading results 
with nucleic acid-binding proteins even after nuclease treatment where nucleic 
acid contaminations are still present. 
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Biosensor 1 FRET signal is robust and reproducible. It is a very simple 
assay, which does not require mixing different reagents or long incubation 
periods. Because of the FRET’s high sensitivity and its suitability for both 
spectroscopy and imaging analysis, much effort has been made to develop 
quantitative experiments and HTS assays (Song et al., 2011; Rogers et al., 2012; 
Schaap et al., 2013; Chakraborty et al., 2014; Wei et al., 2014). However, due to 
the low FRET yield of fluorescent proteins and the complexity of fluorescence 
emissions from the donor and acceptor, it has been a very difficult process to 
evolve FRET into a quantitative assay. Nevertheless, with promising 
improvements in fluorescent proteins, researchers have tried to overcome these 
problems (Kremers et al., 2006; Mastop et al., 2017). The cross-talk in the 
fluorescent protein-based FRET can be corrected for, which minimises these 
issues for example. FRET is usually performed as ratiometric assays, which 
reduces the effects of autofluorescence and spectral interference of media and test 
compounds. But in some cases, if the autofluorescence of compounds overlaps 
with donor emission signal, it may lead to false positive results as we encountered 
with the three compounds from Life Chemicals PPI fragment library. Some 
compounds that strongly absorb UV light can inhibit excitation of the FRET 
donor, which absorbs in the far-UV region (ca. 350 nm). 
FRET methods are relatively easy to automate and to miniaturize. They 
can be used with a wide range of protein sizes, with the provision that the FRET 
pairs must come within a few nanometers from each other. The size of the 
complex can be limited by the distance and the orientation of the fluorescent 
proteins. For very large complexes, the AlphaScreen assay that allows detection 
of interactions within a distance of 200 nm may be more suitable. Alpha 
technologies are adaptable to many assay types, are very sensitive, and are active 
over long distances (200 nm vs 10-20 nm for TR-FRET). The central limitations 
to AlphaScreen and AlphaLisa are the increased expense compared with other 
mix-and-read formats and the sensitivity of the materials to ambient light.  
Glickman et al., 2002, compared AlphaScreen, time-resolved fluorescence 
resonance energy transfer (TR-FRET), and time-resolved fluorescence (TRF), and 
concluded that the AlphaScreen format had the best sensitivity, dynamic range, 
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and decreased plate-reading time. These techniques varied in the detection 
reagents and optical plate-reading system used. Of the three formats, TR-FRET 
assay had the least inter-well variation, most likely because it is a ratiometric type 
of measurement. Both FRET-type and AlphaScreen formats can measure a wide 
range of affinities (Kd’s ranging from low pM to low mM concentrations) 
because there are no wash steps. It is noteworthy that AlphaScreen beads have 
300-3000 proteins/bead, and the protein density can be varied. This multi-valency 
can significantly increase sensitivity, because one PPI per bead pair leads to the 
maximal signal. With FRET methods, each binding partner carries a single label 
so that if some beads are unbound, a lower signal will be generated. However, 
monovalency also implies that the signal will be proportional to the number of 
binding interactions. 
In the absence of structural information regarding the YB-1/hNTH1 
complex, we chose to develop a high throughput FRET-based screening assay to 
search for potential inhibitors of the complex (Figure 4.1).  
	 
Figure 4.1. The steps of high throughput chemical library screening with Biosensor 1 in order to 
find potential inhibitors of YB-1/hNTH1 complex. Inspired from Inglese et al., 2007. The first step 
was the development and optimization of our robust and reliable Biosensor 1 assay. In the second 
step, Life Chemicals and Prestwick Chemical libraries were selected for HTS to find potential YB-
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1/hNTH1 complex. Then, Robotic HTS was performed at CMBA platform with a 0.9 Z' factor 
value. The results obtained from our first and second screenings were analysed for the extent of 
inhibition. The last step is the validation of the hits by dose-response curves in order to obtain IC50 
values. 
As with our FRET measurements on protein mixtures, higher salt 
concentrations significantly affected the FRET efficiencies of the biosensor, 
confirming that salt interferes with the interaction between hNTH1 and YB-1. 
High ionic strength was also found to reduce the FRET of our positive control 
(sYFP2-mTQ2 fusion) most likely as a result of non-specific effects (change in 
chromophore conformation, non-specific interactions between fluorescent 
proteins) (Figure 3.18). To our surprise, the biosensor concentration used also 
affected the levels of FRET. This was in marked contrast with the Fusion 
construct which produced a stable FRET signal regardless of its concentration in 
the reactions, as would be expected for intramolecular FRET. This finding 
suggests that the FRET signal of the biosensor may result from dimerization and 
intermolecular FRET. 
We also observed variable FRET levels of the Biosensor 1 from day to day 
when preparing diluted samples (at 0.2 µM) using different stocks of NaCl 
solutions and different tubes. Using untreated 384-well plates (without non-
binding property) also affected the FRET signal of our Biosensor 1. So although 
using a reduced amount of Biosensor 1 allowed us to screen more compounds 
with a given amount of protein, it did affect to some extent the reproducibility of 
our assay. To minimise the impact of this variability on our screening results, we 
included both positive (0.5 µM 12nt THF oligo) and negative (DMSO) controls in 
each 384-well plate during HTS and alongside all our subsequent measurements 
during validation experiments. In this way, our FRET levels could always be 
compared to those of our controls. 
It is difficult to find a good bioactive control while developing a screening 
assay. High concentrations of detergent and/or urea have been showed to disrupt 
protein interactions (Song et al., 2011), but are not specific to the interaction and 
can affect the fluorescent proteins too. We used a specific substrate of hNTH1 to 
disrupt the FRET signal coming from YB-1/hNTH1 interaction. Addition of 
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hNTH1 substrate (12nt THF dsDNA oligonucleotide) reduces the FRET 
efficiencies of biosensors, but does not affect the signal of sYFP2-mTQ2 fusion 
(Figure 3.20 C). This suggests that the FRET signal results from a specific 
interaction between hNTH1 and YB-1 that has been disrupted by the interaction 
of hNTH1 with its DNA substrate. This may either result from competition for a 
shared binding site on hNTH1 or from a conformational change in hNTH1 upon 
DNA binding that leads to reduced FRET. Small angle X-ray scattering 
measurements performed in J. Timmins’ team have indeed shown that hNTH1 
undergoes a major conformational change upon DNA binding that involves its 
NTD, the region that we have shown to be important for YB-1 binding 
(unpublished data). The hNTH1 substrate was thus used to evaluate the robustness 
of our assay, which based on its Z' factor values was found to be highly robust and 
well suited to screen chemical libraries (Table 3.3). 
We chose two relatively small libraries (~ 1000 compounds) for our initial 
screens for potential inhibitors of the YB-1/hNTH1 complex: the Life Chemicals 
PPI fragment library and the Prestwick Chemical library. These screens were well 
adapted to test the usefulness of our Biosensor 1 as a screening assay and were 
sufficiently diverse to provide us with some initial, promising hits. Moreover, the 
advantage of the Prestwick Chemical library is that it contains 95 % approved 
drugs (FDA, EMA and other agencies), which can facilitate and accelerate 
subsequent drug development processes.  
In HTS, obtaining a single measurement of each compound for the 
primary screen has been associated with a high proportion of false positives (Malo 
et al., 2006). In our case, we performed our measurements at a single compound 
concentration (50 µM) in triplicate to minimize the number of false positives. 
Then, during the secondary screening of 30 selected compounds, we performed 
HTS with 50, 10 and 1 µM compound concentrations in order to investigate their 
concentration-response profiles eliminating weak inhibitors. 
During the last step, validation of the “hits”, we encountered several 
problems. The compounds identified as inhibitors from the Life Chemicals library 
emitted fluorescence at a similar wavelength as the donor (Table 3.5), leading to 
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an apparent increase in Biosensor 1’s mTQ2 signal, which appears as a decreased 
FRET level. Determining the intrinsic fluorescence of compounds is thus very 
important to avoid false positive results and we therefore integrated this step into 
our secondary screening of the Prestwick compounds. This is not only a problem 
in FRET; in AlphaScreen/AlphaLisa assays the compounds can also interfere with 
the assay technology by four mechanisms, including those mimicking biotin, 
quenching singlet oxygen, quenching light, and scattering light (Yasgar et al., 
2016). We observed a drastic AlphaLisa signal decrease with Mitoxantrone (even 
at very low concentrations) during validation tests, suggesting Mitoxantrone, 
which is a dark solution, was quenching the light produced by the AlphaLisa 
beads.  
Our spectral analysis of the selected Prestwick compounds that inhibited 
Biosensor 1 FRET (Figure 3.36) and the comparison of the effects of these 
compounds from different sources (Figure 3.35) revealed that these initial hits 
identified by the CMBA platform may not correspond to the expected 
compounds, but rather to degraded or modified forms of these chemicals. The 
degraded/modified forms of these Prestwick compounds appear to be in most 
cases more active as inhibitors of the YB-1/hNTH1 interaction than their native 
formula. Only Cefsulodin and Mitoxantrone were not affected by long storage 
times and gave similar results when tested from freshly dissolved powders as 
those obtained from the CMBA platform. On HTS platforms, the use of solvents, 
and typically a single solvent (DMSO), for preparation of chemical libraries is a 
necessity for automated screenings. The solvent in which the compounds are 
dissolved may catalyse or participate in certain reactions, leading to the 
degradation of the compounds. There are several studies investigating the stability 
of compounds in DMSO. One of them showed that there is no significant 
degradation after 25 freeze/thaw cycles by high-performance liquid 
chromatography–mass spectrometry analysis, but compound loss was observed 
(Kozikowski et al., 2003). In another study, humidity was shown to be an 
important factor affecting compound stability. The degradation of target 
compounds was showed after treatment at 40ºC in water-free DMSO by UV 
chromatogram. (Cheng et al., 2003). Compound loss or instability during long-
term storage and multiple freeze-thaw cycles may explain why we failed to 
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reproduce the inhibitory effects of some of the selected Prestwick compounds 
when we prepared fresh solutions using powders ordered from Sigma. In some 
cases, storage of the compounds at 4ºC for 2-3 days improved their potency, 
which could also result from slow solubilization of these compounds. 
Additional experiments that might contribute to strengthen our data could be 
achieved by employing gas chromatography-tandem mass spectrometry (GC-
MS/MS) and/or nuclear magnetic resonance (NMR) spectroscopy for further 
clarification of the exact chemical nature of these potential inhibitors. This might 
also be helpful in initiating an advanced structure-activity relationship study. The 
IC50 values of these identified active compounds should be precisely determined 
using the Biosensor 1 assay, but also with an alternative assay such as the 
AlphaScreen. Cytotoxicity tests, like 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assay, should also be performed with the potential 
hits, before testing their ability to inhibit the interaction in cells using our FRET 
assay in our stably transfected MCF7 cells expressing mTQ2-hNTH1. It would 
also be interesting to create a cisplatin-resistant MCF7 cell line to evaluate the 
FRET signal and test for the ability of our potential inhibitors to sensitize this cell 
line. To further explore the importance of the YB-1:hNTH1 stoichiometry on 
complex formation, we could also create 2A co-expression constructs for hNTH1 
and YB-1. 
A manuscript describing these results is in preparation. It will present the 
characterization of the YB-1/hNTH1 interaction in vitro and in vivo using FRET, 
the design and optimization of our Biosensor constructs and the use of Biosensor 
1 as a robust tool for HTS in order to find potential inhibitors for YB-1/hNTH1 
complex. 
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Part II. YB-1/hTopoI complex 
In this work, we have showed that YB-1∆C stimulates the DNA relaxation 
activity of both the full-length hTopoI and a N-terminally truncated form of 
hTopoI (hTopoI-70) in vitro using purified proteins produced in E. coli. We 
demonstrated a direct interaction of YB-1 with hTopoI by FRET and investigated 
the interaction between YB-1 and hTopoI in several cell lines (HeLa, MCF7, and 
PC-3). We detected some FRET signal with MCF7 and PC-3 cells co-transfected 
with mTQ2-hTopoI and YB-1∆C-sYFP2, but further studies will be needed to 
confirm these preliminary results. 
To purify hTopoI, several expression systems have been used in the past, 
with the baculovirus-insect cell system being the most widely used for structural 
analyses (Stewart and Champoux, 1999; Peixoto et al., 2010; Tsai et al., 2010). 
The purification yields reported in these studies were of 250 µg of purified 
hTopoI from 109 HeLa cells and ~ 10mg of purified hTopoI from 3×109 insect 
cells (L. Stewart et al., 1996). In Dr. Joanna Timmins’ lab, this system is not 
commonly used, so we decided to express hTopoI in E.coli BL21 cells using a 
codon-optimized cDNA with either N- or C-terminal His-tags. We observed 
several degraded forms after the nickel affinity purification, with a major 
truncated form with a molecular weight close to 70 kDa. We separated these 
fractions and obtained two active forms of hTopoI (FL and 70) from a single 
purification (Figure 3.41). Our purification yield for the C-terminal His-tagged 
proteins was low with ~ 55 µg for hTopoI-FL and ~ 360 µg for hTopoI-70 (Table 
3.9) from 6 L of E. coli cells, but this was enough for our relaxation activity tests. 
To identify interaction domains of hTopoI, cloning of additional N-terminally 
truncated forms (Figure 3.40) was also performed, but we did not observe any 
expression of these truncated constructs in E. coli BL21 cells. In literature, 
multiple hTopo I-related protein species smaller than the full-length product were 
identified in E. coli expression (Madden and Champoux, 1992). These multiple 
species could be explained by prokaryotic promoter elements and/or prokaryotic 
translation initiation signals leading to expression and/or translation of truncated 
hTopoI forms. They may also arise from proteolytic degradation, although our 
hTopoI mutant in which K172 was replaced with alanine was also subject to 
 
 
 
 
164 
cleavage, suggesting this may not be the main cause of the truncation. In E. coli, 
overexpression of hTopoI gene has also been reported to be highly toxic (Madden 
and Champoux, 1992), which could explain why E. coli cells process the protein 
very rapidly after its production. Multiple degraded species of hTopoI could 
indeed be detected in cell extracts before cell lysis. The overexpression of the 
biosensor construct containing hTopoI in E. coli BL21 cells most likely failed 
because of these major degradation problems.  
Our relaxation activity tests demonstrated that purified hTopoI-FL and 
hTopoI-70 had similar enzymatic activities even at low protein concentration. In 
literature, amino acid residues 191–206 in the N-terminal domain of hTopoI have 
been shown to be involved in controlling the strand rotation step of catalysis and 
mediating contacts to DNA downstream of the cleavage site (Lisby et al., 2001; 
Frøhlich et al., 2004). Our hTopoI-70 is lacking amino acid residues 1-172, 
therefore obtaining the same activity as hTopoI-FL was an expected result and 
confirms that the N-terminal 172 residues are dispensable for hTopoI’s DNA 
relaxation activity. Both forms of hTopoI also exhibited similar sensitivities to the 
TopoI poison, CPT. The intrinsic sensitivity of hTopoI to CPT has been reported 
to be determined by the composition of the conserved core and active site Tyr 723 
containing C-terminal domain (Wright et al., 2015), both of which are present in 
the two purified forms of hTopoI. Finally, we confirmed that YB-1 enhances the 
DNA relaxation by hTopoI (Wu et al., 2014), and additionally demonstrated that 
the nuclear form of YB-1, YB-1ΔC, specifically stimulates the DNA relaxation 
activity of both hTopoI-FL and hTopoI-70, indicating the first 172 amino acid 
residues of the N-terminal domain of hTopoI are not essential for this YB-1ΔC-
dependent stimulation (Figure 3.46).  
We then demonstrated a direct interaction of YB-1ΔC with hTopoI by 
mixing purified fluorescently tagged proteins at 1μM concentration using FRET 
measurements (Figure 3.50). Obtaining a clear FRET signal at 1 µM protein 
concentration, suggests that the YB-1/hTopoI interaction affinity may be higher 
than that of the YB-1/hNTH1 interaction. The FRET efficiencies of the mixtures 
were affected by the position of the fluorescent proteins, as seen for the YB-
1/hNTH1 complex, but to a lesser extent. The highest signal was obtained when 
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both mTQ2 and sYFP2 were fused to the C-termini of hTopoI and YB-1ΔC. The 
FRET signal significantly decreased in the absence of the N-terminal extension of 
hTopoI (hTopoI-70), indicating the first 172 amino acid residues of N-terminal 
domain play an important role in the direct interaction with YB-1ΔC. Because the 
FRET signal with hTopoI-70 was not completely lost, other regions of hTopoI 
may also be needed for the interaction, as suggested by our DNA relaxation 
experiments in which hTopoI-70 was also stimulated by YB-1 C. Alternatively, 
we cannot rule out that the relative orientation of the fluorescent proteins was 
more favourable for FRET in the case of hTopoI-FL compared to hTopoI-70. The 
purity of protein isolates was also critical for FRET measurements. We observed a 
significantly decreased FRET signal when the hTopoI-mTQ2 sample was 
contaminated with small amounts of hTopoI-70-mTQ2. YB-1 has been proposed 
to interact with hTopoI via its cold shock and C-terminal domains and this direct 
interaction is needed for enhancement of hTopoI’s DNA relaxation activity (Wu 
et al., 2014). Our FRET studies clearly show that YB-1ΔC, missing amino acid 
residues 219-324, was potent at interacting with hTopoI and stimulating its 
activity. 
The interaction of YB-1 and hTopoI had previously been detected by co-
immunoprecipitation experiments from human gastric cancer HGC-27, pancreatic 
cancer PANC-1, and human prostate cancer PC-3 cells (Wu et al., 2014). We tried 
to investigate this interaction by fluorescence microscopy using acceptor 
photobleaching method. We were able to express hTopoI constructs (hTopoI-
mTQ2 and mTQ2-hTopoI) in three different mammalian cell lines (HeLa, MCF7 
and PC-3) with low transfection efficiencies. The mTQ2-hTopoI construct 
showed better transfection efficiency and donor fluorescence intensity than the 
hTopoI-mTQ2 construct. Co-transfection of HeLa cells with mTQ2-hTopoI and 
with YB-1ΔC constructs to perform FRET experiments did not work. The 
creation of a stable cell line, which expresses mTQ2-hTopoI constitutively, also 
failed, suggesting that maybe overexpression of hTopoI is toxic to cells. We 
therefore decided to use the 2A self-cleaving peptide-based multi-gene expression 
system (Wang et al., 2015) (Figure 3.54). No significant FRET signal could be 
detected with 2A constructs in HeLa and MCF7 cells (Figure 3.55 and 3.56). In 
PC-3 cells, we did not perform acceptor photobleaching experiments with the 
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cells transfected with the 2A constructs because a majority of cells showed YB-
1ΔC-sYFP2 expression in the cytoplasm instead of in the nucleus (Figure 3.58). 
In theory this 2A construct should provide equal expression (1:1 ratio) of both 
proteins. But a recent study suggests that protein expression decreases by ~70% at 
the second gene position compared to the first gene position in bi-cistronic 2A 
constructs (Liu et al., 2017). An incorrect stoichiometry of the produced YB-
1/hTopoI complex, may explain why no FRET signal was detected with these 2A 
constructs. It is unclear at present why in some cases the YB-1ΔC-sYFP2 
expressed in these 2A constructs was sometimes mislocalised to the cytoplasm. 
Addition of an extra nuclear localisation signal (NLS) did not improve this, 
suggesting that it is not due to a poorly accessible NLS peptide. 
 In co-transfection experiments, a considerable FRET signal was observed 
in both MCF7 and PC-3 cells transfected with mTQ2-hTopoI and YB1ΔC-sYFP2 
compared to negative control cells transfected with mTQ2-hTopoI and sYFP2-
NLS (Figure 3.57 and 3.59). However, as in the case of YB-1/hNTH1, the 
overexpression of YB1ΔC-sYFP2 was required to detect a clear FRET signal, 
indicating that higher oligomeric forms of YB-1 may be needed to interact with 
hTopoI, as has been observed for p53 (Søe and Grosse, 2003). In PC-3 cells, 
many cells expressed sYFP2 constructs at very high levels and a relatively high 
FRET signal could also be measured in negative control samples (Figure 3.59 D). 
The high nuclear protein abundance in PC-3 cells may cause this increased, 
unspecific FRET signal. 
PARP-1, a key regulator of DNA repair events, has been shown to inhibit 
the hTopoI relaxation activity by pADP-ribosylation in vitro (Kasid et al., 1989). 
For this reason, PARP inhibitors are now being used in clinical trials to enhance 
the cytotoxicity of CPT (Das et al., 2016). PARP-1 has also recently been shown 
to be stimulated by YB-1 and this stimulation decreases the sensitivity of cells to 
PARP-1 inhibitors (Alemasova et al., 2018). If YB-1 enhances the activity of 
PARP-1, this could in turn cause inhibition of hTopoI’s catalytic activity by 
pADP-ribosylation. YB-1 thus appears to be playing a complex regulatory role in 
cells via its various interaction partners, and these apparently contradictory 
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findings may result from different regulatory mechanisms in cells and/or different 
protein expression levels in different tumour cells. 
Performing EMSA experiments using labelled DNA substrates to 
investigate the effect of YB-1 on the DNA-binding of hTopoI will provide more 
information about YB-1's stimulatory effect on the relaxation activity of hTopoI. 
Other biochemical and biophysical methods, such as Surface Plasmon Resonance 
(SPR), Isothermal titration calorimetry (ITC), and AlphaScreen, could also be 
used to further investigate the interaction of YB-1 with hTopoI. We failed to 
produce a functional biosensor with YB-1 and hTopoI for inhibitor screening; 
however, alternative approaches such as HTRF could be used for chemical library 
screening. FRET studies of the YB-1/hTopoI complex should be pursued in vivo 
and it would be interesting to investigate the effect of CPT on the interaction in 
cells.  
A manuscript reporting our data regarding the YB-1/hTopoI complex will 
be prepared in the near future.  
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Part III. Both hNTH1 and hTopoI complexes with YB-1 
The intrinsically disordered structure of YB-1 is critical for its interactions 
with several partners and for the different functions it performs in the cell (Lyabin 
et al., 2014). Moreover, post-translational modifications of YB-1 
(phosphorylation, acetylation, and ubiquitylation) resulting from the specific 
activation of signalling pathways in tumour cells may also regulate its functions in 
the cell (Kohno et al., 2003). An increase of the amount of YB-1 in the cell or its 
translocation from the cytoplasm to the nucleus have been shown to cause an 
increase or decrease of mRNAs or proteins encoded by many genes involved in 
cell proliferation, differentiation, multiple drug resistance and DNA repair 
(Eliseeva et al., 2011).  
In MCF7 cells, we observed that YB-1 interacts with both hNTH1 and 
hTopoI, which clearly shows that YB-1 plays a complex, but central role and may 
regulate different cellular processes within a given cell type via its interactions 
with different proteins. In response to genotoxic stress, YB-1 is known to 
translocate into the nucleus and activate the expression of some genes, which are 
responsible for DNA repair, replication and other signalling pathways. It also 
interacts with nuclear proteins to regulate different processes like transcription 
and DNA repair. DNA topoisomerase I plays a role in the pause-release of 
transcription machinery by removing the positive supercoils, which represent a 
mechanical barrier in front of the RNA polymerase II (Baranello et al., 2016). 
Interactions between YB-1 and hTopoI are increased when tumour cells are 
exposed to drug-induced oxidative stress (Wu et al., 2014). By enhancing the 
relaxation activity of hTopoI, YB-1 may facilitate the initiation of gene 
transcription needed for the response to genotoxic stress. This YB-1/hTopoI 
complex formation increased cellular sensitivity to CPT. Meanwhile, the 
stimulation of hNTH1’s AP-lyase activity by YB-1 would result in more efficient 
DNA repair to protect cells from death thereby allowing tumour cells to become 
more resistant to DNA damaging drugs (like cisplatin). The cellular response may 
be different according to the drug used for treatment. 
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Part IV. Conclusions and Future Prospects 
FRET is a versatile method that can be applied both in vitro and in vivo. 
However, compared to a test tube containing purified proteins, cells are much 
more complex systems with a lot of protein-protein, nucleic acid-protein, and 
receptor-ligand interactions. In our acceptor photobleaching experiments, we 
observed varying FRET efficiencies in vivo, but in vitro the FRET signal was 
stable. Further studies will be needed to better understand the molecular 
mechanisms tightly regulating the interactions of YB-1 with its multiple cellular 
partners in vivo.  Characterizing the YB-1 complexes formed under genotoxic 
stress conditions may offer novel treatment strategies against drug-resistant 
tumour cells. 
In the future, the hNTH1/YB-1 Biosensor 1 will be used for screening a 
much larger chemical library (10,000 compounds) in order to identify potent 
inhibitors of the hNTH1/YB-1 interaction. Although it has not worked for hTopoI 
due to degradation problems, our designed Biosensor construct offers a new 
strategy to study protein-protein interactions and to perform HTS for potential 
inhibitors. Several teams at IBS have already shown interest in adapting the 
Biosensor to their needs and a collaboration with Dr. Cécile Morlot will be 
initiated later this year.  
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ANNEX 
1. Original and optimized cDNA sequences of our proteins 
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Figure A.1. hNTH1 sequence alignment of Original cDNA and Optimized cDNA. 
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Figure A.2. YB1 sequence alignment of Original cDNA and Optimized cDNA. 
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Figure A.3. hTopoI sequence alignment of Original cDNA and Optimized cDNA. 
2. PCR primers used and cloning fragments prepared in this work 
Table A.1. Oligonucleotides used as PCR-primers for assembly of three hTopoI 
fragments. Lowercase letters show oligonucleotide tails not identical to the target 
sequence. 
Primer name Primer Sequence 
pEX-A2-hTopoI 
F_ pEX-A2-
FragA 
5’ – ACCTGCTTTTGCTCGCTTGGATCC – 3’ 
R_ pEX-A2-
FragA 
5’ – CTTCCTCTGCTTTTGGGCTCAGC – 3’ 
F_ FragAB 5’ –gagcccaaaagcagaggaagTCGCTACGTTCTTTGCAAAAATGTTGGA– 3’ 
R_ FragB 5’ – cagattgatgTGCTCCACACGAAGGCTACAGC – 3’ 
F_ FragBC 5’ –gtgtggagcaCATCAATCTGCACCCAGAGTTGGAT– 3’ 
R_ FragC 5’ –ccaagcgagcaaaagcaggtTTAAAACTCGTAGTCTTCATCCGCCATG– 3’ 
Table A.2. Assembling the full length hTopoI 
Construct Insert 1 / bp Insert 2 / bp Plasmid / bp Final Product (bp) 
 FragB FragC pEX-A2-FragA  
pEX-A2-hTopoI 796 796 3216 4748 
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Table A.3. Oligonucleotides used as PCR-primers for mammalian expression 
vectors. Green coloured letters: restriction enzyme site; red coloured letters: gene 
specific region; pink colored letters: 2A linker. Lowercase letters show 
oligonucleotide tails not identical to the target sequence. 
Primer name Primer Sequence 
pmTQ2-N1-hNTH1 
For_ hNTH1_N1 5’– AACTCGAGATGTGCTCTCCGCAGGAATCTGG –3’ 
Rev_ hNTH1_N1 5’– TTGGATCCGACAGACCCTGAGCAGCCGGG –3’ 
pmTQ2-C1-hNTH1 
For_ hNTH1_C1 5’– AACTCGAGCTATGTGCTCTCCGCAGGAATCTGG –3’ 
Rev_ hNTH1_C1 5’– TTGGATCCTCACAGACCCTGAGCAGCCGGG –3’ 
psYFP2-C1-YB1 
For_ YB1_C1 5’– AACTCGAGCTATGTCTTCTGAAGCTGAAACCCAACAG –3’ 
Rev_ YB1_C1 5’– TTGGATCCTTATTCAGCACCACCCTGTTCAGCTT –3’ 
psYFP2-N1-YB1ΔC 
For_ YB1_N1 5’– AACTCGAGATGTCTTCTGAAGCTGAAACCCAACAG –3’ 
Rev_ YB1dC_N1 5’– TTGGATCCGATTCCATAACTTCACCCTGAACCGGC –3’ 
psYFP2-C1-YB1ΔC 
For_ YB1_C1 5’– AACTCGAGCTATGTCTTCTGAAGCTGAAACCCAACAG –3’ 
Rev_ YB1dC_C1 5’– TTGGATCCTTATTCCATAACTTCACCCTGAACCGGC –3’ 
pmTQ2-N1-hTopoI 
F_hTopoI 5’ – AACTCGAGCTATGAGCGGCGACCACCTGCAC – 3’ 
R_hTopoI-N1 5’ – TTGGATCCGAAAACTCGTAGTCTTCATCCGCC – 3’ 
pmTQ2-C1-hTopoI 
R_hTopoI-C1 5’ – TTGGATCCGATTAAAACTCGTAGTCTTCATCC – 3’ 
pYB1ΔC-sYFP2-2A-mTQ2-hTopoI 
F_ pmTQ2-C1-
hTopoI 
5’ – gtcgaggagaatcctggcccaATGGTGAGCAAGGGCGAGGAG – 3’ 
R_ pmTQ2-C1-
hTopoI 
5’ – AGAAGACATGGTGGCGACCGGTAGCGC – 3’ 
F_ YB1dC-
sYFP2-2A 
5’ – ccggtcgccaccATGTCTTCTGAAGCTGAAACCCAACAG – 3’ 
R1_YB1dC-
sYFP2-2A 
5’ – tcctctgccctcTCCGCTTCCCTTGTACAGCTCGTCCATGCC – 3’ 
R2_2A 5’ – gtcaccgcatgttagcagactTCCTCTGCCCTCTCCGCTTCC – 3’ 
R3-2A 5’ – tgggccaggattctcctcgacGTCACCGCATGTTAGCAGACT – 3’ 
psYFP2-NLS-2A-mTQ2-hTopoI 
F_ sYFP2-NLS 5’ – CCGGTCGCCACCATGGTGAGCAAGGGCGAGGA – 3’ 
R_ sYFP2-NLS 5’ – tcctctgccctcTCCGCTTCCTCTAGATCCGGTGGATCCTACC – 3’ 
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Table A.4. Cloning of constructs for mammalian expression. 
Construct 
Insert  / 
bp 
Plasmid / 
bp 
RE couple 
used 
Final 
Product 
(bp) 
pmTQ2-N1-hNTH1 950 4690 XhoI / BamHI 5640 
pmTQ2-C1-hNTH1 963 4668 XhoI / BamHI 5631 
psYFP2-N1-YB1 989 4678 XhoI / BamHI 5667 
psYFP2-N1-YB1ΔC 671 4680 XhoI / BamHI 5351 
psYFP2-C1-YB1ΔC 674 4678 XhoI / BamHI 5352 
pmTQ2-N1-hTopoI 2315 4674 XhoI / BamHI 6989 
pmTQ2-C1-hTopoI 2318 4674 XhoI / BamHI 6992 
pYB1ΔC-sYFP2-2A-
mTQ2-hTopoI 
7022 1470 - 8450 
psYFP2-NLS-2A-
mTQ2-hTopoI 
7022 861 - 7883 
pYB1ΔC -sYFP2-NLS-
2A-mTQ2-hTopoI 
7022 1539 - 8561 
Table A.5. Oligonucleotides used as PCR-primers for fluorescent protein coupled 
proteins cloning. Green coloured letters: restriction enzyme site; red coloured 
letters: gene specific region; bleu coloured letters: linker sequence between two 
protein genes. Lowercase letters show oligonucleotide tails not identical to the 
target sequence. 
Primer name Primer Sequence 
pProEX-HTb-hNTH1-mTQ2 /NtailhNTH1-mTQ2 
F_hNTH1 5’ – AAGTCGACGATGTGCTCTCCGCAGGAATCTGG – 3’ 
R_mTQ2 5’ – TTAAGCTTTCACTTGTACAGCTCGTCCATGCCGAG – 3’ 
pProEX-HTb-ND89hNTH1-mTQ2 
F_ND89hNTH1 5’ – AAGTCGACGATGCAGGACTGGCAGCAGCAGCTG – 3’ 
pProEX-HTb-mTQ2-hNTH1 
R_hNTH1 5’ – TTAAGCTTTCACAGACCCTGAGCAGCCGGG – 3’ 
pProEX-HTb-sYFP2-YB1ΔC 
F_sYFP2 5’ – AAGTCGACGATGGTGAGCAAGGGCGAGGAG – 3’ 
R_YB1ΔC 5’ – TTAAGCTTTCATTCCATAACTTCACCCTGAACCGGC – 3’ 
pProEX-HTb-YB1ΔC-sYFP2 
F_YB1ΔC 5’ – AAGTCGACGATGTCTTCTGAAGCTGAAACCCAACAG – 3’ 
pProEX-HTb-hTopoI 
F_hTopoI 5’ – AACCATGGGAATGAGCGGCGACCACCTGCAC – 3’ 
R_hTopoI 5’ – TTCTCGAGTTAAAACTCGTAGTCTTCATCC – 3’ 
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pET21d-hTopoI 
R_hTopoI_CterHis 5’ – TTCTCGAGAAACTCGTAGTCTTCATCCGCC – 3’ 
pET21d-mTQ2-hTopoI 
F_Linker-hTopoI 5’ – tccggactcagatctcgagctATG AGC GGC GAC CAC CTG – 3’ 
R_pET21d 5’ – TCCCATGGTATATCTCCTTCTTAAAGTTAAAC – 3’ 
F_pET21d-mTQ2 5’ – ttaagaaggagatataccatgggaATGGTGAGCAAGGGCGAG – 3’ 
R_Linker-mTQ2 5’ – AGCTCGAGATCTGAGTCCGGACTT – 3’ 
pET21d-hTopoI-mTQ2 
F_mTQ-pET21 5’ – atggacgagctgtacaagCTCGAGCACCACCACCACC – 3’ 
R_Linker-hTopoI 5’ – ggtggcgaccggtggatccgaAAACTCGTAGTCTTCATCCGCC – 3’ 
F_Linker 5’ – TCGGATCCACCGGTCGCCAC – 3’ 
R_mTQ2 5’ – ctcgagCTTGTACAGCTCGTCCATGCCGAG – 3’ 
Table A.6. Cloning of fluorescent protein coupled constructs for bacterial 
expression. 
Construct Insert  / bp Plasmid / bp RE couple 
used 
Final Product 
(bp) 
pProEX-HTb-
hNTH1-mTQ2 
1694 4702 SalI / HindIII 6396 
pProEX-HTb-
NtailhNTH1-
mTQ2 
1025 4702 SalI / HindIII 5727 
pProEX-HTb-
ND89hNTH1-
mTQ2 
1430 4702 SalI / HindIII 6132 
pProEX-HTb- 
mTQ2-hNTH1 
1694 4702 SalI / HindIII 6396 
pProEX-HTb-
sYFP2-YB1ΔC 
1415 4702 SalI / HindIII 6117 
pProEX-HTb- 
YB1ΔC- sYFP2 
1415 4702 SalI / HindIII 6117 
pProEX-HTb-
hTopoI 
2316 4674 NcoI / XhoI 6990 
pET21d-hTopoI 2313 5354 NcoI / XhoI 7667 
pET21d-mTQ2- 
hTopoI 
762 7688 - 8405 
pET21d-
hTopoI-mTQ2 
744 7706 - 8405 
Table A.7. Oligonucleotides used as PCR-primers for Biosensors cloning. Green 
coloured letters: restriction enzyme site; red coloured letters: gene specific region; 
bleu coloured letters: linker sequence between two protein genes. 
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Primer 
name 
Primer Sequence 
Biosensor 1 
For_SYFP2-
YB1ΔC 
5’ – AAGTCGACGATGGTGAGCAAGGGCGAGGAG – 3’ 
R_SYFP2-
YB1ΔC_Bio 
5’ –TTGCTAGCACCTCCGCCGCTTTCCATAACTTCACCCTGAACCGGC– 3’ 
F_hNTH1-
mTQ2_Bio 
5’ – AAGCTAGCGGAGGCGGGACGATGTGCTCTCCGCAGGAATCTGG – 3’ 
R_ hNTH1-
mTQ2 
5’ – TTAAGCTTTCACTTGTACAGCTCGTCCATGCCGAG – 3’ 
Biosensor 3 
F_ND89NT
H1-
mTQ2_Bio 
5’-AAGCTAGCGGAGGCGGGACGATGCAGGACTGGCAGCAGCAGCTG -3’ 
Biosensor 4 
F_drEndoIII
-mTQ2_Bio 
5’ – AAGCTAGCGGAGGCGGGACGATGACTCGCAATTCTGCCTCCCC – 3’  
Biosensor 5 
F_mTQ2_Bi
o 
5’-AAGCTAGCGGAGGCGGGACGATGGTGAGCAAGGGCGAGGAGCTG-3’ 
Biosensor 6 
R_sYFP2_B
io 
5’ – TTGCTAGCACCTCCGCCGCTCTTGTACAGCTCGTCCATGCCGAG – 3’ 
Biosensor 7 
R_mTQ2-
hNTH1_Bio 
5’ – TTGCTAGCACCTCCGCCGCTCAGACCCTGAGCAGCCGG – 3’ 
For_YB1ΔC
-sYFP2_Bio 
5’-AAGCTAGCGGAGGCGGGACGATGTCTTCTGAAGCTGAAACCCAACAG-3’ 
Biosensor hTopoI 
Rev_mTQ2-
hTopoI_Bio 
5’ – TTGCTAGCACCTCCGCCGCTAAACTCGTAGTCTTCATCCGCC– 3’ 
Table A.8. Cloning of Biosensor constructs for bacterial expression. 
Construct Insert  / 
bp 
Plasmid / 
bp 
RE couple 
used 
Final Product 
(bp) 
pProEX-HTb-sYFP2-
YB1ΔC-hNTH1-mTQ2 
1424 
1705 
4692 
SalI / NheI 
NheI / HindIII 
7821 
pProEX-HTb-sYFP2-
YB1ΔC-NtailhNTH1-
mTQ2 
1424 
1036 
4692 
SalI / NheI 
NheI / HindIII 
7152 
pProEX-HTb-sYFP2-
YB1ΔC-ND89hNTH1-
mTQ2 
1424 
1441 
4692 
SalI / NheI 
NheI / HindIII 
7557 
pProEX-HTb-sYFP2-
YB1ΔC-drEndoIII2-
mTQ2 
1424 
1444 
4692 
SalI / NheI 
NheI / HindIII 
7560 
pProEX-HTb-sYFP2-
YB1ΔC-mTQ2 
1424 
748 
4692 
SalI / NheI 
NheI / HindIII 
6864 
pProEX-HTb-sYFP2-
hNTH1-mTQ2 
746 
1705 
4692 
SalI / NheI 
NheI / HindIII 
7143 
pProEX-HTb- mTQ2- 
hNTH1-YB1ΔC-sYFP2 
1703 
1426 
4692 
SalI / NheI 
NheI / HindIII 
7821 
pProEX-HTb- mTQ2- 
hTopoI-YB1ΔC-sYFP2 
3062 
1426 
4692 
SalI / NheI 
NheI / HindIII 
9180 
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3. Protein sequences and properties obtained from ProtParam tool on the 
ExPASy Proteomics Server 
!	 
Figure A.4. Schematic illustration of all purified protein constructs in this work. 
pProEX-HTb-sYFP2-mTQ2 (Fusion) 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMVSKGEELFTGVVPILVE
LDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDH
MKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNIL
GHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPD
NHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 498   
Molecular weight: 55747.04   
Theoretical pI: 5.82 
Extinction coefficients:   
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water.   
Ext. coefficient 49530  
Abs 0.1% (=1g/l) 0.888, assuming all pairs of Cys residues form 
cystines    
Ext. coefficient 49280  
Abs 0.1% (=1g/l) 0.884, assuming all Cys residues are reduced  
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pProEX-HTb-sYFP2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 252   
Molecular weight: 28122.80 
Theoretical pI: 5.86 
Extinction coefficients:   
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water.   
Ext. coefficient 23505 
Abs 0.1% (=1g/l) 0.836, assuming all pairs of Cys residues form 
cystines    
Ext. coefficient 23380  
Abs 0.1% (=1g/l) 0.831, assuming all Cys residues are reduced  
pProEX-HTb-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLST
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 252   
Molecular weight: 28158.83   
Theoretical pI: 5.63 
Extinction coefficients:   
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water.   
Ext. coefficient 26025  
Abs 0.1% (=1g/l) 0.924, assuming all pairs of Cys residues form 
cystines    
Ext. coefficient 25900  
Abs 0.1% (=1g/l) 0.920, assuming all Cys residues are reduced  
Figure A.5. Protein sequences and properties after cleavage of His-tag obtained from ProtParam 
tool on the ExPASy Proteomics Server of fluorescent constructs. Red coloured letters, hexa-His 
tag; pink coloured letters, TEV cleavage site; yellow coloured letters, sYFP2; cyan coloured 
letters, mTQ2. 
pProEX-HTb-sYFP2-YB1ΔC 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
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AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVME- 
Number of amino acids: 478   
Molecular weight: 52672.89   
Theoretical pI: 8.99 
Extinction coefficients:   
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water.   
Ext. coefficient 46885  
Abs 0.1% (=1g/l) 0.890, assuming all pairs of Cys residues form 
cystines    
Ext. coefficient 46760  
Abs 0.1% (=1g/l) 0.888, assuming all Cys residues are reduced  
 
 
pProEX-HTb-YB1ΔC-sYFP2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMSSEAETQQPPAAPPAAPALSAAD
TKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRNDTKEDV
FVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKYAADRNH
YRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYMRRPYGR
RPQYSNPPVQGEVMESDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDA
TYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDFFKSAMPEGYVQERT
IFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQ
KNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSYQSKLSKDPNEKRDH
MVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 478   
Molecular weight: 52612.78   
Theoretical pI: 8.65 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 46885 
Abs 0.1% (=1 g/l) 0.891, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 46760 
Abs 0.1% (=1 g/l) 0.889, assuming all Cys residues are reduced 
Figure A.6. Protein sequences and properties after cleavage of His-tag obtained from ProtParam 
tool on the ExPASy Proteomics Server of YB1ΔC constructs. Red coloured letters, hexa-His tag; 
pink coloured letters, TEV cleavage site; yellow coloured letters, sYFP2; green coloured letters, 
YB1ΔC. 
pProEX-HTb-hNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMCSPQESGMTALSARMLTRSRSLG
PGAGPRGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEGAEPLKV
PVWEPQDWQQQLVNIRAMRNKKDAPVDHLGTEHCYDSSAPPKVRRYQVLLSLMLSSQTKD
QVTAGAMQRLRARGLTVDSILQTDDATLGKLIYPVGFWRSKVKYIKQTSAILQQHYGGDI
PASVAELVALPGVGPKMAHLAMAVAWGTVSGIAVDTHVHRIANRLRWTKKATKSPEETRA
ALEEWLPRELWHEINGLLVGFGQQTCLPVHPRCHACLNQALCPAAQGLSDPPVATMVSKG
EELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTL
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SWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIE
LKGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQ
NTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 571   
Molecular weight: 63198.11   
Theoretical pI: 8.75 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 73840 
Abs 0.1% (=1 g/l) 1.168, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 73340 
Abs 0.1% (=1 g/l) 1.160, assuming all Cys residues are reduced 
pProEX-HTb-mTQ2- hNTH1 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLST
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMCSPQESGMTALSARMLT
RSRSLGPGAGPRGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEG
AEPLKVPVWEPQDWQQQLVNIRAMRNKKDAPVDHLGTEHCYDSSAPPKVRRYQVLLSLML
SSQTKDQVTAGAMQRLRARGLTVDSILQTDDATLGKLIYPVGFWRSKVKYIKQTSAILQQ
HYGGDIPASVAELVALPGVGPKMAHLAMAVAWGTVSGIAVDTHVHRIANRLRWTKKATKS
PEETRAALEEWLPRELWHEINGLLVGFGQQTCLPVHPRCHACLNQALCPAAQGL- 
Number of amino acids: 571   
Molecular weight: 63258.22   
Theoretical pI: 8.97 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 73840 
Abs 0.1% (=1 g/l) 1.167, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 73340 
Abs 0.1% (=1 g/l) 1.159, assuming all Cys residues are reduced 
pProEX-HTb-NtailhNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMCSPQESGMTALSARMLTRSRSLG
PGAGPRGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEGAEPLKV
PVWEPSDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFI
CTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKI
RHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAA
GITLGMDELYK- 
Number of amino acids: 348   
Molecular weight: 38503.57   
Theoretical pI: 6.84 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
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Ext. coefficient 33140 
Abs 0.1% (=1 g/l) 0.861, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 32890 
Abs 0.1% (=1 g/l) 0.854, assuming all Cys residues are reduced 
pProEX-HTb- ND89hNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMQDWQQQLVNIRAMRNKKDAPVDH
LGTEHCYDSSAPPKVRRYQVLLSLMLSSQTKDQVTAGAMQRLRARGLTVDSILQTDDATL
GKLIYPVGFWRSKVKYIKQTSAILQQHYGGDIPASVAELVALPGVGPKMAHLAMAVAWGT
VSGIAVDTHVHRIANRLRWTKKATKSPEETRAALEEWLPRELWHEINGLLVGFGQQTCLP
VHPRCHACLNQALCPAAQGLSDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGE
GEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYI
TADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPN
EKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 483   
Molecular weight: 53652.28   
Theoretical pI: 7.37 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 66725 
Abs 0.1% (=1 g/l) 1.244, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 66350 
Abs 0.1% (=1 g/l) 1.237, assuming all Cys residues are reduced 
Figure A.7. Protein sequences and properties after cleavage of His-tag obtained from ProtParam 
tool on the ExPASy Proteomics Server of hNTH1 constructs. Red coloured letters, hexa-His tag; 
pink coloured letters, TEV cleavage site; cyan coloured letters, mTQ2; blue coloured letters, 
hNTH1. 
pProEX-HTb-mTQ2- hTopoI 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLST
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSGDHLHNDSQIEADFRL
NDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHK
DKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKR
PRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKE
EEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVAT
FFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQ
MSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIM
PEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGE
KDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGET
ADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENK
 
 
 
 
186 
QPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILS
YNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDA
KTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGV
PIEKIYNKTQREKFAWAIDMADEDYEF- 
Number of amino acids: 1024   
Molecular weight: 119594.36   
Theoretical pI: 9.13 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 129315 
Abs 0.1% (=1 g/l) 1.081, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 128690 
Abs 0.1% (=1 g/l) 1.076, assuming all Cys residues are reduced 
pET21d-hTopoI-mTQ2 
MGMSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSE
KKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKD
EPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKN
KDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENV
KFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLS
KCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPP
GLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTE
NIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVA
LYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYY
NKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITL
QQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQL
ADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGT
SKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEFSDPPVATMVSKGE
ELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLS
WGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIEL
KGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQN
TPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKLEHHHHH
H- 
Number of amino acids: 1020   
Molecular weight: 119412.04   
Theoretical pI: 9.03 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 129315 
Abs 0.1% (=1 g/l) 1.083, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 128690 
Abs 0.1% (=1 g/l) 1.078, assuming all Cys residues are reduced 
hTopoI70-mTQ2 
LKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYE
PLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKN
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IITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIAN
FKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTW
LVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKV
RQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGK
DSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTY
NASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKID
AKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENK
QIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEFSDPPVAT
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT
LVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL
VNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLA
DHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKL
EHHHHHH- 
Number of amino acids: 847   
Molecular weight: 98778.29   
Theoretical pI: 8.98 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 126335 
Abs 0.1% (=1 g/l) 1.279, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 125710 
Abs 0.1% (=1 g/l) 1.273, assuming all Cys residues are reduced 
Figure A.8. Protein sequences and properties after cleavage of His-tag obtained from ProtParam 
tool on the ExPASy Proteomics Server of hTopoI constructs. Red coloured letters, hexa-His tag; 
pink coloured letters, TEV cleavage site; cyan coloured letters, mTQ2; orange coloured letters, 
hTopoI. 
Biosensor 1 
pProEX-HTb-sYFP2-YB1ΔC-hNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVMESGGGASGGGTMCSPQESGMTALSARMLTRSRSLGPGAGP
RGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEGAEPLKVPVWEP
QDWQQQLVNIRAMRNKKDAPVDHLGTEHCYDSSAPPKVRRYQVLLSLMLSSQTKDQVTAG
AMQRLRARGLTVDSILQTDDATLGKLIYPVGFWRSKVKYIKQTSAILQQHYGGDIPASVA
ELVALPGVGPKMAHLAMAVAWGTVSGIAVDTHVHRIANRLRWTKKATKSPEETRAALEEW
LPRELWHEINGLLVGFGQQTCLPVHPRCHACLNQALCPAAQGLSDPPVATMVSKGEELFT
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQ
CFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGID
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FKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIG
DGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 1046   
Molecular weight: 115297.25   
Theoretical pI: 8.86 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 120725 
Abs 0.1% (=1 g/l) 1.047, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 120100 
Abs 0.1% (=1 g/l) 1.042, assuming all Cys residues are reduced 
Biosensor 2 
pProEX-HTb-sYFP2-YB1ΔC-NtailhNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVMESGGGASGGGTMCSPQESGMTALSARMLTRSRSLGPGAGP
RGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEGAEPLKVPVWEP
SDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGK
LPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEV
KFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIE
DGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLG
MDELYK- 
Number of amino acids: 823   
Molecular weight: 90602.70   
Theoretical pI: 8.48 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 80025 
Abs 0.1% (=1 g/l) 0.883, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 79650 
Abs 0.1% (=1 g/l) 0.879, assuming all Cys residues are reduced 
Biosensor 3 
pProEX-HTb-sYFP2-YB1ΔC-ND89hNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
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DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVMESGGGASGGGTMQDWQQQLVNIRAMRNKKDAPVDHLGTEH
CYDSSAPPKVRRYQVLLSLMLSSQTKDQVTAGAMQRLRARGLTVDSILQTDDATLGKLIY
PVGFWRSKVKYIKQTSAILQQHYGGDIPASVAELVALPGVGPKMAHLAMAVAWGTVSGIA
VDTHVHRIANRLRWTKKATKSPEETRAALEEWLPRELWHEINGLLVGFGQQTCLPVHPRC
HACLNQALCPAAQGLSDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDA
TYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQERT
IFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQ
KNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDH
MVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 958   
Molecular weight: 105751.42   
Theoretical pI: 8.48 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 113610 
Abs 0.1% (=1 g/l) 1.074, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 113110 
Abs 0.1% (=1 g/l) 1.070, assuming all Cys residues are reduced 
Biosensor 4 
pProEX-HTb-sYFP2-YB1ΔC-drEndoIII2-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVMESGGGASGGGTMTRNSASPRLPAGARARAPQVLSALGRLY
PDARTELVFNTPFELLVATVLSAQATDVSVNAATPALFAAYPDAHALSQATADDIEPYIR
SIGLYRGKAKNLAALARLLVERHGGEVPNDFDAVVALPGAGRKTANVVLSNAYDYPAIAV
DTHVGRLARRLGLSVQTNPDKVEADLQKLFPRDRWVFLHHALILHGRRVCHARKPQCPSC
ELASFCPKVGVEHVEGSDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGD
ATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQER
TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADK
QKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRD
HMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 959   
Molecular weight: 105193.50   
Theoretical pI: 8.15 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 87600 
Abs 0.1% (=1 g/l) 0.833, assuming all pairs of Cys residues form 
cystines 
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Ext. coefficient 87100 
Abs 0.1% (=1 g/l) 0.828, assuming all Cys residues are reduced 
Biosensor 5 
pProEX-HTb-sYFP2-YB1ΔC-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSSEAETQQPPAAPPAAP
ALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRN
DTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKY
AADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYM
RRPYGRRPQYSNPPVQGEVMESGGGASGGGTMVSKGEELFTGVVPILVELDGDVNGHKFS
VSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAM
PEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYFSD
NVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLS
KDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 727   
Molecular weight: 80257.9   
Theoretical pI: 7.11 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 72910 
Abs 0.1% (=1 g/l) 0.908, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 72660 
Abs 0.1% (=1 g/l) 0.905, assuming all Cys residues are reduced 
Biosensor 6 
pProEX-HTb-sYFP2-hNTH1-mTQ2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSY
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGGGASGGGTMCSPQESGMTALSAR
MLTRSRSLGPGAGPRGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEK
GEGAEPLKVPVWEPQDWQQQLVNIRAMRNKKDAPVDHLGTEHCYDSSAPPKVRRYQVLLS
LMLSSQTKDQVTAGAMQRLRARGLTVDSILQTDDATLGKLIYPVGFWRSKVKYIKQTSAI
LQQHYGGDIPASVAELVALPGVGPKMAHLAMAVAWGTVSGIAVDTHVHRIANRLRWTKKA
TKSPEETRAALEEWLPRELWHEINGLLVGFGQQTCLPVHPRCHACLNQALCPAAQGLSDP
PVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPV
PWPTLVTTLSWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFE
GDTLVNRIELKGIDFKEDGNILGHKLEYNYFSDNVYITADKQKNGIKANFKIRHNIEDGG
VQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDE
LYK- 
Number of amino acids: 820   
Molecular weight: 90747.1   
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Theoretical pI: 7.43 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 97345 
Abs 0.1% (=1 g/l) 1.073, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 96720 
Abs 0.1% (=1 g/l) 1.066, assuming all Cys residues are reduced 
Biosensor 7 
pProEX-HTb-mTQ2-hNTH1-YB1ΔC-sYFP2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLST
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMCSPQESGMTALSARMLT
RSRSLGPGAGPRGCREEPGPLRRREAAAEARKSHSPVKRPRKAQRLRVAYEGSDSEKGEG
AEPLKVPVWEPQDWQQQLVNIRAMRNKKDAPVDHLGTEHCYDSSAPPKVRRYQVLLSLML
SSQTKDQVTAGAMQRLRARGLTVDSILQTDDATLGKLIYPVGFWRSKVKYIKQTSAILQQ
HYGGDIPASVAELVALPGVGPKMAHLAMAVAWGTVSGIAVDTHVHRIANRLRWTKKATKS
PEETRAALEEWLPRELWHEINGLLVGFGQQTCLPVHPRCHACLNQALCPAAQGLSGGGAS
GGGTMSSEAETQQPPAAPPAAPALSAADTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIA
TKVLGTVKWFNVRNGYGFINRNDTKEDVFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEG
EKGAEAANVTGPGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSES
APEGQAQQRRPYRRRRFPPYYMRRPYGRRPQYSNPPVQGEVMESDPPVATMVSKGEELFT
GVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQ
CFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGID
FKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIG
DGPVLLPDNHYLSYQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 1046   
Molecular weight: 115297.25   
Theoretical pI: 8.86 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 120725 
Abs 0.1% (=1 g/l) 1.047, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 120100 
Abs 0.1% (=1 g/l) 1.042, assuming all Cys residues are reduced 
Biosensor Topo 
pProEX-HTb-mTQ2-hTopoI-YB1ΔC-sYFP2 
MSYYHHHHHHDYDIPTTENLYFQGAMGSGIQRPTSTMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLSWGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYFSDNVYITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLST
QSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSGLRSRAMSGDHLHNDSQIEADFRL
NDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHK
DKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKR
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PRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKE
EEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVAT
FFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQ
MSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIM
PEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGE
KDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGET
ADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENK
QPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILS
YNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDA
KTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGV
PIEKIYNKTQREKFAWAIDMADEDYEFSGGGASGGGTMSSEAETQQPPAAPPAAPALSAA
DTKPGTTGSGAGSGGPGGLTSAAPAGGDKKVIATKVLGTVKWFNVRNGYGFINRNDTKED
VFVHQTAIKKNNPRKYLRSVGDGETVEFDVVEGEKGAEAANVTGPGGVPVQGSKYAADRN
HYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQRRPYRRRRFPPYYMRRPYG
RRPQYSNPPVQGEVMESDPPVATMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGD
ATYGKLTLKLICTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDFFKSAMPEGYVQER
TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADK
QKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSYQSKLSKDPNEKRD
HMVLLEFVTAAGITLGMDELYK- 
Number of amino acids: 1499   
Molecular weight: 171633.39   
Theoretical pI: 9.05 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm 
measured in water. 
Ext. coefficient 176200 
Abs 0.1% (=1 g/l) 1.027, assuming all pairs of Cys residues form 
cystines 
Ext. coefficient 175450 
Abs 0.1% (=1 g/l) 1.022, assuming all Cys residues are reduced 
Figure A.9. Protein sequences and properties after cleavage of His-tag obtained from ProtParam 
tool on the ExPASy Proteomics Server of Biosensor constructs. Red coloured letters, hexa-His tag; 
pink coloured letters, TEV cleavage site; yellow coloured letters, sYFP2; green coloured letters, 
YB1ΔC; blue coloured letters, hNTH1; cyan coloured letters, mTQ2; purple coloured letters, 
drEndoIII2; orange coloured letters, hTopoI. 
4. Sequence of 12nt THF dsDNA oligonucleotide 
!	 
Figure A.10. Illustration of 12nt THF dsDNA oligonucleotide. X: dSpacer, Tetrahydrofuran 
(THF).  
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